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History of Drug Discovery 
 
From the medicinal use of plants to modern drug discovery, the quest to discover 
healing drugs has always been associated with scientific research.  In the 18th and earlier 
centuries, natural product extracts, particularly those derived from botanical species, 
proved the main source of folk medicine.  During the Dark Ages the art of healing was 
intertwined with magic and religion; however Paracelsus in the 16th century was 
advocating the use of specific drugs to treat certain diseases.1 
The beginning of the 19th century marks a critical junction owing to the advances 
made in the fields of chemistry and physiology. As pharmacologically active compounds 
were for the first time extracted from plants, patients began to receive a purified drug 
instead of a product of variable composition. In 1803 morphine was isolated from plants 
by Friederich Adam Sertürner.2 Salicylic acid, the precursor of aspirin, was isolated in 
1874 from willow bark. Various, more potent painkillers, such as codeine, were isolated 
from the opium poppy. Although synthesis of the first synthetic pharmaceutical drug, 
aspirin, occurred in the latter half of the nineteenth century, it was not until the early 
1900s that the recognition of aspirin as a universal pain reliever was realized 3 and this 
discovery spawned the era of therapeutic agents. 
The modern age of drug discovery began in 1937 with the discovery of the 
antibacterial action of sulfonamide. In 1943, Fleming discovered penicillin4 and in 1947, 
streptomycin momentarily defeated tuberculosis.5 The seeds for the concept of rational 
drug design were laid in the 1940s and 1950s by George Hitchings and Gertrude Elion in 




with anticancer activity.6 However, the era of DNA and medicine was largely stimulated 
by the elucidation of the double-helical structure of DNA by Watson and Crick in 1953.7  
Exactly half a century – to the month – after this historical publication, the US Human 
Genome Project announced that the human genome sequence was “substantially 
complete”.8  
Around the mid-1970s began the era of recombinant DNA technology and 
molecular cloning: the first recombinant DNA molecules were generated and studied in 
1972.9, 10 Then in the 1980s and early 1990s, developments in molecular biology and 
virology had a major impact on the scientific understanding of the replication of the 
retrovirus, Human Immunodeficiency Virus (HIV). 11, 12 11, 12 The polymerase chain 
reaction (PCR)13 of the 1980s resulted in major advances in biotechnology that have had 
significant impact on drug discovery. In the 1990s, the concepts of combinatorial 
chemistry, molecular modeling and bioinformatics heralded a new age in drug discovery. 
The beginning years of the new millennium saw further advances in drug discovery based 
on state-of-the art chemistry, new advances in biology, enzyme-based molecular 
syntheses, proteomics and genomics, recombinant biomolecules, high-throughput 
screening and gene and cell therapy.14 
 
Drug discovery process 
 
The modern drug discovery process consists of sequential steps (Fig. 1.1). Once a 




candidate. The lead candidate is then submitted to preclinical (animal) trials and 
eventually clinical trials.  
 
Figure 1.1: The main steps in Drug Discovery.  
 
This is not a straightforward process, in reality a large number of iterative cycles are 
involved in which a project will revolve until, finally, a promising molecular candidate is 
found that fits the profile needed to proceed to the next step.  
• Target identification or target discovery attempts to identify principally 
proteins, whose modulation might inhibit or reverse the progression of a 
particular disease.15 
• The validation step involves confirming the relevance of the target protein in a 
disease process. This step ideally requires both gain and loss of function studies 
using recent technological advances such as genomics, proteomics, small 
interfering RNA and mouse knockout models.16 
• The hit discovery phase identifies compounds that interact with the target 
protein and modulate its activity. Principally, High throughput screening (HTS) 
is used to test large numbers of compounds for their ability to affect the activity 
of the target protein. Other methods such as Fragment-Based Drug Discovery 




• During the optimization phase, small organic molecules are chemically 
modified and pharmacologically characterized in order to obtain compounds 
with suitable pharmacodynamics (efficacy, potency, selectivity in vitro and in 
vivo, physicochemical properties) and pharmacokinetics (ADME-Tox) 




The ability to identify active compounds that modulate a particular biomolecular 
pathway is a key step in drug discovery. Over the past decades, most pharmaceutical 
companies have used combinatorial chemistry and HTS resulting in the rapid 
identification of active molecules from large compound libraries.17 
However, high attrition rates in the latter stages of drug development were 
observed, mainly due to selection of compounds with ADME-Tox characteristics  (Box 
1) that led to limited solubility, permeability and metabolic instability of compounds.18 In 
addition, HTS has important limitations including large numbers of false positives19 and 
false negatives20 meaning the output of the screen requires detailed analysis and follow-
up. Lipinski and colleagues examined a series of clinically tested drug molecules and 
BOX 1: ADME-Tox 
 
ADME-Tox is an acronym in pharmacokinetics and pharmacology for Absorption, 
Distribution, Metabolism, Excretion, and toxicity. It describes the disposition of a 
pharmaceutical compound within an organism. In vitro or in silico analysis of 
compounds during the lead optimization stage permits efficient prioritization of drug 
candidates. Most large pharmaceutical companies now routinely screen leads for in vitro 
toxicity and cytochrome p450 inhibition in order to minimize potential toxicity events 




analyzed their properties. They introduced the concept of drug-likeliness with the Rule of 
Five21 which constitutes a set of rules designed to predict whether or not a molecule is 
likely to be orally bioavailable i.e. has ideal ADME properties.  
A further refinement of the concept of drug likeness was introduced : an analysis of 
drugs and their patented leads was made by Oprea and colleagues.22 Based on the 
expected increase in molecular weight during the optimization process, it was suggested 
that the  compounds used for screening should be lead-like23 (Mw: 100-350 Da, and 
ClogP=1-3). A new approach for lead generation involving screening libraries of 
compounds significantly smaller and functionally simpler than drug molecules was 
developed: this approach is often referred to as “fragment-based” discovery.  
Fragment Based Drug Discovery (FBDD) aims to create drug leads from small 
molecular building blocks.  Since many of the building blocks were initially derived from 
marketed drugs, they have become known as drug fragments or simply fragments. Once 
appropriate fragments are identified, structure based methods are used to elaborate them 
towards potent and specific lead molecules. This technique was first introduced in 1981 
by Williams Jencks who wrote that the affinities of whole molecules could be understood 
as a function of the affinities of separate parts.24 This article spawned interest in the area 
of ligand-receptor interactions and provided a theoretical model for early work in which 
component fragments of biotin were found to bind weakly to streptavidin.25 Further 
studies on HMG-CoA reductase inhibitors, showed that these inhibitors could be 
understood as a linkage of two fragments, each binding to distinct sites on the enzyme.26 
It was not until 1996 however, that the first practical demonstration of an FBDD method, 




published by researchers at Abbott Laboratories.27 In these studies, NMR was used to 
detect the weak interactions of the fragments with the target and determine the binding 
site.  
The definition of a fragment varies, but usually refers to molecules weighing less 
than 300 Da, as proposed originally by Congreve and colleagues28 in their “rule of three” 
or Ro3. The rule of three is defined as a compound with molecular weight < 300 Da with 
fewer than 15–20 heavy atoms, less than 3 hydrogen bond donors and 3 hydrogen bond 
acceptors, number of rotatable bonds < 3 and TPSA (total polar surface area) < 60 Å2) 
and high aqueous solubility (ClogP ≤ 3).29 The main advantage of FBDD is represented 
by the low molecular weight of the fragments of ligands used in screening for binding to 
a target protein. Due to the simplicity of the fragments it is possible to test a reasonable 
area of chemical space with small numbers of compounds. The number of potential 
molecules with up to 30 heavy atoms is estimated at more than 1060, 30 whereas the 
number of potential fragments with up to 12 heavy atoms has been estimated at 107. 31 
Thus, FBDD can screen a much greater proportion of the chemical space than HTS, 
hence increasing the chances to find new molecular entities.  
 In the past decade FBDD has become a powerful tool for discovering new leads. 
In 2007, 13 different institutions reported the development of more than 50 potent (IC50 
<100 nM) inhibitors against diverse protein targets starting form weakly binding 
fragments.32 To date, at least 18 drugs derived from FBDD have entered the clinic and 3 
of them targeted protein kinases.33 AT7519, an inhibitor of cyclin-dependent kinase 2 




Therapeutics by means of X-ray crystallography which was used to advance initial 
fragment hits to an experimental drug. The development of PLX4032, a selective 
inhibitor of the kinase B-Raf,36, 37 began with a crystallographic screening of fragments 
and then selectivity and potency were improved during the course of optimization. It has 
been shown that the success of FBDD is significantly improved when 3D structure 
information is available.32 Thus far, X-ray crystallography has been the primary structural 
tool driving FBDD.  
 As FBDD screens small molecules, they are correspondingly weaker than most hits 
from HTS,38 with typical binding affinities in the range of 1 µM - 10 mM KD. 
Accordingly, biophysical screening methods, including NMR and X-ray crystallography 
are particularly suitable, given the range of binding affinities they can detect. Recently, 
an NMR ligand based technique called Target Immobilized NMR Screening (TINS) was 
developed in our laboratory.39 TINS as its name indicates, screens a collection of 
fragments for binding to an immobilized target using NMR. The method involves 
immobilization of a target protein and a reference protein on a commercially available 
resin. A flow-injection, dual-cell sample holder40 can be placed in the magnet to enable 
tubeless, stop-flow screening of fragments by automated injection of mixtures containing 
up to 8 compounds into the immobilized protein samples.  
 
Receptor tyrosine kinases and Cancer  
 
Protein kinases constitute one of the largest and most functionally diverse gene 




involved in gene expression, metabolic pathways, cell growth and differentiation. 
Kinases are particularly prominent in signal transduction and coordination of complex 
functions such as the cell cycle. A number of diseases and disease symptoms result from 
the dysregulation of kinases or from mutations in kinases.41  
More than 500 different protein kinases are found in the human genome including 
several subfamilies differentiated by the type of amino acid residue phosphorylated (Tyr, 
Thr or Ser). The family can also be divided into receptor and non-receptor kinases. 
Receptor tyrosine kinases (RTK’s) are cell surface, transmembrane proteins responsible 
for the transduction of regulatory signals from the extra- to the intracellular milieu. RTKs 
are expressed in several cell types and are critical components in signal transduction 
pathways involved in cellular proliferation, differentiation, migration and metabolism.42 
Kinases such as the platelet-derived growth factor (PDGF) and epidermal growth factor 
(EGF) receptors are commonly activated in cancer cells and are known to contribute to 
tumorigenesis.43  In most cases, gene amplification, translocation, mutation or 
overexpression are responsible for the acquired transforming potential of oncogenic 
RTKs.44 
Anticancer approaches that function through the prevention or interception of 
dysregulated RTK signaling include the development of selective compounds that target 
the extracellular ligand binding domain or the intracellular tyrosine kinase domain. From 
the approval of the first kinase inhibitor, imatinib,45 for the treatment of chronic 
myelogenous leukemia (CML) in 2001 to the approval of vandetanib46 in early 2011, 
protein kinases have developed into one of the most important target classes in oncology 




limited selectivity and target multiple kinases.47 In addition, half of the inhibitors that 
have entered clinical trials target kinases that are already the target of approved drugs.48 
Thus, there is significant demand for breakthrough therapies directed towards previously 




The erythropoietin-producing hepatocellular (Eph) family of receptor tyrosine 
kinases are key regulators of diverse cellular functions including cell proliferation, 
differentiation and migration.49 In addition to the roles that kinases are traditionally 
associated with, Eph receptors are also key factors in processes such as axon growth and 
angiogenesis.50, 51 To date 14 different human Eph receptors and 8 different ligands, 
known as ephrins, have been identified.52 The ephrins are divided into two subclasses A 
and B, based on their glycosylphosphatidylinositol (GPI)-anchored or transmembrane 
structure, respectively. The receptors are also classified into 2 families, EphA and EphB, 
depending on the binding affinity for either the A or B ephrins respectively.53 The most 
well known exception to this general rule is EphA4, which binds both A- and B-class 
ligands.54-56   
In addition to its normal role in cellular regulation, over expression of EphA4 has 
been observed in a variety of malignant carcinomas including gastric cancer57 and 
cutaneous lymphomas58 among others. Furthermore, the over-expression of EphA4 seems 
to be critical for tumor growth in a significant percentage of prostate cancers.59 In 




suggest that blocking EphA4 function might be beneficial for the treatment of spinal cord 
injuries.60, 61 The ability to modulate the activity of this family of receptors could prove 





The aim of the research project that is the subject of this thesis was to develop high 
affinity inhibitors of the tyrosine kinase EphA4. In light of the success of FBDD, 
particularly for developing kinase inhibitors, we sought to implement the paradigm in a 
multi-laboratory, collaborative effort to develop EphA4 inhibitors with optimized, drug-
like characteristics. To reach this goal, a consortium consisting of three complementary 
academic groups and three Dutch companies was created. The principle investigators on 
the project were:  Dr. Tensen from the department of dermatology at the Leiden 
University Medical Center (LUMC), Dr. de Esch from the Division of Medicinal 
Chemistry at the Vrije Universiteit (VU) and Dr. Siegal from the Leiden Institute of 
Chemistry (LIC). The companies involved in the project were: Pyxis Discovery, ZoBio 





Figure 2.2: Overview of the research project organization. Main stages of the project are 
shown with the participants. The academic groups were: LU, Leiden University with Dr. 
Siegal, VU, Vrije University with Dr. de Esch and LUMC, Leiden University Medical 
Center with Dr. Tensen. The companies were ZoBio, Pyxis and PamGene. 
 
The overall structure of the project is outlined in Figure 2.2. The ligand discovery 
was based on two complementary approaches: an NMR-based ligand screen and a 
computational screen. The NMR based ligand screening was performed at Leiden 
University in collaboration with ZoBio using TINS.39  As input for ligand screening, a 
diversity library highly optimized for TINS was previously developed by Pyxis 
Discovery in collaboration with ZoBio.62 In silico screening of the EphA4 kinase domain 
and design and synthesis of new ligands was performed by the Ph.D. candidate Oscar van 




group of Dr. Tensen and in parallel, biophysical characterization of the hits was 
performed at Leiden University. Structural studies of EphA4 were carried out with the 
support of the Nederlands Kanker Instituut (NKI-AVL) in Amsterdam.   
 
Overview of the thesis 
This thesis is divided into chapters that cover the discovery of small molecule 
inhibitors of EphA4.  Chapter 2 presents an overview of biomolecular NMR in drug 
discovery. Chapter 3 describes the initial steps in ligand discovery and characterization 
including the screening of a fragment library for compounds that bind to the kinase 
domain of EphA4. Chapter 4 describes the crystallization and structure elucidation of the 
EphA4 kinase domain in the native state. In addition, the co-crystallization of this domain 
with a well known kinase inhibitor, Dasatinib, is presented. The in silico ligand screen 
performed by the group of Dr. de Esch in Amsterdam yielded an interesting and potent 
inhibitor of the EphA4 kinase domain. The discovery of this compound and the 
biochemical characterization as well as the crystal structure is described in Chapter 5.  
Biophysical characterization of the fragments discovered with TINS is presented in 
Chapter 6. Finally, in the concluding remarks the results from these chapters are put into 






















Chapter 2   
 
Advances in Biomolecular 







Over the past decades nuclear magnetic resonance spectroscopy has been evolved 
into a mature technique in support of structure based drug design. A significant number 
of industrial and academic laboratories employ NMR to provide information on the 
nature of molecular interactions.  In this Chapter, the major applications of NMR in 




Farenc C. and Siegal G. Recent Advances in Biomolecular NMR for Drug Discovery. 
Chapter from “Recent Advances in Biomolecular NMR” in the RSC Biomolecular 




The use of NMR in industrial drug discovery has come and gone in waves over the 
years. In the 1990s significant investments in high field instruments and personnel were 
made on the basis of NMR as a tool to rival X-ray crystallography in the elucidation of 
3D structures of protein-small molecule complexes. Unfortunately the field did not 
deliver within the timescales and throughput required to support commercial efforts and 
many NMR departments were reorganized. Subsequently the group at Abbott 
Laboratories lead by Stephen Fesik introduced the concept of using NMR to screen 
through collections of so-called drug fragments for binding to a protein target. Although 
the underpinnings of Fragment Based Drug Discovery (FBDD) can be traced back to 
academia,63 the clear demonstration of the usefulness of NMR for commercial ends lead 
to substantial new interest. In the intervening 15 years NMR has become a mainstay of 
the fragment screening, validation and elaboration process. 
 The primary reason that NMR is so useful for characterizing fragments is the 
exquisite sensitivity of the technique to intermolecular interactions. This sensitivity is 
manifested in two different phenomena: the chemical shift and relaxation. The chemical 
shift with its intimate relationship to the immediate chemical environment of a nucleus is 
a ubiquitous probe that is readily and simply available. In practice the chemical shift is 
most often used in conjunction with NMR spectroscopy of the target (protein or target 
observed NMR), where it can not only differentiate specific, reversible binding from 
artifactual interactions, but, given the availability of the sequential assignment, can define 
an approximate binding site. Protein observed methods typically require isotopic labeling 
placing certain limitations on the applicability of the method. The very large difference in 
relaxation behavior between a small molecule and a protein is typically exploited to 
Advances in Biomolecular NMR in Drug Discovery 
 
 25 
characterize binding by observing changes in the NMR spectrum of the small molecule 
(ligand observed NMR). Ligand observed methods require substantially less protein, 
which need not be labeled, and may be more sensitive than protein observed methods, but 
may be more prone to artifacts. 
Due to the demonstrated utility of NMR for drug discovery, there continues to be 
developments in the field that are both evolutionary and revolutionary. In this review we 
highlight selected recent accomplishments in the use of NMR for finding and 
characterizing small molecule ligands primarily during the very early stages of pre-
clinical drug discovery. In addition, exciting developments in detecting molecules 
binding to targets inside living cells will also be presented.  In this chapter, the emphasis 
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1.   NMR for ligand discovery 
 
At present ligand discovery and characterization comprises the major use of NMR 
in the drug discovery process. Despite the fact that NMR has been used for more than 15 
years in this role, interesting new methods continue to be developed and exciting results 
continue to flow. Interestingly, a recent poll on Practical Fragments 
(http://practicalfragments.blogspot.com/) suggests that including both protein and ligand 
observed techniques, NMR is the most frequently used method of fragment screening.  
 
1.1.   Protein observed NMR 
 
Protein observed screening is the only NMR method which provides information on 
the ligand binding site as well as the mode of binding to the protein. Despite the fact that 
it was introduced 15 years ago,27 protein observed NMR remains the gold standard for 
identifying weak, yet specific binding of fragments to targets and differentiating these 
from non-specific or artifactual interactions. The very nature of the technique introduces 
some limitations such as the requirement for isotope labeling and the restriction to 
small/medium sized proteins. However, advances such as the introduction of TROSY,64 
particularly in conjunction with selective labeling schemes that introduce NMR visible 
isotopes only at e.g. methyl groups,65 have allowed complete backbone assignment and 
ligand screening of considerably larger proteins.   
Among target-based NMR techniques, the heteronuclear single quantum coherence 




used to detect ligand binding. This technique monitors chemical shift perturbations 
(CSPs) in the [15N,1H]-HSQC spectrum upon ligand binding. An application of this 
method to BACE-1, a protease that is a target for Alzheimer’s disease, was recently 
published.66 Since the location of BACE is within the brain, small molecule inhibitors 
must first traverse the blood brain barrier. This extra requirement places further 
restrictions on BACE inhibitors than other proteases, a class of targets already considered 
challenging. The group of Daniel Wyss developed an efficient scheme to produce labeled 
protein from inclusion bodies and used the protein to screen about 10,000 fragments 
before the sequential assignment was available. By first titrating known peptide analogs, 
the relevant CSPs were determined and hits from the screen were selected by their effect 
on these resonances. When the sequential assignment became available (via triple 
labeling and through bond methods),67 binding to the active site was confirmed for 9 
independent classes of compounds.68 This latter publication also contains many 
suggestions for successful elaboration of initial hits discovered by NMR. The most 
promising fragment exhibited instability and therefore the HSQC experiment was used to 
screen for stable isosteres that also bound the active site aspartates of BACE-1. Although 
this search was not ultimately fruitful, structure activity relationship (SAR) information 
gathered led to the conceptualization of a new core which was also characterized by 
NMR. The ability of the HSQC experiment to quickly discern different binding modes of 
the BACE inhibitors proved to be critical for the project. The approach has successfully 
yielded a compound that is now in clinical trials. 
In an interesting twist to HSQC screening, Holak and coworkers69 developed the 
antagonist induced dissociation assay (AIDA) screen for inhibitors of protein-protein 
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interactions. This method monitors changes that occur when a large protein (more than 30 
kDa) binds to a smaller protein (less than 20 kDa). When the complex is formed, the 
resonances broaden due to increased transverse relaxation. In its initial incarnation the 
smaller protein (the N-terminal p53 binding domain of MDM2) was isotopically labeled 
and mixed with the larger protein (the N-terminal 350 amino acid residues of p53) 
resulting in the disappearance of most of the MDM2 peaks. Addition of molecules that 
disrupt the protein-protein interaction restore the spectrum of MDM2. In contrast, if 
compounds simply bind one partner the spectrum is unchanged.  Variants of this 
technique have been recently implemented: A 1D proton version of AIDA70 and SEI-
AIDA.71 The 1D proton NMR version of AIDA monitors ligand binding though the effect 
on Trp proton resonances, alleviating the requirement for labeled protein. The SEI- AIDA 
(SEI for Selective Excitation Inversion) combines the 1D proton technique with a 
selective excitation of protein resonances which enables shorter relaxation delays.  
Finally, protein observed NMR is commonly used to validate hits selected via a pre-
screen. A nice illustration is provided by the virtual screening of the disheveled PDZ 
domain.72, 73 Titration of 15 hits from the screen into 15N-HSQC labeled PDZ showed that 
all hits bound the peptide binding site with the most potent in the low µM range. One of 
the hits blocked Wnt signaling in a cellular assay. 
 
1.2. Ligand observed NMR 
 
Ligand observed NMR is most commonly used amongst all screening techniques as 




Ligand based NMR techniques are mostly based on the difference in size between the 
ligand and the protein. The size difference manifests itself in numerous observables such 
as enhanced relaxation or a change in the diffusion coefficient. In addition, complex 
formation may be observed by transfer of magnetization from protein to fragment or by 
changes in the chemical shift or lineshape of 19F spins in a ligand. 
 
1.2.1.     Relaxation methods 
 
In NMR, relaxation is the process which restores equilibrium magnetization. Two 
different types of relaxations can be distinguished and can be characterized by their rate: 
longitudinal relaxation and transverse relaxation. Longitudinal relaxation is a complex 
function of molecular weight while transverse relaxation increases with molecular 
weight. Ligand observed NMR techniques using relaxation methods are based upon the 
fact that a ligand bound to the protein adopts the relaxation properties of the complex, i.e. 
transverse relaxation will be greatly enhanced. 
As just described, larger, more slowly tumbling molecules relax much faster than 
small molecules. By extension, immobilization of the target on a solid support will 
further enhance transverse relaxation such that the difference with a small molecule in 
solution is at least 2 orders of magnitude. We have constructed an NMR fragment 
screening apparatus based on this principle which we call TINS for Target Immobilized 
NMR screening.39 TINS uses differences in the spectrum of the small molecule in the 
presence of the target and a reference protein to detect binding. In a first, TINS was used 
to screen a fragment collection for specific binding to a membrane protein, DsbB that 
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forms part of a disulfide catalytic cascade in gram negative bacteria.74 Membrane 
proteins are particularly challenging due to the very high level of false positives that arise 
from non-specific binding to the hydrophobic solubilization media. In this case the 
reference sample is used to cancel out the non-specific component of binding. More 
recently, we have also succeeded in screening a GPCR using TINS.75 
NMR relaxation can also be enhanced by use of paramagnetism, i.e. the interaction 
between unpaired electrons and the nuclear spin. Two types of interaction can be defined 
depending on the nature of the paramagnetic center. Isotropic centers give rise to a purely 
distant dependent increase in the transverse relaxation rates of nuclear spins 
(paramagnetic relaxation enhancement or PRE) where anisotropic centers tend to cause a 
shift in the resonance frequency of spins (Pseudo contact shift or PCS). If a paramagnetic 
center (a spin label) is attached to a protein at a defined site, it is possible to measure 
distance dependant and/or angle dependant affects on the NMR spectrum of a ligand 
bound in the vicinity of the spin label. The first ligand screening technique to take 
advantage of a spin label was called SLAPSTIC (Spin Labels Attached to Protein Side 
chain as a Tool to identify Interacting Compounds).76 The use of a spin label for 
screening not only enhances the sensitivity of the method, it enhances the specificity and 
is selective for a small binding site in proximity to the spin label. This latter property was 
put to use to find ligands specific for the hydrophobic binding pocket of the HIV-1 fusion 
protein gp41.77 Here the spin label was attached to the terminus of an engineered α-
helical peptide derived from the C-terminus of gp41. The peptide was truncated such that 
the hydrophobic binding site on the target remained open for small molecule binding. By 




to include in docking procedures leading to a model of the ternary complex. Similarly, a 
lanthanide binding peptide was fused to the SH2 domain of Grb2 where proof of concept 
data demonstrated the feasibility of the system for screening for weakly binding, small 
molecules.78 The authors then used PCS to elucidate the structure of a complex of a 
phosphotyrosine peptide in fast exchange with the SH2 domain and a non-peptidic 
inhibitor in slow exchange. In both cases the correspondence between the structures 
determined using paramagnetic affects and one based either on X-ray crystallography or 
NOEs was reasonable. The power of the system lies in the specificity of the screen and 
the ability to rapidly get structural information from the same system. 
The Pellecchia group has recently published79 an interesting twist on paramagnetic 
labeling that is reminiscent of the earlier work from Novartis.76 The group aimed to 
develop inhibitors of the protein tyrosine phosphatase of Yersina pestis. A spin labeled 
phosphotyrosine mimetic was developed and a library of about 500 low molecular weight 
compounds was screened for proximal binding. 8 positives from the screen were then 
linked to the phosphotyrosine mimetic to yield a series of novel bidentate compounds 
with low or even sub-µM IC50s against the YopH phosphatase and activity in a cell-based 
assay. 
 
1.2.2.     Magnetization transfer methods 
 
Method based on the transfer of magnetization from or via the target are the most 
popular in drug discovery as they are applicable to large protein complexes and require 
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low protein concentrations. A wide variety of techniques have been developed over the 
years. 
 
Saturation transfer difference (STD) developed by Mayer and Meyer80 was one of 
the first methods proposed for ligand observed screening of fragment libraries and 
remains one of the most popular.  This method consists of selectively saturating a 
resonance of the protein. The saturation is efficiently spread over the entire protein via 
spin diffusion and if a ligand binds the saturation is propagated from the protein to the 
compound by cross relaxation at the ligand-protein interface. This method requires a 
large excess of ligand and allows measurements using a low protein concentration. STD 
can also be used to obtain structural information on the complex using a technique known 
as epitope mapping81 (see below). Although widely used, STD does suffer from being 
sensitive to the size of the target (where bigger proteins are better), artifactual 
magnetization transfer and a limited affinity range (10 nM < KD < 1-2mM).82, 83 
Typically, STD is used in combination with other ligand observed techniques such as 
waterLOGSY (see below) to eliminate false positives from screening data.84 
One interesting modification to STD, called Group Selective-STD, directly 
saturates certain classes of 1H’s of the target (e.g. amide) in a selective manner. The 
method avoids the dependence on spin diffusion which is inefficient for proteins less than 
20 kDa. For 15N labeled targets an elegant manner of directly saturating the amide 1Hs 
has been developed.85 In order to insure that saturation is absolutely specific for the 
target, the method uses a half-filter to eliminate magnetization from 1Hs not attached to 




When the ligand resonances do not overlap with the amide region of the protein, the half-
filter can be removed to improve sensitivity. Although perhaps not ideal for screening 
large libraries of ligands that will inevitably contain resonances near  those of the amide 
protons of proteins, the method has been put to good use to elucidate protein-ligand 
structures (see below).86 
One of the reasons for the popularity of STD is the ability to apply it to a wide 
variety of systems to detect ligand binding. Recent applications of STD include 
lipopolysaccharides,87 glycoproteins88 and nucleotide sugar transporters.89 Perhaps the 
most interesting and challenging application has been to detect binding of ligands to 
membrane proteins, either purified GPCRs90 or in live cells.91 
 Water-ligand Observed via Gradient SpectroscopY (WaterLOGSY) is a commonly 
used alternative to STD.92 Based on the observation that ligand binding sites frequently 
also contain bound waters, the technique makes use of the abundance of water to 
efficiently transfer magnetization to a ligand in close proximity via multiple pathways. 
As the method is very sensitive, requires low protein and modest ligand concentrations, it 
has found frequent application in fragment based drug discovery. However, one has to 
take care that the magnetization is not transferred to the ligand via an artifactual 
mechanism such as chemical exchange and therefore, as with STD, other ligand observed 
techniques are frequently combined with WaterLOGSY. A nice example of this 
combination came from the Novartis group who used WaterLOGSY in association with 
T1ρ relaxation93 to screen a small library of 500 compounds for binding to Abl kinase 
where the active site was blocked with imatinib.94 Interestingly, this approach yielded 
biophysically validated ligands that targeted the myristate site.  However, the compounds 
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were non-functional inhibitors. The reason for this is discussed below in the section 
Protein-Ligand Structures. Another recent example demonstrates the capability of the 
combination of virtual screening and WaterLOGSY to generate validated hits for protein-
protein interaction targets.25 The calcium binding protein S100B binds the C-terminus of 
p53 where it is thought to inhibit the transcription regulation function and may play a role 
in the progression of cancer. A collection of 123,000 commercially available compounds 
was screened using 3 different in silico approaches; importantly however, the ensemble 
of NMR structures of S100B was used as input for each. 280 hits from the virtual screen 
were purchased and binding to S100B was assayed using WaterLOGSY. The most 
interesting compounds from WaterLOGSY were titrated into 15N-labelled protein 
samples to confirm binding and determine the binding site (yet another example of the 
use of protein observed NMR to validate screening hits). This approach successfully 
yielded 5 selective inhibitors that bound at the p53 binding site with reasonable ligand 
efficiency. The most potent inhibitor was soaked into a crystal of S100B and indeed 
bound to the same site as a peptide from p53.  
In the original implementation of WaterLOGSY, water magnetization is destroyed 
prior to acquisition. Subsequently one must wait in order for equilibrium magnetization 
to be restored. Jahnke and coworkers recently described a polarization optimized version 
(PO-WaterLOGSY) in which (a portion of the) water magnetization is selectively 
returned to the Z axis, partially negating the need for a relaxation delay. Thus the PO-
WaterLOGSY is said to speed throughput by a factor of 3-5. Aroma-WaterLOGSY, 
which selects that aromatic signals of ligands, effectively achieves similar results to PO-




Just as STD can provide details of the ligand-protein interaction that can help define 
the ligand binding mode, WaterLOGSY can provide information on the ligand-water 
interaction. Solvent Accessibility and protein Ligand binding studies by NMR 
spectroscopy (SALMON)96 utilizes the difference in the sign of the NOE for free and 
protein-bound ligands to determine which portions of the ligand are solvent exposed. 
This information was sufficient to differentiate two possible ligand binding orientations 
that were compatible with the electron density derived from X-ray diffraction 
experiments. 
Interligand NOEs for PHARmacophore MApping (INPHARMA) is a method 
closely related to trNOE (see below) with the twist that the NOE is relayed by the 
protein.30 INPHARMA transfers magnetization between 2 small molecules that compete 
for binding to the same site via an NOE to or from the protein. INPHARMA allows 
indirect mapping of the binding pocket structure of a macromolecule: if the structure of 
one of the ligands bound to the protein is available, then an unknown ligand can be 
oriented on the protein. A particularly impressive example of this was the recent 
elucidation of the binding orientation of a number of ligands of the GPCR GPR40.90  
Although not strictly a magnetization transfer method, Interligand NOEs (ILOEs) 
measures direct NOEs between 2 ligands that simultaneously bind a protein and are 
within 5-7 Å of each other. The method can be used to screen for pairs of ligands that can 
be subsequently elaborated based on the relative orientation provided by the NOE 
information.31,97 In the latter publication, fragment screening identified two ligands that 
simultaneously bound to pantothenate synthetase from M. tuberculosi. However, no 
structural information was available and the hydrophobic ligands aggregated and bound 
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the protein specifically and non-specifically. Chemical modification of the fragments 
addressed the aggregation and using the ILOE experiment the orientation of the 2 
fragments was established. Subsequent linking yielded an 860 nM inhibitor from 800 µM 
and 1 mM fragments, suggesting that the binding of the fragments was not perturbed in 
the linked compound.  
 
1.2.3.    Fluorinated molecules. 
 
19F NMR has proven to be a useful tool in drug discovery. 19F NMR is sensitive (the 
γ is similar to the 1H) and the spins resonate across a broad spectrum. Although direct 19F 
screening of fragments has been proposed,98 the method clearly requires a fluorine atom 
in each member of the library and thereby limits the number and type of compounds 
available. However, when known ligands99 or enzyme substrates are available,100 then 
incorporation of fluorine into these molecules can lead to a high throughput, reliable 
assay that selects for ligands for a specific binding site (via competition binding) or with 
biochemical activity. More recently the combined use of cryoprobe technology and 
optimized pulse sequences has led to considerable increases in the throughput (up to 10 
fold) of this experimental approach.101 The group of Giralt has taken the approach of 
simultaneously screening for inhibitors of 2 different proteases by 19F labeling substrates 
specific for each and mixing them.41,102 In addition to throughput considerations, 19F 
NMR can be used to characterize fragment screening hits. In one interesting case, 19F 
labeled ATP was used to help characterize fragments binding to the kinase PDK1 and a 





2.   Hit prioritization 
 
High-throughput screening (HTS) has been widely used in drug discovery to screen 
large libraries (up to 3 or 4 million compounds) for (typically) biological modulation of a 
target.103 HTS screens may result in a few hundred to many thousands of positives. 
Among these “hits” many are not the result of specific, reversible interaction with the 
target but rather non-specific effects such as interference with the assay itself or 
commonly aggregation.19 Thus, there is an emerging need to triage the list of HTS hits. 
At Pfizer, Miller and colleagues have conducted hit prioritization campaigns using 
biochemical and biophysical techniques.104 The first validation step consists of an 
orthogonal enzymatic assay to validate the results of the HTS screen. Then, to ensure 
integrity, a resynthesis step of the compound is carried out followed by SAR studies. 
Finally, STD and ITC are used in parallel as a last step of validation. This extensive 
triage of compounds allows classification in distinct series and the majority of unwanted 
compounds are eliminated in the early stages. One caveat is that in our experience, many 
HTS hits have very limited aqueous solubility rendering ligand observed NMR 
challenging. 
As hits from a fragment or HTS screen are progressed, the affinity typically drops 
into the nM range. In this range koff becomes slow on the NMR timescale and the KD is 
less than the protein concentration typically required for either ligand or protein observed 
NMR. In such cases determining the affinity using NMR is problematic. However, in a 
series of compounds often the relative affinities are more important than the absolute 
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affinities. Jahnke and colleagues have developed a method to acquire the relative affinity 
of 2 compounds whose absolute affinities may be close or widely separated.47 The 
method can be implemented using either protein or ligand observed spectroscopy and has 
proven useful in the elaboration of fragments. Although the protein observation method is 
the most robust, it is more restrictive than the ligand observed.  
 
3.    Protein-Ligand structures 
 
Structure based drug design has become the de facto standard method for targets in 
which high throughput crystallography is enabled. An analysis of FBDD projects 
suggested that the success rate (as measured by achieving inhibition better than 100 nM) 
was 3 fold higher when 3D structures of protein-ligand complexes was available.105 NMR 
and X-ray crystallography remain the only methods for protein structure determination, 
while, for commercial drug discovery, it is imperative that this information is rapidly 
available. There have been a number of exciting developments that are beginning to 
enable NMR to provide structural information in the time frame demanded. Below, we 
point out a few that are, in our opinion, the most exciting. 
While ultimately it is ideal to have high resolution 3D structures of the protein-
ligand complex, information about the conformation of the ligand itself can be valuable. 
The transferred NOE (trNOE) is a simple technique that can be applied to a variety of 
targets. A NOESY spectrum of a ligand in rapid exchange with the target is acquired 
under conditions of ligand excess. NOEs between 1Hs of the ligand only build up when 




determine the conformation of the ligand in the bound state. This method is applicable to 
large proteins of which only small amounts are available, but requires relatively high 
compound concentrations and therefore the compounds must be quite soluble. TrNOE 
has been used to determine the conformation of the bound form of weak inhibitors of 
MurD ligase, an enzyme that contributes to the formation of peptidoglycan.21 Epitope 
mapping was carried out using STD and the NMR information was used to restrain 
molecular dynamics calculations generating models of the protein-ligand complex. 
Although crystal structures of the complex were available, they did not explain the weak 
protein-ligand interaction. The NMR experiments suggested that the ligands are highly 
dynamic in the bound state, potentially explaining the unexpectedly low potency. 
If the protein can be isotopically labeled, group selective STD can provide 
information on the types of 1Hs on the protein that are close to 1Hs of the ligand. This 
approach has been elegantly used to map the carbohydrate binding site of galectin 1.86 
Protein amide resonances can be directly and efficiently saturated, while ligand resonance 
can be eliminated, if necessary, through a half filter. However, due to the relative size of 
the STD signal and the natural abundance of 13C, carbon attached 1Hs must be selectively 
saturated to avoid artifacts. In principle, if the structure of the target is known, restraints 
derived from such a study could be used to guide molecular docking efforts even in the 
absence of the sequential assignment.  
The chemical shift is a readily available parameter that contains information on not 
only the chemical environment, but also the conformation about a nucleus. As noted, 
perturbations to the NMR spectrum of a protein have long been used for detecting 
binding of e.g. small molecules. Returning to the work on Abl kinase, differences in the 
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chemical shift of Val 525 were correlated with the presence of myristate in its binding 
pocket and the attendant activation of the enzyme.94 By selectively 15N labeling Val 
residues of Abl, the authors developed a conformation specific assay that could be used 
to detect allosteric ligands and differentiate agonists from antagonists. The assay was 
used to screen hits for their ability to induce the same active conformation as myristate. 
This assay confirmed the activity of the known allosteric modulator, GNF-2. However, 
GNF-2 had liabilities related to non-specificity. The assay was then used to discover 
novel allosteric agonists of Abl. 
Unfortunately, despite numerous efforts, it is not yet possible to directly convert 
chemical shift information into structure constraints. However, there have been 
significant achievements in using protein CSPs to guide docking. In one example, amide 
CSPs from an [15N,1H] HSQC were used to guide the docking of compounds to the 
β subunit of the transcription factor CFB.106 Thirty five compounds had been selected 
from in silico screening amongst which, four were validated in the HSQC experiment. 
After directed library synthesis, two, more potent compounds were selected for detailed 
experimentally guided docking. The docking suggested two possible orientations for the 
cores of the two compounds, one of which gave a better correlation to the experimental 
data. The binding site was distal to the binding site of the 2nd subunit of CFB, Runx1, and 
the compounds acted as allosteric inhibitors. In an attempt to step beyond the state of the 
art, González-Ruiz and Gohlke have developed a method that quantitatively exploits 
amide proton CSPs for protein-ligand docking.107 This method combines standard scoring 
by the DrugScore function108 (which describes the protein –ligand interactions) with 




comparison is achieved by back calculating the CSP based exclusively on ring currents. 
After testing the approach on a set of crystal structures, the authors applied it to 3 real 
world cases for which CSP data was available. In two of the 3 cases the docking pose was 
quite good, however the 3rd differed substantially. The authors’ analysis of the reasons for 
the differences highlight the complexities of the approach, which include the effects of 
hydrogen bonds between the ligand and protein and CSPs resulting from conformational 
and/or dynamic changes that occur upon ligand binding. In yet another example, both 
CSPs and intermolecular NOEs were used to guide the docking of the prodrug Losartan 
to glycoprotein  VI, a target for anti-thrombotics.109 
Instead of trying to derive direct structural constraints from CSPs, one can analyze 
the data in terms of binding models. Auto-FACE (Auto-Fast chemical Exchange 
analyzer) fits titration data from an e.g. [15N,1H] HSQC experiment to multiple possible 
models of protein-ligand interaction.110 The models include simple two site binding, 
multiple site with or without sequential binding and allosteric contributions. The authors 
claim that residues directly involved in ligand binding can be differentiated from those 
affected by e.g. conformational changes, by analyzing the “initial rate of perturbation”. 
Isothermal titration calorimetry suggested a 4 state binding model for the system being 
investigated where the last state was non-specific. The NMR titration data was analyzed 
in terms of the binding constant and the initial rate and magnitude of the perturbation. 
This data suggested two distinct binding sites with different affinities for the compound, 
which agreed well with the ITC data (free, low affinity and high affinity complex). 
Interestingly, the two sites correspond to two sites predicted by JSURF111 using CSPs 
from low and high concentrations of the ligand. For a more extensive review of the use of 
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chemical shift information for protein structure elucidation see the recent comprehensive 
review by Mulder and Filatov.112  
Solving the NMR structure of a large protein remains a challenge. Recently, 
Schwalbe and colleagues achieved specific resonance assignment of roughly half of the 
primary structure of DXR (DOXP reductoisomerase), an 87 kDa homodimer that is a 
potential anti-infective target,113 by using 3D heteronuclear experiments with uniform 
15N,13C and 2H labeling. The authors measured intermolecular NOEs between the protein 
and the cofactor NADPH thus potentially enabling the structure of the complex to be 
determined using the known crystal structure. However, no intermolecular NOEs to a 
bound inhibitor could be detected. Selective labeling of amino acid residues can be a 
powerful alternative to uniform labeling that can enable sequential assignment of even 
very large proteins. In one particular example, the 723 residue Malate Synthase was 
labeled uniformly along the backbone while the sidechains of I, L and V residues were 
selectively labeled with a linear pattern of 13C,2H where the terminal methyl groups were 
additionally protonated.114 Such a scheme can enable through bond assignment of the 
backbone and nearly complete assignment of the methyl resonances. Since methyl 
containing residues are typically well distributed at ligand binding sites,65 the method of 
Tugarinov and coworkers could be used to determine structures of even very large 
ligand-protein complexes in an efficient manner. Nonetheless, through bond assignment 
techniques are insensitive and time demanding for large proteins. Direct assignment of 
selectively labeled methyl resonances could make the approach highly efficient. Very 
recently, the group of Clore115 has used paramagnetic relaxation enhancement (PRE) to 




domain of the E. coli protein Enzyme 1. Five different site specific Cys mutants of the 
protein were used to attach nitroxide radical containing tags. The distant dependent PRE 
rate was measured for each methyl using a simple HMQC experiment and the 
information was used in a Metropolis MonteCarlo calculation to determine the 
assignments. The PRE assignments were then used to compare experimental vs predicted 
methyl-methyl NOEs for validation purposes. While the technique clearly requires the 
generation of multiple cysteine mutants (the authors suggest 1 mutant per 6 kDa), when 
feasible it should lead to rapid resonance assignment. 
 In many cases the structure of a protein may be known but obtaining crystals with a 
ligand bound, particularly the weak binding ligands typical of fragment based drug 
discovery, may not be possible. Paramagnetic tags provide one attractive approach to 
solving this issue. The group of Otting116 first showed that it is possible to calculate the 
structure of ligand in rapid exchange with a protein to which a lanthanide ion is bound at 
an intrinsic metal binding site.  If the orientation of the paramagnetic tensor is known 
with respect to the protein coordinates, then both distance and angular information can be 
derived from the magnitude of the pseudocontact shift. A more recent example of the 
approach applied to a protein in which a lanthanide binding tag has been fused to the 
protein was provided in the section on paramagnetism for ligand discovery.78 The 
additional example of a non-covalently bound peptide tag was also provided.77 These 
methods are particularly exciting as once the tagged protein is available and the tensor 
orientation determined, structure constraints are rapidly determined by titrating the ligand 
or tag and acquiring simple 1D 1H spectra of the ligand. In principle then, the methods 
should be quite high throughput. 
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While X-ray crystallography remains the structural method of choice when 
available, it may have shortcomings. A recent example is provided by the structure of the 
growth factor receptor-bound protein 2 (Grb2) SH2 domain.117 The crystal structure 
consisted of a domain swapped dimer to which inhibitors bound to a hinge region 
between the dimers. The use of perdeuterated protein and assignment of the 
intermolecular NOEs gave a well defined solution structure which consisted of a 1:1 
complex of protein and inhibitor. The correct structure suggested vectors for 
elaboration/improvement of this non-phosphate containing ligand. The protein 
Mesencephalic astrocyte-derived neurotrophic factor (MANF) provides a second 
interesting example of a significant difference between the crystal and solution 
structure.58 Where the crystal structure indicated a disordered C-terminal domain, the 
NMR structure clearly demonstrated the existence of a SAP domain. Interestingly, the 
SAP domain of the protein Ku70 inhibits the pro-apoptotic activity of Bax. A similar role 
for the SAP domain of MANF would be consistent with the demonstrated ability of 
MANF to protect neurons of rats. When a crystal structure is not sufficient to observe 
loops due to high disorder, NMR can become an asset, especially when important 
residues for activity are located in these loops. In one example, two inhibitors of the 
proline rich kinase (PYK2) were thought to stabilize the relatively rare DFG-out, inactive 
form of the kinase.118 As with most kinases, the DFG loop was not visible in the crystal 
structure of the protein-ligand complex. 15N labeling of Phe residues was used in 
conjunction with TROSY-HSQC to demonstrate changes in the spectrum consistent with 





4.     In-cell NMR spectroscopy 
 
In-cell NMR spectroscopy holds great potential as a tool to discover and validate 
the interaction of small molecules with pharmaceutical targets in a natural milieu. We 
make no attempt to comprehensively review this field here (we refer the reader to a 
recent review on the subject),119 but rather focus on two recent developments that we feel 
are important for drug discovery.  
STINT-NMR was developed as a method to study protein-protein interactions 
inside living bacterial cells using NMR spectroscopy.120 This method uses sequential 
expression of the two proteins whose interaction is to be studied. The target protein is 
first expressed using 15N labeled medium, in order to obtain a [15N,1H]-HSQC spectrum  
inside the living cell. The growth medium is subsequently changed and the interacting 
protein is overexpressed without labeling. The HSQC spectrum of the target changes 
upon increasing concentration of the interacting protein. Screening small molecule 
interactor libraries (SMILI-NMR) uses STINT-NMR to screen libraries of small 
molecules for protein-protein interaction inhibitors with activity in the cell.121 SMILI-
NMR represents the first effort to use in-cell methods to screen compound libraries. 
Combined with the methods described below this could prove to be a powerful method to 
combine biophysical sensitivity with biological activity. 
While the initial in-cell NMR experiments used isotope labeled proteins in E. 
coli,122 for drug discovery it is critical to assess small molecule functions in eukaryotic 
and preferably mammalian cells. While the seminal work of Selenko123 demonstrated that 
in-cell NMR in eukaryotic cells was feasible, this work relied on injection of purified, 
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isotope labeled protein into Xenopus oocytes. More recently the elegant work of Inomata 
and colleagues has demonstrated high resolution HSQC spectra of proteins inside living 
human cells. This method uses cell penetrating peptides124 to deliver protein into the 
cytosol. The peptides are covalently linked to the protein and the release is made upon 
enzymatic activity or reductive cleavage.125 Importantly, the method was used to show 
both FK506 and rapamycin binding to 15N labeled FKBP in HeLa cells. 
 




In 2008 a group of experienced NMR spectroscopists in industry and academia 
wrote on the perspective for the use of NMR for drug discovery.126 It is greatly exciting 
to note that many of the developments that have been highlighted in this review are in 
areas that the authors of the perspective defined as being important for the future 
expansion of NMR within industry. Although NMR now faces increased competition 
from other methods in the area of ligand discovery, the value of its contributions 
throughout the drug discovery pipeline make the investment in instrumentation and 












Chapter 3   
 
Functional immobilization of EphA4 
and application of fragment based drug 






Protein kinases are considered to be one the most important group of drug target and 
aberrant kinase activity is implicated in a variety of human diseases. Recent studies have 
demonstrated that a particular receptor tyrosine kinase, EphA4, is overexpressed in 
several cancers. The ability to modulate the activity of this enzyme is therefore an 
attractive therapeutic strategy and we aimed to find small molecules inhibitors of EphA4 
activity. We sought to apply a ligand screening technology, Target immobilized NMR 
Screening (TINS), to this particular target. The kinase domain of EphA4 was functionally 
immobilized on resin and a library of drug fragments was subsequently screened using 
the TINS technology. Hits obtained with TINS were biochemically characterized using a 
commercially available enzyme inhibition assay. In addition, selected compounds were 






Eph receptors regulate numerous developmental and cellular processes such as cell 
attraction/repulsion, adhesion/detachment and migration, thereby influencing 
morphogenesis and organogenesis.127 Recently, EphA4 has been identified as a validated 
target for the treatment of certain skin lymphomas.58 Subsequently, others have 
demonstrated the importance of EphA4 in prostrate cancer and pancreatic cancer.128, 129 
Therefore we aimed to develop small molecules inhibitors targeting the kinase domain of 
EphA4. The kinase domain of EphA4 is centrally located in the cytoplasmic portion of 
the protein, adjacent to a sterile α domain (SAM) and a C terminal PDZ domain binding 
motif130 (Fig. 3.1). N-terminal to the kinase domain is a short amino acid sequence 
referred to as the juxtamembrane segment (JMS). The JMS domain contains tyrosine 
residues that must be phosphorylated to allow full activation of the kinase activity,131 a 
mechanism of regulation that is unique to the Eph receptors. Extensive studies of this 
domain have shown that the JMS acts as an additional level of regulation and directly 
influences catalytic activity.132, 133 
Fragment Based drug discovery (FBDD) has become a powerful approach for 
generating novel chemical entities targeting pharmaceutical targets. FBDD screening 
libraries consist of a small set (1,000-20,000 compounds) of molecules which are called 
“fragments” i.e. their physicochemical properties comply with the “Rule of Three”.29 
(Ro3, Mr < 300 Da, cLogP <3, H-bond donors < 3, H-bond acceptors < 3, number of 
rotatable bonds < 3 and TPSA (total polar surface area) < 60 Å2). These fragments 
typically bind to the target with KD greater than 10 µM. To detect these weak binding 
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affinities, sensitive biophysical techniques are required, such as Target Immobilized 
NMR Screening (TINS) that has been developed in our laboratory.39, 40 In this technique, 
the target protein to be screened is immobilized on a solid support (a chromatography 
resin). The immobilized target, along with a sample of a reference protein, is placed 
inside a flow injection, dual-cell sample holder40 in the NMR magnet. The compounds to 
be screened are injected in presolubilized mixes containing 3-8 compounds at 500 µM 
each.  For each mix, an independent 1D 1H spectrum of the compounds in the presence of 
the target or a reference protein is acquired using spatially selective spectroscopy.134 
Compounds binding to the target are detected by the decrease in peak amplitude which 
results from the greatly enhanced transverse relaxation experienced in the bound state. 
Weak, non-specific interactions typically observed between compounds and proteins are 
cancelled by the presence of a reference sample. This reference sample consists routinely 
of the PH domain of the cellular kinase AKT as this protein was shown to be essentially 
refractory to small-molecule binding.135 The aim of this study was to functionally 
immobilize the tyrosine kinase domain of EphA4, in order to submit this protein by 
Target Immobilized NMR Screening (TINS). We investigated several different 
immobilization chemistries resulting in covalent or non-covalent attachment leading to 
either oriented or non-oriented samples. Immobilization on resin was quantified and the 
amount of active protein on resin was determined. As functional immobilization of this 
protein was not as straightforward as expected, several TINS screens were performed. 
Using a commercially available enzyme inhibition assay, the hits obtained with TINS 
were biochemically characterized and interesting compounds were submitted to 





Figure 3.1: Domain structure of Eph receptors. The extracellular domain consists of an 
N-terminal ligand binding domain, followed by a cysteine-rich domain and two 
fibronectin type III repeats136, 137 a single membrane-spanning segment, a juxtamembrane 
segment (JMS), a tyrosine kinase domain (KD), a sterile α domain (SAM) domain and a 
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The Actigel ALD resin (Sterogene, Carlsbad, CA, USA) was used in a 50% slurry 
in all experiments. The resin was washed three times with filtered water then twice with 
PBS (10 mM Na2HPO4, 2 mM KH2PO4, pH 7.4, 137 mM NaCl, 2.7 mM KCl) by 
centrifugation at 500 rpm for 5 min and resuspended in an equal volume of the same 
buffer. 
 
SNAP-tag Kinase Domain: 
 
Expression and purification of the SNAP-tagged Kinase Domain: 
The murine EphA4 kinase domain (amino acids 606-846) was cloned into a pSNAP-
tag®(T7) Vector from New England Biolabs (MA, USA) generating an N-terminal 
SNAP-tag fused to the kinase domain: SNAP-KD with an intervening region containing 
an amino acid sequence efficiently hydrolyzed by the tobacco etch virus (TEV) protease. 
The cloning procedure was performed by colleagues at the LUMC. The expression 
plasmid was transformed into E. coli BL21-AI competent cells. Protein expression was 
induced overnight at 18°C with 0.2% arabinose. A cell pellet corresponding to 1 liter of 
culture was resuspended in 30 ml of lysis buffer (50 mM HEPES pH 7.5, 500 mM NaCl, 




EDTA-free) from Roche, lysed using a French press and centrifuged at 35,000 х g for 45 
min at 4°C. 
 
SNAP-KD Immobilization: 
The benzylguanine (BG) resin was prepared by coupling a benzylguanine derivative 
BG-polyethyleneglycol (PEG)-NH2 (New England Biolabs (MA, USA)) to Actigel ALD 
resin. BG-PEG-NH2 was first solubilized in N,N-dimethyl formamide (DMF) to a final 
concentration of 100 mM, then diluted in water to a final concentration of 5 mM. One ml 
of Actigel ALD resin, the solution of BG-PEG-NH2 and coupling reagent (1 M 
NaCNBH3) at a final concentration of 0.1 M were mixed together and placed at 18°C and 
gently rotated for 18h. After immobilization, the supernatant was removed after a 5 min 
centrifugation at 500 rpm. To block the remainder of the free aldehyde sites on the resin, 
the resin was resuspended with 1 ml Tris buffer (100 mM Tris, pH 7.5) and 0.1 M of 
coupling reagent and incubated for 2 h at room temperature. The reducing agent was then 
removed by washing the resin four times with Tris buffer (100 mM Tris, pH 7.5). 
Crude lysate of SNAP-KD was incubated with 1 ml of benzyl-guanidine resin and 
placed at 4°C with gentle rotation for 18h. Then the resin was washed with phosphate 
buffer. The SNAP-KD resin was then incubated with 20 mM ATP and 20 mM MgCl2 in 
order to fully activate it. 
To obtain the isolated KD in solution, the immobilized SNAP-KD was treated with 
TEV protease (1:1 molar ratio) fused to a 6His tag expressed and purified according to 
published protocols138 for 24 hr at 20°C in TEV activity buffer (25 mM NaPi, 125 mM 
NaCl, pH 7.4, 5 mM DTT). The resin was centrifuged for 5 min at 500 rpm, and the 
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supernatant containing the KD cleaved and TEV protease was collected. To remove TEV 
protease, the sample buffer was exchanged for binding buffer and then applied to a 5 ml 
HisTrap column. 
 
Quantification of SNAP-KD immobilization efficiency: 
To determine the approximate amount of SNAP-KD immobilized, a method of 
protein quantification using Coomassie Blue R was employed139. Protein standards were 
made with a known concentration of an immobilized reference protein (AKT). 
A portion of the resin suspension to be assayed was placed in a microcentrifuge 
tube (40 μl of 50% slurry). The resin was incubated with 100 μl of the Staining Solution 
(0.25% Coomassie Blue R, 30% methanol, and 10% acetic acid) for 10 min at room 
temperature. The sample was then centrifuged at 13000 rpm for 1 min and the 
supernatant was removed. The pelleted resin was washed twice with 1 ml of the 
Destaining Solution (30% methanol and 7.5% acetic acid). After a few seconds of mixing 
to insure that the pellet was well suspended in the solution, the sample was centrifuged 
for 1 min at 13000 rpm. The bound dye was eluted by suspending the pellet in 0.4 ml of a 
solution containing 1% SDS and 1% sodium bicarbonate. To this suspension was added 
0.6 ml of methanol and the solution was mixed well to ensure thorough suspension of the 
resin. The resin was pelleted by centrifugation at 13000 rpm for 3 min and the 
supernatant fluid was decanted and saved for determination of the bound protein content 
of the resin sample. The amount of dye in the supernatant fluids from the elution step was 





Quantification of SNAP-KD activity: 
To determine whether the activity of the unbound protein was comparable to the 
one immobilized on resin, we used a filter binding assay.140 Each reaction consisted of 3 
μM of EphA4 in solution or immobilized in PBS buffer. Aliquots of 40 μl were placed in 
microcentrifuge tube and reaction solution consisting of 20 mM MgCl2, 10 μM poly 
E4:Y1 (Sigma, St. Louis, MO), 50 μM ATP + 0.1 μCi [γ-32P]-ATP per reaction (Perkin 
Elmer, 6000 Ci/mmol 10 mCi/ml) in assay buffer (60 mM HEPES, pH 7.5, 0.2 mM DTT, 
10 mM KCl) was added to the samples. After one hour incubation at room temperature 
with gentle shaking, 10 μl aliquots were spotted on P81 phosphocellulose 
chromatography paper (Whatman, cation exchanger) and allowed to air-dry. The P81 
filter arrays were washed three times with 300 ml of 75 mM orthophosphoric acid, for 10 
min each time with gentle shaking. Washing progress was monitored with a Geiger 
radioactivity counter. The P81 filter arrays were finally washed briefly with acetone and 
left to dry under a chemical hood. In order to quantify the quantity of radioactivity 
incorporated, different dilutions of [γ-32P]-ATP were spotted on the P81 phosphocellulose 
chromatography paper and left to dry under a chemical hood. The P81 paper arrays were 
exposed to the storage phosphor screens for an hour then analyzed with a BioRad 
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Avi fusion Kinase Domain  
 
Construction of the Avi fusion Kinase Domain plasmid: 
All restriction endonucleases, T4 Polynucleotide Kinase and T4 Polynucleotide 
Kinase Reaction Buffer were purchased from New England Biolabs (MA, USA). 
The pET28a vector plasmid (Invitrogen) containing the murine EphA4 kinase 
domain described in Chapter 4 was used as a template for this cloning procedure. The 
vector was digested with NheI-HF and BamHI in appropriate buffer for one hour at 37°C. 
The reaction mixture was run on a 1% agarose gel and then gel purified with GFX gel 
purification kit (Qiagen). 
The single stranded oligonucleotides (oligonucleotide 1: 5’-CTA-GCG-GCC-TGA-
ACG-ATA-TTT-TTG-AAG-CGC-AGA-AAA-TTG-AAT-GGC-ATG-AAG-3’ and 
oligonucleotide 2: 5’-GAT-CCT-TCA-TGC-CAT-TCA-ATT-TTC-TGC-GCT-TCA-
AAA-ATA-TCG-TTC-AGG-CCG-3’) were purchased from Eurogentec and 
reconstituted in DNase/RNase free water at a concentration of 200 μM. To increase the 
ligation efficiency, 500 pmol of oligonucleotides were 5’ phosphorylated (5’ PO4) with 
10 units of T4 Polynucleotide Kinase in presence of 400 μM ATP and 5 mM DTT in T4 
Polynucleotide Kinase buffer for 1 hour at 37°C.  
An equal amount of phosphorylated oligonucleotides were mixed together in a PCR 
tube and heated at 95°C for 2 min, and then re-annealing was done at RT for 5 min. 
Ligation reactions were performed with a molar ratio of linearized vector to re-
annealed oligonucleotides of approximately 1:6 for 18 h at 16°C in the presence of T4 




min) before transformation into E. coli DH5α cells. Transformed cells were propagated 
for 1 h before spreading onto Luria-Bertani (LB) agar. Plasmid DNA was purified from 
cultivated positive colonies, and analyzed by PCR reaction with oligonucleotide 2 and the 
T7 Forward primer (Eurogentec). The PCR reaction consisted of one cycle of 1 minute of 
denaturation at 95°C, 30 cycles of 1 minute of denaturation at 95°C, 1 minutes of 
hybridization at 55°C and 2 minutes of elongation at 72°C and a last cycle of 1 minute of 
denaturation at 95°C, 1 minutes of hybridization at 55°C and 5 minutes of elongation at 
72°C. Plasmids giving the expected PCR product were submitted to confirmation via 
sequencing. 
 
Expression and purification of the Avi-KD: 
The Avi fusion EphA4 kinase domain expression plasmid was transformed into E. 
coli BL21-CodonPlus (DE3)- RP competent cells. Protein expression was induced 
overnight at 18 °C. A cell pellet corresponding to 1 liter of culture was resuspended in 30 
ml of lysis buffer (50 mM Sodium phosphate pH 8.0, 300 mM NaCl, 20 mM imidazole, 
0.05% Tween 20, 10% glycerol and 0.01% beta-mercapto-ethanol) supplemented with a 
protease inhibitor cocktail (complete EDTA-free) from Roche, lysed using a French press 
and centrifuged at 37,000 х g for 45 min at 4°C. The supernatant was applied to a 5 ml 
HisTrap HP column (GE Healthcare) with a peristaltic pump at 4°C for 1 hour (Binding 
buffer: 20 mM Tris-HCl pH 7.6, 500 mM NaCl and 5 mM imidazole). After extensive 
washing, the recombinant protein was eluted with binding buffer plus 500 mM imidazole. 
The sample buffer was then exchanged for 10 mM Tris pH 8.0, 500 mM Potassium 
glutamate. The biotinylation reaction was performed according to manufacturer 
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recommendations (Avidity, LLC). The protein sample at a concentration of 40 µM was 
incubated with 2.5 µg birA enzyme in 50 mM bicine buffer, pH 8.3 supplemented with 
10 mM ATP, 10 mM MgOAc, 50 µM d-biotin. After 30 min incubation at 30°C, the 
reaction mixture was applied to a 1 ml HisTrap HP column (GE Healthcare), and washed 
with binding buffer. The biotinylated protein was eluted with binding buffer plus 500 
mM imidazole.  
 
Immobilization of biotinylated KD 
The streptavidin resin was prepared by coupling streptavidin (Invitrogen) to Actigel 
ALD resin. Streptavidin was dissolved in 1.2 ml PBS at a concentration of 150 µM. The 
solution of Streptavidin, 1.2 ml of Actigel ALD resin and coupling reagent (1 M 
NaCNBH3) at a final concentration of 0.1 M were mixed together and placed at 4°C and 
gently rotated for 18h. After immobilization, the supernatant was removed after a 5 min 
centrifugation at 500 rpm. To block the remainder of the free aldehyde sites on the resin, 
the resin was resuspended with 1 ml Tris buffer (100 mM Tris, pH 7.5) and 0.1 M of 
coupling reagent and incubated for 1h at room temperature. The reducing agent was then 
removed by washing the resin four times with Tris buffer (100 mM Tris, pH 7.5). 
The biotinylated kinase domain of EphA4 was obtained as described above and was 
incubated with 1 ml of streptavidin resin and placed at 4°C with gentle rotation for 18h. 







Target Immobilized NMR Screening 
 
Immobilized EphA4 and the reference protein were each packed into a separate cell 
of a dual-cell sample holder40 in deuterated PBS buffer. A homemade packing reservoir 
has been built to fit on top of the dual-cell sample holder and double the volume of each 
cell. The resin (as a 50% slurry) is pipetted in to each cell one at the time, allowed to 
settle by gravity and packed at a pressure of 0.5 bar. The cell was attached to a Spark 
autosampler via capillary tubing and inserted into an 8 mm, 1H selective, flow-injection 
probe in a 500 MHz magnet. Mixes of typically 3-4 fragments were made by dilution of a 
100 mM stock of each compound in d6-DMSO such that the final compound 
concentration was 500 µM. Upon injection of each mix into the dual-cell sample holder, 
the flow was stopped and spatially selective Hadamard spectroscopy26 was used to 
acquire a 1D 1H spectrum of each sample separately in the EphA4 cell and in the 
reference cell. A CPMG T2 filter of 2 ms or 80 ms depending on the screen was added 
prior to signal acquisition to suppress resonances arising from the resin. Periodic 
injection of a mix containing reference molecules (500 µM Imidazole, 500 µM Na 
Acetate, 250 µM TSP, and 500 µM TMA) during the entire screen was used as a measure 
for reliability of sample injection. 
 
Kinase Inhibition Assay 
 
Kinase activity was measured using the ADP Hunter Plus assay kit according to the 
manufacturers recommendations (DiscoveRx, Birmingham, UK). In this assay ATP 
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turnover, and the subsequent generation of ADP, is measured in a two-step process. 
Reaction mixtures (20 µl) were prepared in black polypropylene 384 well flat bottom 
plates (Greiner, Stonehouse, UK) and contained 100 nM His-tagged EphA4-KD, 33 µM 
ATP (determined as Km for this kinase preparation), 200 µg/mL E4:Y1 (Sigma, St. 
Louis, MO) as substrate and increasing concentrations of inhibitors. Assay buffer (pH 
7.4) contains 20 mM NaCl, 15 mM HEPES, 20 mM MgCl2, 1 mM EGTA and 0.1% 
Tween20. After 75 min at 30oC, reagents A and B from the kit were added and the 
fluorescence intensity was measured with a Tecan infinite F200 Reader (Tecan, Grödig, 
Austria) after 60 min incubation at 30oC, with an Ex of 535 nm and Em of 590 nm and 25 
reads per well. Standard curves, ranging from 30 nM to 75 µM ADP (dynamic range of 
the kit), were used as an internal assay control. Background was measured in reactions 
containing no substrate and subtracted from those containing E4:Y1. For confirmed hits, 
the effects of the inhibitors on the enzymes in the ADP detection step were determined in 
assay buffer and reagents A and B only. 
The percentage of inhibition (PIN) per reaction was calculated as follows: 
PIN (%) = [1- (Afragment-Apositive control)/(Anegative control-Apositive control)] х100% 
where Afragment and Anegative control are the signal in Response Units (RU) measured in the 
presence of the fragment and without fragment, respectively, whereas Apositive control is the 
signal in RU in the presence of dasatinib, a known inhibitor that abrogates EphA4 









Crystals of the kinase domain of EphA4 were grown as described in Chapter 4. 
Stocks solutions of compounds in DMSO were diluted with mother liquor and added to 
EphA4 crystal (final concentration from 1mM to 30 mM) for an exposure time ranging 
from 5 min to 36 hrs at 20°C. Then crystals were flash-frozen using 20% glycerol plus 
the reservoir solution. Diffraction data was collected at 100K at the ESRF (Grenoble, 
France). Datasets were merged and processed using XDS142 and Pointless143 from the 
CCP4144 suite and the structure was solved by molecular replacement using AMoRe145. 
The apo EphA4 kinase domain (PDB ID: 2Y6M) was used as a search model (c.f. 
Chapter 4). The structure was subsequently refined using PHENIX146 and COOT147 was 

















Functional immobilization of EphA4 
 
In order to insure the physiological relevance of ligands discovered using TINS, it 
was important to retain full enzymatic activity of EphA4 upon immobilization. Therefore 
a number of immobilizations chemistries were investigated including: covalent, non-
oriented immobilization via Schiff’s base chemistry, oriented, covalent immobilization 
via glutathione S-transferase (GST), oriented covalent immobilization via the reaction of 
the SNAP tag with benzyl guanine and oriented non-covalent immobilization via biotin-
streptavidin binding. 
The first trials aimed to immobilize the kinase domain via the Juxtamembrane 
segment JMS-KD (amino acids 591-846). The JMS-KD protein was expressed and 
purified according to previous publications.132 The purified protein was immobilized on 
sepharose resin using non-oriented immobilization via Schiff’s base chemistry between 
the primary amines of the protein and the aldehyde groups present on the commercially 
available resin. The immobilization was carried out in the presence of AMP-PNP, an 
analog of ATP, to protect labile amines in the active site. The protein was immobilized at 
a concentration of 100 µM on resin and the activity of the protein was monitored by 
incorporation of radiolabeled phosphate from [γ-32P]-ATP into a peptide substrate (Fig. 
3.2A). We observed that the amount of 32P incorporated into the peptide substrate, and 
hence the activity of the protein, is influenced by the immobilization. Immobilized 




Moreover, the presence of AMP-PNP did not appear to influence the enzymatic activity 
of immobilized protein. Therefore, we investigated other immobilization chemistries. 
As the protein as purified is a fusion with GST, it was logical to assay 
immobilization via covalent interaction with glutathione. The GST fusion JMS-KD 
protein was immobilized on glutathione beads from GE Healthcare at a concentration of 
80 µM and the enzymatic activity was assessed. As shown in Figure 3.2B, the protein 
immobilized on resin presented activity comparable to the protein in solution. Since 
immobilization via the GST tag appeared to yield fully functional protein, it was decided 
to carry out a TINS ligand screening experiment (see below). However, the results gave 
an unexpected profile: most of the compounds showed preferential binding to the 
reference. For that reason we decided to investigate other approaches to functionally 
immobilize EphA4. 
As immobilization of the wild type JMS-KD was unsuccessful, other protein 
constructs from the literature were investigated. Previous mutational studies of the 
tyrosine kinase of EphA4 indicated that mutation of tyrosine 742 to alanine in the kinase 
domain yielded a constitutively, highly active protein.133 This mutant protein (JMS-KD 
Y742A) was expressed and purified. Immobilization of JMS-KD Y742A on resin using 
non-oriented immobilization via Schiff’s base chemistry in the presence of AMP PNP 
was assayed as described above. As shown in Figure 3.2C, the mutant JMS-KD Y742A 
has more activity than the wild type protein in solution. However, when immobilized on 
resin the mutant protein retained only 5% of the activity of an equivalent amount of 
protein in solution. 
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Since various attempts to immobilize the JMS-KD protein failed to yield 
sufficiently active enzyme, it was decided to focus on the kinase domain only (amino 
acids 606-846). For this purpose a second oriented immobilization based on a fusion to 
the SNAP-tag protein was employed.148 The SNAP-tag is a protein based on human O6-
alkylguanine-DNA-alkyltransferase (hAGT) and can be covalently attached to beads 
conjugated to benzyl guanine. The SNAP tag protein was fused to the Kinase Domain 
(SNAP-KD) with a TEV protease recognition site in between. The amount of 
immobilized protein was quantified on resin and the activity was assessed and compared 
to the KD in solution. Since purification of the SNAP-KD was based on the covalent 
bonding between SNAP and benzyl guanine, we could not obtain pure SNAP-KD in 
solution. Therefore the soluble KD, obtained by proteolytic digestion of the immobilized, 
purified SNAP-KD, was used for enzymatic activity comparison (Fig. 3.2D).  The soluble 
KD cleaved from SNAP exhibited greater enzymatic activity than the JMS-KD, as 
previously reported132. The immobilized SNAP-KD has similar enzymatic activity to the 







Figure 3.2: Enzymatic activity of EphA4 immobilized using a variety of approaches. The 
amount of 32P incorporated into the peptide substrate is presented.  A) Non-oriented 
immobilization via Schiff’s base chemistry. (Column 1) JMS- KD in solution. (Column 
2) JMS- KD immobilized without AMP-PNP. (Column 3) JMS- KD immobilized in 
presence of 5 fold molar excess of AMP-PNP. B) Oriented, covalent immobilization via 
GST fusion. (Column 1) GST tagged JMS-KD in solution (Column 2) JMS-KD 
immobilized on Actigel via Schiff based chemistry (Column 3) GST tagged JMS-KD 
immobilized on glutathione beads. C) Non-oriented immobilization via Schiff’s base 
chemistry. (1) JMS-KD in solution (2) JMS-KD Y742A in solution (3) JMS-KD Y742A 
immobilized on Actigel ALD resin in presence of 5 molar excess of AMP PNP. D) 
Oriented covalent immobilization via SNAP fusion. (1) JMS-KD in solution (2) KD in 
solution (3) SNAP-KD immobilized on benzyl guanidine resin. The activity in each bar is 
normalized for the amount of protein. 
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Target Immobilized NMR Screen (TINS) 
 
Ligand screening using TINS requires immobilized protein. During the search for 
functional immobilization, the GST fusion JMS-KD proved to be functional when 
immobilized on glutathione beads. We decided to pursue ligand screening using this 
protein and as a reference we selected the GST protein immobilized on glutathione beads. 
A complete screen of about 1200 compounds was performed. The data resulting from the 
screen could be analyzed directly by comparing peaks from TINS spectra with the 
individual reference spectra of each fragment (Fig. 3.3).  The ready identification of 
binders enabled a totally automated analysis of the complete screening data from Fourier 
Transform and phasing to comparison of peak amplitudes and ligand identification. The 
analysis was performed using in-house written routines implemented in TopSpin, the 





Figure 3.3: Detection of ligand binding to immobilized EphA4 using TINS. The 1D 1H 
NMR spectrum of 3 different fragments in solution (1-3) is shown. The 1H NMR spectra 
of a mix of 3 fragments in presence of EphA4 (4- blue spectrum) or in presence of 
reference (4- red spectrum) are presented. The encircled region shows reduction in peak 
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The results of the screen are presented in Figure 3.4A. Binding is represented by the 
peak heights in the presence of the target (T) divided by peak heights in the presence of 
the reference (R). A T/R ratio higher than 1 indicates preferential binding of a compound 
to the reference and conversely, a ratio lower than 1 shows preferential binding to the 
target protein. The frequency of occurrence of the T/R ratio of each compound gives a 
profile of the screen that is unique for each target. Surprisingly, in the present screen 
most of the compounds showed preferential binding to the reference: only 6 compounds 
exhibited binding to the target. Apparently the isolated GST protein has high levels of 
non-specific small molecule binding. 
 
Figure 3.4: T/R distribution for TINS ligand screening by compound. The graph presents 
the number of compounds with a T/R in each of the bins presented on the x-axis. T/R 
ratios are binned into equal groupings from 0.1 to 1 and 1 to 10, the number of 
compounds in each bin is plotted. A) Screen of GST fusion JMS-KD, B) Screen of 






Since the screen of the GST immobilized KD did not yield the desired fragment 
ligands, we investigated an alternative approach. As shown in Figure 3.2 immobilization 
of the SNAP-KD fusion via SNAP resulted in an apparently fully functional protein. 
Therefore, we used this immobilization procedure to screen the fragment library a second 
time. As seen in the screen of GST-KD, the choice of the reference is crucial. In the 
screen of the SNAP-KD, the SNAP protein alone was initially immobilized as a 
reference. As shown in Figure 3.4B, out of the 650 compounds screened most exhibited 
preferential binding towards the target. Despite the fact that SNAP had proven to have 
very low intrinsic small molecule binding capacity149, it is not an ideal reference. We then 
decided to use the PH domain of human AKT as a reference protein as it had been used in 
a large number of successful TINS screens. The TINS ligand screen of SNAP-KD vs. 
AKT PH was performed using two different T2 relaxation periods of 80 ms and 2 ms. The 
relaxation period is used to suppress the broad resin signal but it also allows more time 
for the fragments to diffuse and encounter an immobilized binding site. A short T2 time 
will result in detection of compounds biased toward high affinity while a long T2 time 
will detect compounds biased towards specificity for the target protein (cf. supplementary 
Figure S1 A and B) 




Figure 3.5: Ligand screen of the SNAP fusion KD vs. AKT as a reference: T/R 
distribution by compound. The graph presents the number of compounds with a T/R in 
each of the bins presented on the x-axis. T/R ratios have been binned into equal grouping 
from 0.1 to 1 and 1 to 10, the number of compounds in each bin is plotted. A) Screen 
with a T2 (relaxation period) of 80 ms, B) Screen with a T2 (relaxation period) of 2 ms. 
 
Once the screens were completed, in-house developed routines were used to 
transform and analyze the data. The T/R ratios are binned into equal groupings from 0.1 
to 1 and 1 to 10 and the number of compound in each bin is plotted (Fig. 3.5). The cut-
off, although arbitrary, was selected in order to differentiate compounds with better target 
binding properties from the rest of the fragments. With a T2 delay of 80 ms, 1191 
compounds were screened resulting in 82 “hits” (positives) for SNAP-KD, defined as 
fragments which had a T/R ratio lower than 0.4. The screen using a T2 delay of 2 ms was 
run on 651 compounds and resulted in 26 hits with a T/R ratio lower than 0.5. The 




3.9% which is well within the range observed with TINS (3-9.5%). Hits from both 
screens were selected and then further characterized using an enzyme inhibition assay. 
 
Hit validation using enzymatic assay 
 
The TINS assay identifies compounds that simply bind to EphA4. A logical next 
step is to characterize the biological activity of the TINS hits using an enzyme inhibition 
assay. The enzyme inhibition study was performed at a single concentration of each 
fragment to generate an initial ranking of the biological activity. Hits from the TINS 
screens (at 2 ms and 80 ms), as well as several non-binders, were selected for further 
characterization (Table 3.1).  
 
 
Table 3.1: Characterization of TINS fragments screening hits via enzyme inhibition. 
 TINS screen at 80 ms  
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A total of 182 compounds were individually assayed at 500 µM in the kinase 
inhibition assay. Fragments were considered “inhibitory” when they exhibited a 
percentage of inhibition or PIN value above 10% which was 3 times the average standard 
deviation of the entire enzymatic assay. Compounds which interfered with the assay were 
excluded from the analysis. Out of the remaining 169 compounds, 25 exhibited biological 
activity: 23 inhibitors and 2 activators. The 23 fragments inhibitors were further analyzed 
for potency (IC50) by dose response experiments (Fig. 3.6, Table 3.2 and Appendix B). A 
complete description of the fragments studied in this thesis is provided in Appendix A. 
Dose-response experiments were carried out with increasing fragment 
concentration, from 8 nM to 1.5 mM, while ATP and peptide substrate were kept in 
excess. Dasatinib, a known inhibitor of Eph family members including EphA4,47, 141 was 
used as a positive control. Dasatinib titrated over 2 log orders and exhibited a Hill 
coefficient of -2.9. The Hill coefficient is a measure of cooperativity in a binding process 
and for enzyme targets with simple kinetic mechanisms (no complex allosteric regulation, 
for example), a Hill slope of one is expected. However, in the present situation, as the 
enzyme concentration significantly exceeds the KD value of Dasatinib, a steep dose-
response (i.e. a Hill slope > 1) is expected.150  
Intriguingly, most of the dose-response curves for the fragments tested appeared to 
saturate at 50% of full inhibition at high compound concentration (~1.5 mM). Four of the 
23 fragments showed less than 20% of full inhibition and/or steeper than expected Hill 
coefficients (Appendix A). The most potent compounds were 1 and 2, which showed 
saturation at 50% and 75% respectively of full inhibition. Compounds which had an IC50 






Figure 3.6: Inhibition curves of selected hits from the TINS screen. The curve represents 
the mean ± Standard Error of Mean (S.E.M) of experiments performed in triplicate. All 
curves were from GraphPad Prism using a sigmoidal dose response curve model with 
variable slope. 
 
Table 3.2: Inhibition values of selected hits from the TINS screen. Inhibitory constants, 
top and bottom plateau values and Hill coefficient are provided. 
Compound IC50 (µM) Y value at the 
top plateau the 
curve  
Y value at the 
bottom plateau 
of the curve 
Hill coefficient 
1     82 ±20  105.3±0.9   46.9±2.3  -1.40±0.18 
2    110±26  107.0±1.2   30.9±2.9  -2.04±0.33 
Dasatinib 0.024±0.001    98.8±0.9     8.1±0.8  -2.91±0.17 
 
 





To evolve the low affinity TINS fragments into high affinity inhibitors, compounds 
1, 2, 5, 6 and 16 to 20 were submitted to hit optimization via in silico methods. In this 
approach fragments are progressively grown by means of modeling and docking to make 
further interactions with the protein. Optimized compounds were then resubmitted to 
validation via the enzymatic assay. Then, to determine the binding mode, we attempted to 
determine the structure of the most potent compounds bound to EphA4 KD by 
crystallography. 
Many strategies are available for obtaining crystals of protein-ligand complexes.151 
The most resource-effective method of obtaining the structure of a protein–ligand 
complex is by soaking the ligand of interest into ligand-free protein crystals (i.e. 
incubation of the crystal with the compound).  As the crystal structure of the kinase 
domain of EphA4 was solved (c.f. Chapter 4), soaking experiments were set up in order 
to obtain crystals of protein-ligand complexes. The structure of a compound from the in 
silico screening effort bound to EphA4 KD was successfully solved using this soaking 
procedure (c.f. Chapter 5). We have therefore initially set up soaking experiments for the 
fragment screening hits using similar conditions i.e. 30 mM fragment concentration with 
incubation times of 6 hrs. Various fragment concentrations (from 1 to 30 mM) and 
exposure time to the crystal (from few minutes to 36 hours) were assayed without any 
observable degradation (monitored using a microscope) of the crystal.  Most of the 
compounds did not display any or only minor solubility problems (as judged by a lack of 




compounds either optimized in silico or TINS fragments were sent to a synchrotron in 
order to obtain high resolution diffraction data. Most of the crystals exhibited weak 
diffraction i.e. less than 7 Å, however the datasets for compounds 1, 2, 6, 17, as well as a 
dataset for an optimized fragment originated from 2 were of sufficient quality to solve 
using molecular replacement techniques. Unfortunately, no electron density was observed 
for any of these compounds which could have various explanations. First, that under 
these conditions the ligands did not bind to the KD or there was insufficient occupancy 
within the crystal roster. Second, it is possible that the fragments were not sufficiently 
ordered to yield observable electron density or that the fragments bind in multiple ways 
to the same site.  
As the pH of the crystallographic conditions (pH 5.5) was quite different from the pH 
of the kinase assay (pH 7.5), there was a possibility that this pH difference might 
influence fragment binding. Thus we decided to use biophysical techniques as an 
additional filter for fragment binding before submitting them to crystallographic analysis. 
Multiple biophysical techniques, such as 2D NMR and Surface Plasmon Resonance 
(SPR) were employed at a pH similar to the crystallographic conditions to further 
characterize fragment binding to the EphA4 KD. This biophysical analysis of the TINS 
fragments is presented in Chapter 6. 
 
Functionality of Biotinylated EphA4 
 
During the SPR analysis of TINS fragment screening hits, the SNAP tagged KD 
protein yielded poor results (c.f. Chapter 6 for details). These SPR results combined with 
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the surprisingly low confirmation rate of TINS screening hits in the enzyme inhibition 
assay led us to doubt the validity of the initial screen on the SNAP tag fusion protein. 
Therefore we decided to pursue a third immobilization procedure in order to determine 
whether the SNAP fusion had unknowingly influenced the ligand screening procedure. In 
this immobilization approach, streptavidin is first immobilized on beads using Schiff’s 
base chemistry and subsequently used to bind the biotinylated KD. In order to biotinylate 
the EphA4 outside of the KD (and minimize the possibility of interference with 
enzymatic activity), a 15 amino acid peptide (GLNDIFEAQKIEWHE), called an Avi 
Tag, was inserted at the N-terminus. This sequence is efficiently biotinylated by the 
biotin ligase (BirA) from E. coli.152  
The biotinylated KD was immobilized on the streptavidin resin and the 
functionality of the protein was compared to protein in solution via a spectrophotometric 
coupled assay.131 We observed a steady rate of NADH oxidation of 2.66 (ΔA340/s)/µmol 
of kinase and 1.77 (ΔA340/s)/µmol of kinase for soluble and immobilized protein 
respectively (Fig. 3.8). The rate of the reaction was close to the value previously reported 
of 2.12 (ΔA340/s)/µmol of kinase.131 These results suggest the biotinylated protein 






Figure 3.7: Enzymatic activity of biotinylated EphA4 immobilized and in solution. 
Analysis was performed using a coupled in vitro kinase assay where production of ADP 
is coupled to the oxidation of NADH through pyruvate kinase and lactate dehydrogenase. 
Both proteins were assayed at 1 µM. The graph shows the reduction of NADH observed 





Target Immobilized NMR Screen (TINS) of biotinylated EphA4 
 
In order to screen the ZoBio fragment collection, biotinylated KD and biotin were 
immobilized on the streptavidin resin at a solution equivalent of 100 µM. A total of 1306 
fragments were screened as described above with a T2 delay of 2 ms. The screen resulted 
in 62 hits for biotinylated EphA4, defined as fragments with a T/R ratio < than 0.8. The 
profile of this screen is summarized in Figure 3.8. For more clarity we will refer to 
biotinylated KD screen as Biot-KD screen. Orthogonal validation of the screening hits 
was generated using SPR (c.f. Chapter 6). 




Figure 3.8:  Comparison of TINS ligand screens: T/R distribution by compound. The 
graphs present the number of compounds with a T/R in each of the bins presented on the 
x-axis. The T/R ratios were binned into equal grouping from 0.1 to 1 and 1 to 10. The 
black histogram is from the TINS screen of SNAP EphA4 KD while the screen of 
biotinylated EphA4 KD is represented in red. For comparison, the TINS profile of an 
unrelated kinase, Pim1, is shown in green.  
 
 
In order to judge the influence of the immobilization method we compared the 
results of the screens of the SNAP and biotinylated EphA4 KDs (Fig 3.8). The profile of 
the Biot-KD screen is different from the profile for the 2 ms screen of SNAP-KD. The 




toward target binding. A priori, one would expect that a large collection of randomly 
chosen small molecules would not show bulk preferentially binding to a protein if non-
specific interactions are properly accounted for. The data suggests that non-specific 
binding is better cancelled out in the Biot-KD screen and therefore we hoped that hits 
from this screen would fare better in subsequent analysis.  
In addition to comparing the profile of the Biot and SNAP-KD screens, it can also 
be informative to compare the T/R value for individual compounds. As shown (Fig. 3.9A, 
comparison of T/R values acquired using the same NMR parameters yields no 
correlation). In Figure 3.9B, shows the T/R values for the subset of compounds from both 
screens for which enzyme inhibition data are available. Of the compounds selected as 
“hits” in the Biot-KD screen, 5 were characterized in the enzyme inhibition assay. Two 
out of 5 inhibited EphA4 activity, meanwhile none of the 4 “hits” from the SNAP-KD 
exhibited inhibition. Although the numbers are small, the limited data does suggest that 
the Biot-KD screen yielded slightly more biologically active compounds. Out of the 430 
compounds tested in both, only one is considered a “hit” in both screens (T/R ratio lower 
than 0.5 in the SNAP-KD 2 ms screen and T/R ratio lower than 0.8 in the Biot-KD 
screen) , yet this compound did not inhibit enzymatic activity.  




Figure 3.9: Comparison of the KD TINS screens at a T2 relaxation time of 2 ms. In x 
axis is presented the T/R ratio of the biotinylated KD screen (Biot-KD) is plotted and in y 
axis the T/R ratio of the SNAP-KD screen is shown. A) The 430 compounds in common 
to both screens are plotted. B) Only the compounds for which enzyme inhibition data was 
available are shown. Compounds represented by green dots were inhibitory, while those 

















The goal of this study was to find hit matter that could potentially be developed into 
high affinity inhibitors of the kinase activity of EphA4. In order to accomplish this goal 
we screened a fragment library for binding to EphA4 using TINS. This method requires 
immobilization of the protein with retention of function. Achieving a high level of 
functionality of immobilized EphA4 required investigation of a number of 
immobilization chemistries. We first attempted to immobilize the protein via Schiff’s 
base chemistry. This approach, based on the direct, covalent attachment of protein via 
primary amines, has proven useful in numerous other TINS screens including kinases.39 
A previous direct immobilization of the protein kinase Pim1149 was performed in the 
presence of AMP-PNP and yielded functional protein. However, in our case this direct 
method did not yield functional immobilized EphA4. Even in the presence of AMP-PNP 
to protect the binding site, the protein remains mostly inactive on resin. At pH 7.4, the 
Schiff’s base reaction is rather specific for the amino terminus. However, lysines with 
perturbed pKa’s may also react at this pH.  One such residue could be Lys656 whose 
importance for enzyme activity has been established in mutagenesis studies.131 Lys656 is 
located outside the binding site, thus presence of AMP-PNP would not prevent coupling 
to this amino acid residue. 
As the direct immobilization of EphA4 was unsuccessful, a number of other 
immobilization techniques were tested.  First, the GST fusion JMS-KD was covalently 
immobilized using glutathione beads. This immobilization appeared to yield fully 
functional protein and subsequently the protein was screened using Target Immobilized 
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NMR Screening. The results of the screen showed an unexpected profile: fragments were 
preferentially binding to the reference protein (GST) suggesting that GST has high 
intrinsic (possibly non-specific) small molecule binding and therefore interferes with 
ligand screening. In order to overcome the difficulties encountered with the GST 
immobilization, the immobilization of EphA4 mutants was investigated. Previous 
mutagenesis studies have identified constitutively active mutants of EphA4 kinase 
activity that could prove useful for ligand screening.131 Immobilization of several of these 
mutants was investigated but did not yield a functional immobilization of the protein.  
As several other protein kinases were successfully screened using the TINS 
technology, we tried to understand the reason for the failure with EphA4. The major 
difference between these protein kinases and EphA4 resides in the presence of the JMS. 
As it was possible that this segment was interfering with the functionality of the 
immobilized protein, we decided to focus on the kinase domain of EphA4. Oriented 
functional immobilization of EphA4 kinase domain was achieved via a SNAP tag and the 
protein was screened using the TINS technology. Initially, the protein reference used was 
the SNAP protein itself but all the compounds screened appeared to preferentially bind to 
the target protein. Although SNAP has been successfully used as a reference in TINS in 
order to cancel weak, non-specific interactions that are observed between compound and 
protein,149 in this case the reference did not seem to function appropriately. Therefore, we 
used the PH domain of AKT as a reference and screened nearly 1200 compounds using a 
T2 delay (relaxation time) of 80 ms resulting in 82 hits. A second screen of 651 
compounds using a T2 of 2 ms yielded 26 hits. To validate these results, the TINS profile 




As seen in Figure 3.8, the two TINS profiles were very similar, suggesting that SNAP-
KD protein was behaving as expected.    
Since TINS simply identifies compounds that bind to a protein, it is important to 
validate the hits in terms of biological activity. The hits from the TINS screen were 
biochemically characterized using a kinase assay which yielded a surprisingly low 
validation rate (15% of the fragments exhibited biological activity). For comparison, 
nearly 75% of hits from Pim1 showed enzyme inhibition (Masakazu Kobayashi, personal 
communication). Among the fragments that were characterized as inhibitory, most 
presented peculiar dose response curves with a steep Hill slope. One possible explanation 
for this observation is that the compounds precipitated at the higher concentrations in the 
assay conditions.153 Moreover, the dose response-curves appeared to level off below 
100% inhibition which can be characteristic of compounds that non-specifically 
aggregate.150 Still, it is unlikely that all these compounds precipitated or aggregated as the 
library was carefully designed and the compounds assessed for solubility at high 
concentration (~ 3 mM).62 Compounds that exhibited some inhibition and presented an 
interesting chemical scaffold were selected for crystallographic structure determination. 
Soaking experiments were undertaken and the complex of a compound that originated 
from the in silico screen was successfully solved (Chapter 5). However, none of the 
fragments that originated from the TINS screen successfully yielded a structure. The 
appearance of crystals was monitored with a microscope and despite the lack of visually 
detectable changes, most of these crystals did not diffract to high resolution. However, 
the experimental electron density map could be obtained for several crystals, but no 
density was observed for the ligand. It is possible that the fragments were not sufficiently 
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ordered to yield observable electron density or that the fragment did not bind the protein 
under the crystal formation conditions. As the pH of the crystallographic conditions is far 
from the pH of the biochemical assay, there was a possibility that the pH difference could 
negatively influence binding of the fragments. Thus we decided to employ extra 
biophysical filters such as SPR and 2D NMR prior to submitting compounds to soaking 
trials (Chapter 6). 
The lack of biochemical validation of the hits from TINS and the low yield of 
crystal structures led us to consider another TINS screen. Moreover, SPR studies 
presented in Chapter 6 yielded an alternative means to achieve functional immobilization 
of EphA4, i.e. via the streptavidin/biotin interaction. Biotinylated EphA4 was 
subsequently immobilized for TINS studies. Nearly 1300 compounds were screened and 
the results were compared to those from the SNAP-KD screen. Surprisingly, little 
correlation was observed between the two screens, even if both proteins remained active 
when immobilized. Moreover, the TINS profiles are different for the two screens (Fig. 
3.8). At this point it is not clear where the variability comes from. However, the 
experience within the laboratory and ZoBio is that TINS screens typically exhibit good 
reproducibility (Gregg Siegal, personal communication). In addition, the ability to 
consistently crystallize different batches of apo KD suggests that variability in the protein 
preparations was minimal.  
Previously, Pim1 was successfully screened using TINS. Approximately 75% of the 
hits were validated using a biochemical assay. In addition, the X-ray crystallographic 
structure was determined for 37 out of 50 compounds.  In our case, only 15% of the hits 




gain further insight into the possible source of these problems, the compounds were 
analyzed with orthogonal biophysical methods including SPR and protein observed NMR 

























Figure S1: Simulation of the peak amplitude in the TINS experiment. The relative 
peak amplitude is plotted against the T2 time in ms. The relative peak amplitude for the 
target and the reference is shown in blue and red respectively. The resulting T/R ratio is 
represented with yellow dots and the signal from the interbead space i.e. in solution is 
shown in black dots. In the simulation in A, the compound exhibits tight binding to the 
target and weak binding to the reference. In B, the compound exhibits the same binding 
to the target while binding to the reference has been simulated with only 10 fold weaker 
affinity.  In A, the T/R ratio is indicative of binding at all T2 times where in B binding is 






Chapter 4   
 
Crystal structure of EphA4 kinase 






The Eph family of receptor tyrosine kinases regulates diverse cellular processes while 
the over-expression of a member of this family, EphA4, has been reported in a variety of 
malignant carcinomas. To gain insight into molecular mechanisms and to facilitate 
structure-based inhibitor design, we solved the crystal structure of the native EphA4 
kinase domain in both the apo and dasatinib bound forms. Analysis of the two structures 
provides insight into structural features of inhibitor binding and revealed a hydrophobic 
back-pocket in the ATP- binding site of EphA4 which was previously unidentified. The 
structures suggest a route towards development of novel and specific inhibitors. 
 
C. Farenc, P. H. Celie, C. P. Tensen, I. J. de Esch and G. Siegal. Crystal structure of the 
EphA4 protein tyrosine kinase domain in the apo- and dasatinib-bound state. FEBS 








Receptor Tyrosine Kinase signaling generally contributes to a malignant phenotype 
by aberrantly transducing growth-promoting stimuli.44 Both overexpression and 
constitutive activity of these receptors due to mutation have been demonstrated to occur 
frequently in various malignancies.43 Recently, EphA4 was identified as a validated 
target for the treatment of certain skin lymphomas.58 Subsequently, others have 
demonstrated the importance of EphA4 in prostate cancer.59  
Eph receptors share a common topology where the extracellular region consists of: 
an N-terminal ephrin binding domain, a cysteine-rich region and two fibronectin type III 
repeats near the single membrane-spanning segment. The cytoplasmic region contains a 
short amino acid sequence referred to as the juxtamembrane segment (JMS), the highly 
conserved tyrosine kinase domain (KD), a C terminal sterile α domain (SAM) and a PDZ 
domain binding motif.130 The JMS domain contains tyrosine residues that must be 
phosphorylated to allow full activation of the kinase activity131 which is unique to the 
Eph receptors. In the crystal structure of EphB2, the JMS forms an α-helix that interacts 
with the kinase domain and prevents it from adopting an ordered, active structure, thus 
providing another level of regulation.132 NMR studies of EphB2 have shown that upon 
activating phosphorylation events, the JMS and KD undergo increased conformational 
exchange.133 It was postulated that autoinhibition was achieved via the JMS “locking” the 
N and C terminal lobes of the KD in an unproductive conformation. Thus the additional 
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regulatory switch represented by the JMS could potentially also be a target for inhibitor 
design. 
Dasatinib is a well-known kinase inhibitor that was approved for use in cases of 
imatinib resistance in chronic myeloid leukemia (CML).154 Although dasatinib was 
primarily designed as a selective inhibitor of the Src and BCR-Abl kinases,155 it was 
found to have a broader inhibition spectrum which includes members of the Eph family. 
47, 141 However, no crystal structure of dasatinib in complex with a member of this family 
has thus far been elucidated. Since no structure of the wild type kinase domain was 
available, we wished to gain insight into the active form and to facilitate structure-based 
inhibitor design by determining the crystal structure of the EphA4 kinase domain in both 




















The murine EphA4 kinase domain (amino acids 606-846) was commercially 
synthesized. The gene was cloned into a pET28a vector (Invitrogen) generating an N-
terminal 6His tag fused to the kinase domain with an intervening region containing an 
amino acid sequence efficiently hydrolyzed by the tobacco etch virus (TEV) protease. 
The purified protein contained a single non-coded glycine at the N terminus after 
cleavage. 
 
Expression and Purification of EphA4 kinase domain 
 
The EphaA4 kinase domain expression plasmid was transformed into E. coli BL21-
CodonPlus (DE3)- RP competent cells, this specific strain contains extra copies of genes 
coding for rare codons R and P enabling efficient high expression of mammalian proteins 
that make use of these codons. Protein expression was induced overnight at 18 °C. A cell 
pellet corresponding to 1 liter of culture was resuspended in 30 ml of lysis buffer (50 mM 
Sodium phosphate pH 8.0, 300 mM NaCl, 20 mM imidazole, 0.05% Tween 20, 10% 
glycerol and 0.01% beta-mercapto-ethanol) supplemented with a protease inhibitor 
cocktail (complete EDTA-free) from Roche, lysed using a French press and centrifuged 
at 37,000 х g for 45 min at 4°C. The supernatant was applied to a 5 ml HisTrap HP 
column (GE Healthcare) with a peristaltic pump at 4°C for 1 hour (Binding buffer: 20 
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mM Tris-HCl pH 7.6, 500 mM NaCl and 5 mM imidazole). After extensive washing, the 
recombinant protein was eluted with binding buffer plus 500 mM imidazole. The 6His 
tag was removed by treatment with TEV protease (1:1 molar ratio) fused to a 6His tag 
expressed and purified according to published protocols138 for 24 hr at 20°C in TEV 
activity buffer (25mM NaPi, 125 mM NaCl, pH 7.4, 5mM DTT). To remove TEV 
protease, the sample buffer was exchanged for binding buffer and then applied to a 5 ml 
HisTrap column. The unbound, cleaved EphA4 was incubated with 20 mM ATP and 20 
mM MgCl2 in order to fully activate it.  After an hour at 4°C, the protein was diluted 10 
fold in 10 mM HEPES pH 7.5, 10 mM NaCl and applied to a 1 ml HiTrap Q column (GE 
healthcare) that had been pre-equilibrated with the same buffer. The fractions containing 
the EphA4 kinase domain, which did not bind to the column, were then concentrated to 5 
ml and applied to a Sephacryl S-200 HR column (HiPrep 16/60; GE Healthcare) 
equilibrated in 10 mM HEPES, 500 mM KCl and 1 mM DTT. This procedure yielded a 
protein that was homogenous as judged by Coomassie blue staining of SDS-PAGE gels 
and enzymatically active (not shown). A single purification from a liter of cell culture 
yielded between 3 and 6 mg of pure protein. Purified EphA4 kinase domain was 
concentrated to 11 mg/ml for crystallization using a Centricon-10 (Amicon). 
 
Crystallization of the EphA4 kinase domain 
 
Crystals were grown at 20°C using the sitting-drop vapor-diffusion method. The 




containing 15-21% polyethylene glycol 10K, 100 mM ammonium acetate and 100 mM 
bistris pH 5.5. Rod-like crystals appeared after 1-3 days. 
 
Co-crystallization of EphA4 kinase domain in complex with dasatinib 
 
Dasatinib (N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-
methylpyrimidin-4-ylamino)thiazole-5-carboxamide) 156 was added to the purified 
protein at a final concentration of 1 mM in dimethyl sulfoxide (molar ratio 
dasatinib/protein of 3) and mixed with an equal volume of a reservoir solution containing 
15-21% polyethylene glycol 10K, 100 mM ammonium acetate and 100 mM bistris pH 
5.5. Crystals appeared after 1-3 days. 
 
X-ray data collection, structure determination and refinement. 
 
Crystals were flash frozen using the reservoir solution supplemented with 20% 
glycerol as a cryoprotectant. Diffraction data for the apo protein was collected at the 
Swiss Light Source (SLS, beamline X06SA) and at the European Synchrotron Radiation 
Facilities (ESRF, beamline ID23-2) for the inhibitor bound. Datasets at 1.5 Å for the apo-
protein and 1.55 Å for the inhibitor complex were processed using XDS157 and 
Pointless158 from the CCP4i suite.159 The apo-structure was solved by molecular 
replacement using the program AMoRe.160 A mutant of EphA4 was used as a search 
model (PDB ID: 2HEL). From the AMoRe solution, a model was built and input into 
ARP/wARP161 for automated tracing. The dasatinib-bound structure was solved by 
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molecular replacement (AMoRe) using the native protein as a search model. The 
structures were refined using rigid body refinement within the program REFMAC5.162 
This was followed by restrained refinement with PHENIX163 interspersed with rounds of 
model building with COOT.164 A summary of the data collection and refinements 
statistics is presented in Table 4.1. 
 
Table 4.1: Data collection and refinement statistics 
Data collection Apo EphA4 Dasatinib-bound EphA4 
PDB ID 2Y6M 2Y6O 
Space group P212121 P212121 
Cell constant α=β=γ=90° A=32.41, b=91.64, c=98.35 a=32.41, b=91.64, c=98.35 
α=β=γ=90° Resolution (Å) 1.7 1.54 
Total observations 87,554 173,478 
Unique reflections 31,531 41,896 
Completeness (%) 97.2 (97.3)a 95.4 (82.8) 
Rmergeb(%) 4.6 (25.0) 6.9 (32.2) 
Average I/σI 13.1 (4.1) 14.8 (4.5) 
Refinement   
Rwork/Rfree (%) 18.61/21.95 18.01/20.05 
Temperature factor (Å2) 
(Å) 
20.1 19.2 
rmsd bond lengths (Å) 0.006 0.006 
rmsd bond angles (°) 0.966 0.994 
rmsd bond dihedrals (°) 11.864 16.84 
 
aValues in parentheses are for the highest resolution bin. 
bRmerge = ΣhklΣj |Ihkl, j - <Ihkl>|/ ΣhklΣj Ihkl, j , where I is the intensity for the jth measurement 




Results & Discussion 
 
Apo enzyme structure 
 
The phosphorylated kinase domain of murine EphA4 (residues 606-846, referred to 
as EphA4 KD) was crystallized in the apo form and the structure was determined at 1.7 Å 
resolution. The crystallographic model contains one molecule in the asymmetric unit and 
was refined to an Rwork =17.49% and Rfree= 20.32%. The overall bilobed structure typical 
of kinases is well ordered except for three N-terminal residues and five C-terminal 
residues and residues 765-787 of the activation segment. The N-terminal lobe consists of 
the characteristic five-stranded β sheet and a single large α helix (αC) while the C-
terminal lobe is larger and mainly α-helical, but includes a two stranded anti-parallel β-
sheet as expected (Fig. 4.1). Protein kinases contain a number of conserved elements that 
contribute to the enzyme activity including: a hinge region connecting the two lobes, a 
glycine rich loop or p-loop, a catalytic loop and an activation loop, all of which are 
present in the EphA4 structures. The activation loop includes a consensus Asp-Phe-Gly 
(DFG) motif sequence that is critical for ATP binding165 and is highly conserved among 
kinases.166 
The present structure is characteristic of a phosphorylated, and therefore activated, 
form of a kinase domain.167 First, the αC-helix is in the ATP proximal position allowing 
the formation of the conserved Lys653-Glu670 salt bridge which coordinates the alpha and 
beta phosphate groups of ATP via polar contacts. Second, the activation loop is 
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disorganized and adopts the so-called “DFG-in” conformation168 with the side-chain of 




Figure 4.1: Overview of the crystal structure of the EphA4 kinase domain. (A) Ribbon 
representation of the apo-EphA4 kinase domain crystal structure. The N-terminal lobe, 
shown in pink, consists of a five-stranded anti-parallel β-sheet and one α-helix (αC). The 
C-terminal lobe, in grey, is mainly α-helical. The p-loop is colored orange, the hinge 
region in green, the catalytic loop in blue and the activation loop in red. (B) Same as in A 
with a 90° rotation about the z axis. Residues important for kinase activation (Lys653, 
Glu670 and Phe765) are shown in stick representation. All molecular graphics were 






Comparison of Eph receptor crystal structures. 
 
An EphA4 protein consisting of the kinase domain and the adjacent juxtamembrane 
segment (JMS), which comprises the mutations Y596/602F in the JMS and Y742A in the 
KD, has been previously crystallized (PDB ID: 2HEL).133 We refer to this structure as 
EphA4 JMS-KD. Although the resolution of this structure is 2.35 Å, the JMS is almost 
completely disordered. Overall, the structures of the two proteins are very similar with an 
r.m.s. deviation of 0.633 Å for the superimposition of 208 Cα atoms (Fig. 4.2A and Table 
4.2). The C terminal lobe is nearly identical in the two structures with the exception that 
five less amino acid residues of the activation loop of EphA4 KD could be modeled. As 
the catalytic and activation loops are spatially close to each other in the EphA4 KD 
structure, the presence of the bulky side-chain of Tyr742 in the catalytic loop leads to 
reduced interaction with the activation loop and its subsequent disorganization. The 
Y742A mutation in EphA4 JMS-KD removes the tyrosine side-chain allowing repacking 
and stabilization of the activation loop. In contrast, the N-terminal lobe shows greater 
differences between the KD and JMS-KD structures. The largest difference observed is in 
the location of the αC-helix where a 4.5 Å movement of the Cα of Asp661- upward and 
outward in the KD structure causes the displacement of the entire alpha helix. The αC-
helix contains a kink that leads to a bend of the long axis by 14° at about the midpoint of 
the helix (Fig. 4.2A). The kink is similar in both structures, however the relative position 
of the alpha helix is different, which in turn influences the position of the conserved Lys-
Glu salt bridge. The salt bridge is also influenced by the position of the p-loop which is 
shifted upwards in the KD structure compared to the JMS-KD structure. Thus, although 
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the two crystals structures share an almost identical amino acid sequence, there are 
significant structural differences.  
To try and determine whether the structural differences between EphA4 KD and 
JMS-KD are related to the presence of the JMS, we compared this pair to the structures 
of another KD JMS-KD pair from the Eph family. Crystal structures of the closely related 
kinase EphB2 have been solved both in the active state (EphB2 KD, PDB ID: 2HEN) 
which comprise a D754A mutation in the activation loop)133 and the auto-inhibited state 
(EphB2 JMS-KD, PDB ID: 1JPA).132 In the EphB2 JMS-KD structure, a Y604/610A 
mutation in the JMS has been made to prevent activation, which results in an enzyme 
with constitutively low activity.131 Overall, the structures of the 2 pairs of kinases are 
similar except for the αC-helix and the p-loop which present slight changes (Fig. 4.2B 
and Table 4.2). The αC-helix exhibits a similar kink in all the structures, the cause of 
which was previously attributed to the JMS.132 However, a subsequent crystal structure of 
EphA2 was reported which also exhibited a bent conformation of the αC-helix despite the 
absence of a JMS (Fig. 4.2C).170 The situation is similar with the present crystal structure 
of EphA4 KD, i.e. a kink in the αC-helix even though the JMS is absent. This observation 
confirms the previous suggestion133 that the presence of the JMS in the EphA4 JMS-KD 
structure is not responsible for the kink in the αC-helix. However, the relative position of 
the αC-helix is different in all the structures (Fig. 4.2C). In the present structure of active 
EphA4, the position of the αC-helix is closer to the auto-inhibited JMS-KD of EphB2, 
indicating that the details of the position of the αC-helix do not necessarily correlate with 




The variability of the p-loop in all 4 structures shown in Fig. 4.2C, which influences 
the position of the conserved Lys-Glu salt bridge, is even greater than the αC-helix. In 
the kinase domain of EphA4, the position of the salt bridge is shifted, creating a larger 
hydrophobic pocket than in the other Eph receptor kinases, including specifically the 
EphA4 JMS-KD (Fig. 4.2D). Other Eph receptor kinase domains that have been 
crystallized without the JMS or mutations lack this hydrophobic pocket due to the 
position of the salt bridge (Fig. 4.3). In addition, it seems likely that this pocket is present 
in the active, full-length kinase considering inhibition of EphA4 by dasatinib has been 
demonstrated in the cell141 and dasatinib occupies this back pocket in our crystal structure 
(see below). This newly discovered back-pocket should allow for both enhanced 
specificity and potency for EphA4 inhibitors. 
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a The number of Cα atoms used for superposition is given in parenthesis. 




Figure 4.2: Comparison of the EphA4 crystal structure with the kinase domain of other 
Eph receptor. (A) Superimposition of EphA4 structures: EphA4 KD (grey), EphA4 JMS-
KD (2HEL, red); Shown in bond representation: the residues contributing to the 
conserved salt bridge Lys-Glu and the Tyr/Ala residue in the activation loop (B) 
Superimposition of EphA4 and EphB2 structures: EphA4 KD (grey), EphA4 JMS-KD 
(2HEL, red), EphB2 KD (2HEN, blue), EphB2 JMS-KD (1JPA, yellow). (C) 
Superimposition of EphA4, EphB2 and EphA2:  closer view of the N-lobe, the residues 
contributing to the conserved salt bridge Lys-Glu are shown in bond representation while 
the dots represent the van der Waal’s surface of the salt bridge. EphA4 KD (grey), 
EphA4 JMS-KD (2HEL, red), EphB2 KD (2HEN, blue), EphB2 JMS-KD (1JPA, 
yellow), EphA2 KD (1MQB, green). (D) Close up view of the ATP binding pocket of 
EphA4. The dots show the ATP binding pocket and the back hydrophobic pocket is 
circled in yellow. The orange, green, cyan and red elements represent respectively the p-





Figure 4.3: Comparison of the EphA4 crystal structure with the kinase domain of other 
Eph receptors from the protein databank containing no mutations. (A) Superimposition of 
structures: EphA4 KD (grey), EphA3 KD (2QOB, blue) EphA5 (2R2P, magenta) EphA8 
(3KUL, yellow); Shown in bond representation: the residues contributing to the 
conserved salt bridge Lys-Glu while the dots represent the ATP binding pocket of 
EphA4. (B) Same representation but counter clockwise rotated about the z axis by an 
angle of 20°. 
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Structure of EphA4-dasatinib complex 
 
Dasatinib is an ATP competitive inhibitor that targets multiple kinases. Amongst 
the numerous targets of dasatinib, it has been shown to inhibit EphA4.47, 141 Using a 
commercially available kinase assay (ADP Hunter Plus, DiscoveRx), the IC50 of dasatinib 
for the kinase domain of EphA4 was 25 nM (cf. Chapter 5, Fig. 5.1). However, no 
structural information regarding the binding of dasatinib to EphA4 is available. In order 
to address this issue, dasatinib was co-crystallized with EphA4 KD under conditions 
identical to the apo protein. The structure of the complex was solved to 1.55 Å resolution 
and refined to an Rwork = 18.01 % and Rfree= 20.05% (Fig. 4.4 and Table 2). Structural 
alignment of the apo and the dasatinib bound forms of EphA4 KD gives an r.m.s 
deviation of 0.150 Å over 220 Cα atoms. Although the 3D structures are very similar, the 
B factors of the apo and inhibitor bound proteins are subtly different (Fig. 4.5). B-factors 
are a measure of the order in the unit cell. Careful inspection reveals that the backbone 
atoms have on average slightly lower B-factors in the inhibitor bound complex while the 
side-chains have somewhat larger B-factors. Dynamic behavior in solution may give rise 
to increased B-factors. Interestingly, a similar pattern of dynamic changes on ligand 
binding (decreased dynamic behavior of the backbone and increased dynamics of the 
sidechains) has been observed in NMR.171 The pattern of changes in the B-factors 
suggests a thermodynamic explanation for binding i.e. that reduced entropy of the 
backbone in the dasatinib bound form is compensated by increased entropy in the 
sidechains. As a result, the net entropic change of ligand binding is minimal. The reduced 




dasatinib bound protein allowing two additional amino acids to be modeled. As with the 
apo protein, the αC-helix is in the ATP proximal position allowing the formation of the 
conserved Lys653-Glu670 salt bridge indicative of the kinase active state167 while the 
activation loop is  also in the “DFG-in” conformation.168  
Dasatinib makes several hydrogen bonds to the hinge and occupies the hydrophobic 
pocket behind the Thr699 residue which is commonly referred to as the ‘gatekeeper’ 
residue.172 The side-chain of the gatekeeper residue sterically controls inhibitor binding to 
the hydrophobic pocket.173 There are three main hydrogen bonds between dasatinib and 
the kinase: one between the nitrogen of the amino-thiazole ring and the amide nitrogen of 
Met702, another between the amino group of the amino-thiazole ring with the carbonyl 
oxygen of Met702 and a third one between the amide nitrogen of dasatinib and the side-
chain hydroxyl oxygen of Thr699. The 2-chloro-6-methyl phenyl group of dasatinib 
occupies the hydrophobic pocket and makes extensive van der Waal’s (vdW) contacts 
with Lys653, Glu670, Met674, Ile683, Ile697 and Thr699. The amino-thiazole ring has vdW’s 
contacts with Leu753 and Ala651, in addition to the previously described hydrogen bond. 
The pyrimidine ring extends out of the binding pocket and makes vdW contact with 
Ile627.  The hydroxyethyl-piperazine group is largely solvent exposed. 
In an analysis of the Eph receptor family,47 it was observed that, except for EphA6 
and EphA7, dasatinib inhibited all of the Eph receptors. Interestingly, the gatekeeper 
residue in EphA6 is Val and Ile in EphA7, while in all other members of the family it is 
Thr. The bulky gatekeeper residues in EphA6 and EphA7 likely obstruct access to the 
hydrophobic pocket. The pattern of inhibition is not surprising since dasatinib was 
designed to access the hydrophobic pocket created by the mutation of the gatekeeper 
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residue from Ile to Thr in Abl kinase that lead to resistance to imatinib. It seems likely 
that the mode of binding of dasatinib observed here is similar for the other Eph receptors 









Figure 4.4. Binding mode of dasatinib to EphA4. (A) Overview of the binding 
interaction. Dasatinib and residues that interact with it are shown in bond view, hydrogen 
bounds are indicated by black dashed lines. (B) View of dasatinib overlaid with the 






Figure 4.5. Average B factor per residue number. In black the values for main chain, and 
in red values for the side-chains. Solid lines are values for the apo-form and the dashed 







Structural comparison with other kinases bound to dasatinib. 
 
Since a number of other dasatinib bound structures have been elucidated, it is useful 
to compare the present structure to these. We have selected four representative structures, 
two from the Src family (Src174, and Lyn175), the Ableson kinase (Abl)176 and Bruton’s 
tyrosine kinase (BTK)177 for comparison with our dasatinib-bound EphA4 structure. In all 
five structures, the 2-chloro-6-methyl phenyl group of dasatinib occupies a hydrophobic 
pocket adjacent to the ATP-binding site behind the gatekeeper residue, which in all cases 
is a Thr (Fig. 4.6A). All 5 structures exhibit an αC-helix in the ATP-proximal position, 
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the salt bridge between Lys and Glu and an activation loop with the “DFG-in” 
conformation. The kink in the αC-helix is present in all the structures and the position of 
the helix is slightly different in each (Fig. 4.6B). However, the salt bridge is in the same 
position in all the structures. Although the binding mode of dasatinib is globally similar 
in all the structures, two different binding orientations are observed for the 2-chloro-6-
methyl phenyl group of dasatinib. The chloride is pointing toward the C-terminal lobe in 
the Src, Lyn and EphA4 complexes (Fig. 4.6C), while the chloro substituent is pointing in 
the opposite direction in the Abl and BTK complexes (Fig. 4.6D). However, it is not clear 
why the different binding orientations are observed, it may be related to the resolution. In 
the present, relatively high resolution EphA4 structure, the orientation of the chloro 
substituent pointing toward the C-terminal lobe fit the electron density better. 
In addition to the hydrophobic pocket, differences are observed in the p-loop in 
both Abl and BTK structures compared to EphA4. There is a 7.7Å movement of the Cα 
of Abl Gly250 towards the ATP binding site in comparison to the corresponding EphA4 
Gly630 (Fig. 4.6D). The p-loop of BTK shows a similar movement to Abl, although to a 
slightly lesser extent, with a 3.65Å movement of the Cα of BTK Gly411 towards the ATP 
binding site in comparison to the corresponding Gly630 of EphA4. Moreover, Abl Tyr253 
makes several vdW’s contacts with the amino thiazole of dasatinib that are absent in the 
other complexes. The p-loop in BTK and Abl packs closer to the core of the kinase as 
evidenced by the shorter distance between the methyl substituent of the pyrimidine ring 
and the p-loop of BTK (8.69 Å to Gly411)  and Abl (7.12 Å to Gly250) in comparison to 
EphA4 (9.85 Å to Gly630), thereby partially shielding dasatinib from solvent. The position 








Figure 4.6. (A) Sequence alignment of a portion of the EphA4 kinase domain with other 
RTKs that bind dasatinib: Lyn, BTR, c-Src and Abl. Variable residues are indicated in 
blue; and the residues that interact with dasatinib are shown in red. The potency of 
dasatinib inhibition of each kinase is indicated on the right. (B) Superimposition of 
EphA4 (2Y6O, grey), Lyn (2ZVA, blue), c-Src (3G5D, magenta), BTK (3K54, yellow) 
and Abl (2GQG, red). The residues contributing to the conserved salt bridge are shown in 
bond representation. (C) Superimposition of EphA4 (2Y6O, grey), Lyn (2ZVA, blue) and 
c-Src (3G5D, magenta). The residues contributing to the conserved salt bridge and the 
gatekeeper residue (Thr) are shown in bond representation. (D) Superimposition of 
EphA4 (2Y6O, grey), BTK (3K54, yellow) and Abl (2GQG, red), in addition to the 
residues contributing to the salt bridge and the gatekeeper residue (Thr), selected residues 
in the p-loop are shown in bond representation (Gly250 and Tyr253 for Abl, Gly411 for BTK 
and Gly630 for EphA4).  





We have elucidated the structure of the native EphA4 kinase domain and the first 
structure of this domain in complex with an inhibitor. The structure of the native kinase 
domain suggests that the JMS in EphA4 is not responsible for the change in the relative 
position of the αC-helix as was previously suggested 133. In addition, the structure reveals 
a hydrophobic back-pocket in the ATP-binding site of EphA4 which was unknown 
before. The crystal structure of EphA4 in complex with dasatinib revealed a binding 
mode closely related to the one exhibited by Src family members, c-Src and Lyn.  
Access to the hydrophobic pocket is governed by the gatekeeper residue while the 
size of the pocket appears to be governed by the position of the Lys-Glu salt bridge. The 
gatekeeper residue is conserved among 12 of the 14 human Eph receptors while, in our 
structure, the position of the conserved salt bridge is shifted, offering a larger 
hydrophobic pocket than in the other Eph receptors. This unique combination of 
gatekeeper and position of the salt bridge suggests a manner to design new, EphA4 
specific inhibitors. Further mutational experiments targeting the ATP binding site and the 
hydrophobic pocket in particular could shed light on the potential to develop EphA4 
specific compounds.  
 
 
PDB accession numbers 
Atomic coordinate and structure factors of apo- EphA4 and dasatinib-EphA4 were 






























Chapter 5   
 




The in silico identification, optimization and crystallographic characterization of a 
6,7,8,9-tetrahydro-3H-pyrazolo[3,4-c]isoquinolin-1-amine scaffold as an inhibitor for the 
EphA4 receptor tyrosine kinase is described. A database containing commercially 
available compounds was subjected to an in silico screening procedure which was 
focused on finding novel, EphA4 hinge binding fragments. This resulted in the 
identification of 6,7,8,9-tetrahydro-3H-pyrazolo[3,4-c]isoquinolin-1-amine derivatives as 
EphA4 inhibitors. Hit exploration yielded a compound with 2 μM (IC50) affinity for the 
EphA4 receptor tyrosine kinase domain. Soaking experiments into a crystal of the EphA4 
kinase domain yielded a 2.11Å X-ray structure of the EphA4 – inhibitor complex, which 
confirmed the binding mode of the scaffold as proposed by the initial in silico work.  
 
This chapter is based on the following publication in which my contribution to the work 
involved crystallography and structure analysis. 
O. P. van Linden, C. Farenc, W. H. Zoutman, L. Hameetman, M. Wijtmans, R. Leurs, C. 
P. Tensen, G. Siegal and I. J. de Esch, Fragment based lead discovery of small molecule 







The erythropoietin-producing human hepatocellular (Eph) carcinoma receptor tyrosine 
kinase family is the largest sub-family of receptor tyrosine kinases. These membrane 
spanning receptors and their ligands (ephrins) play critical roles in the developmental 
stage of vertebrates and are involved in processes such as axon guidance and 
angiogenesis.51 There are nine EphA receptors and five EphB receptors in the human 
genome. This classification is based on early insights with respect to the activating 
ligands. It was believed that the EphA receptors promiscuously interact with 
glycosylphosphatidylinositol-anchored ephrin-A ligands, while the EphB receptors 
promiscuously interact with the transmembrane ephrin-B ligands. More recently it has 
been shown that the EphA4 receptor and the EphB2 receptor are exceptional as they are 
capable of binding both A and B types of ephrins.178, 179 It has been demonstrated that the 
Eph receptors and ephrins are overexpressed in various tumor types.51 For example, the 
EphA4 receptor, normally only expressed in the developing brain, was found to be highly 
overexpressed in tumor cells of cutaneous T-cell lymphomas (CTCL),180 prostate cancer 
and pancreatic cancer.181, 182 The potential oncogenic properties of EphA4 became evident 
from studies on prostate and pancreatic cancer cell lines, where down regulation of 
EphA4 with siRNA reduced cell viability.183 These results suggest that EphA4 might be a 
promising target for pharmacologic intervention. Furthermore, it has been suggested that 
EphA4 inhibition might be beneficial for the treatment of spinal cord injuries.184, 185 These 
data validate the concept of developing EphA4 inhibitors as potential drugs and selective 
EphA4 blockers are therefore desired. Although high affinity kinase inhibitors show cross 
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activity towards EphA4186, 187 and small molecules can antagonize ephrin binding and 
EphA4 activation,188 none of these compounds has any specificity for EphA4. Therefore, 
our aim was to identify novel scaffolds capable of specifically inhibiting the EphA4 
kinase activity. Towards this end, we designed a detailed pharmacophore screening 
model, which targets the well described hinge region and gatekeeper189 residue in the 
ATP binding site. By using an in silico screening cascade, a database containing a large 
number of commercially available compounds was reduced to a small set of hit scaffolds, 





Materials and methods 
 
 
Kinase Inhibition Assay 
 
Kinase activity was measured using the ADP Hunter Plus assay kit according to the 
manufacturers (DiscoveRx, Birmingham, UK) recommendations. In this assay ATP 
turnover, and the subsequent generation of ADP, is measured in a two-step process. 
Reaction mixtures (20 µl) were prepared in black polypropylene 384 well flat bottom 
plates (Greiner, Stonehouse, UK) and contained 100 nM His-tagged EphA4-KD, 33 µM 
ATP (determined as Km for this kinase preparation), 200 µg/mL E4:Y1 (Sigma, St. 
Louis, MO) as substrate and increasing concentrations of inhibitors. Assay buffer (pH 
7.4) contains 20 mM NaCl, 15 mM HEPES, 20 mM MgCl2, 1 mM EGTA and 0.1% 
Tween20. After 75 min at 30oC, reagents A and B from the kit were added and the 
fluorescence intensity was measured with a Tecan infinite F200 Reader (Tecan, Grödig, 
Austria) after 60 min incubation at 30 oC, with an Ex of 535 nm and Em of 590 nm and 
25 reads per well. Standard curves, ranging from 30 nM to 75 µM ADP (dynamic range 
of the kit), were used as an internal assay control. Background was measured in reactions 
containing no substrate and subtracted from those containing E4:Y1. Dasatinib was used 
as a positive control. For confirmed hits, the effects of the inhibitors on the enzymes in 
the ADP detection step were determined in assay buffer and the reagents A and B only. 
 
 





The crystal structure of apo EphA4 kinase domain and the kinase domain bound to 
dasatinib have been elucidated.190 Briefly, purified apo kinase domain was used to grow 
crystals at 20°C using the sitting-drop vapour-diffusion method. The purified EphA4 
kinase domain was mixed with an equal volume of a reservoir solution containing 15-
21% polyethylene glycol 10K, 100 mM ammonium acetate and 100 mM bistris pH 5.5. 
Rod-like crystals appeared after 1-3 days. Crystals of apo protein were soaked in drops of 
compound 73 at 30 mM. After 6 hours incubation at 20°C, crystals were flash-frozen 
using 20% glycerol plus the reservoir solution. Diffraction data was collected at 100 K at 
the ESRF. Datasets at 2.12 Å resolution were merged and processed using XDS142 and 
Pointless143 from the CCP4144 suite and the structure was solved by molecular 
replacement using the program AMoRe.145 The apo EphA4 kinase domain was used as a 
search model. The structure was subsequently refined using the program PHENIX146 and 
the program COOT147 was used for model building. An overview of the quality of the 












Table 5.1: Data collection and refinement statistics. 
Data collection EphA4 in complex with 
compound 27 
PDB ID 2XYU 
Space group P212121 
Cell constant α=β=γ=90° a=32.54, b=91.54, c=97.95 
Resolution (Å) 2.12 
Total observations 17378 
Unique reflections 16232 
Completeness (%) 99.5 (98.2)a 
Rmergeb(%) 13.8 (69) 
Average I/σI 8.5 (1.9) 
Refinement  
Rwork/Rfree (%) 18.94/22.98 
Temperature factor (Å2) (Å) 20.96 
rmsd bond lengths (Å) 0.009 
rmsd bond angles (°) 1.024 
rmsd bond dihedrals (°) 12.221 
aValues in parentheses are for the highest resolution bin. 
bRmerge = ΣhklΣj |Ihkl, j - <Ihkl>|/ ΣhklΣj Ihkl, j , where I is the intensity for the jth measurement 
of an equivalent reflection with the indices h,k,l. 
 





The in silico screening of the EphA4 kinase domain, design and synthesis of new 
ligand as well as docking studies were performed by the Ph.D. candidate Oscar van 
Linden in the group of Dr. de Esch.  
The screening model describes the pharmacophore features needed for interactions 
between the EphA4 kinase domain (more specifically, the ATP binding site) and putative 
ligands. The apo structure of EphA4 (PDB ID: 2HEL)191 was one of the templates used to 
construct the model. To accurately define ligand-receptor interacting features, the apo-
EphA4 structure was superimposed on the crystal structures of two related kinases.192 
These crystal structures contain ligands which are known to have affinity for EphA4, 
namely AMPPNP and dasatinib (Fig. 5.1). AMPPNP, the structural analog of the 
endogenous substrate ATP, is expected to bind to the kinase domain in a similar fashion 
as ATP. Meanwhile, quantitative analysis of a variety of inhibitors using a panel of 
kinases revealed that the drug dasatinib has high affinity for the EphA4 receptor.187 The 
structure of EphA3 co-crystallized with AMPPNP and the structure of ABL1 co-
crystallized with dasatinib were superimposed on the apo-structure of EphA4. The 
binding mode of AMPPNP was derived from the EphA3-AMPPNP complex I (PDB 
ID:2QO9, Fig. 5.2A).193 The AMPPNP adenine ring interacts with the kinase hinge 
region by forming two hydrogen bonds with the backbone atoms of residues Met702 and 
Glu700. A third, water mediated, hydrogen bond to the adenine ring is formed by Thr699, 
the kinase gatekeeper residue. The ribose hydroxyl groups and phosphate oxygen atoms 






Figure 5.1. Structures of AMPPNP (left) and dasatinib (right). 
 
From inspection of the Abl1-dasatinib complex II (PDB ID: 2GQG, Fig. 5.2B),194 it 
is evident that the thiazole-2-amine moiety of dasatinib makes two hydrogen bonds with 
the kinase hinge region by interacting with the backbone atoms of Met318. An additional 
hydrogen bond to the hydroxyl group of the gatekeeper residue Thr315 is formed by the 
amide nitrogen. The orthogonally oriented 2-chloro-6-methylphenyl ring probes the 
ABL1 kinase hydrophobic back-pocket, a pocket that is often used in kinase inhibitor 
development to improve potency and increase selectivity over other kinases.189 The apo 
crystal structure of EphA4 was aligned with complexes I and II. The detailed side and 
top views of the superposed complexes (Fig. 5.2C and 5.2D) illustrate the binding modes 
of both ligands. 
The MOE-2007 Pharmacophore Query Editor was used for the generation of the 
pharmacophore query based on the superposed complexes. Combining the 
pharmacophore features of AMPPNP and dasatinib resulted in the identification of the 
well-known donor–acceptor–donor motif,195 visualized by the pharmacophore features 
F1, F3 and F5 (Fig. 5.2E). On the protein side, the corresponding features to F3 and F5 
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are shown (F2 and F6 respectively). These corresponding features in the screening model 
assure the correct directionality of a potential hydrogen bond donor / acceptor. The amide 
nitrogen atom of dasatinib forms a hydrogen bond with the gatekeeper residue Thr699, by 
donating a hydrogen to the hydroxyl oxygen atom of this threonine residue. This is 
indicated by pharmacophore feature F7. The threonine gatekeeper, however, is able to 
interact with ligands by either accepting or donating a hydrogen atom for hydrogen 
bonding. Pharmacophore feature F7 is therefore annotated as donor or acceptor and F8 
describes the corresponding feature to F7. Only ~20% of the eukaryotic protein kinases 
have a threonine residue as gatekeeper196 and specifically addressing interactions with 






Figure 5.2: A, binding mode of AMPPNP in EphA3 (complex I, PDB ID: 2QO9). B, 
binding mode of dasatinib in Abl1 (complex II, PDB ID: 2GQG). C, superposition of 
complexes I (green carbon atoms), II (orange carbon atoms) and the apo structure of 
EphA4 (light pink carbon atoms, PDB ID: 2HEL). D, detailed top view of superposed 
complexes I (green carbon atoms), II (orange carbon atoms) and apo-EphA4 (light pink 
carbon atoms). E, annotation of pharmacophore features; F1, F5 = H-bond donor, F6 = 
H-bond donor projection, F3 = H-bond acceptor, F2 = H-bond acceptor projection F4 = 
aromatic center, F7 = H-bond donor or acceptor, F8 = H-bond donor or acceptor 
projection. F, pharmacophore screening model, constrained by the exterior volume. The 
excluded volume on the amino acid residues that make up the shape of the binding site is 
not shown for clarity of presentation. Annotations of pharmacophore features are similar 
to that in Figure 5.4. 
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The cores of the adenine and thiazole rings make up the aromatic feature F4. To 
constrain the size of potential hit compounds, an exterior volume filter was created (Fig. 
5.2F) in the center of the ATP binding site. Around the carbon atom 5 of the dasatinib 
thiazole ring, a box of 11x10x7 (LxWxH) Angstrom was drawn in which the exterior 
volume was placed. The shape of the binding site was defined by the addition of an 
excluded volume which matched the van der Waals radii of the atoms from the residues 
that make up the binding site. These efforts led to a pharmacophore model that consists of 
eight features, which was used for the in silico screening of a database containing 
commercially available compounds 
 
In silico screening cascade 
 
The MOE-2007 Vendor Compound 3D Collection containing 2.7 million 
commercially available compounds, which were conformationally pre-sampled into 171.8 
million conformations, was subjected to an in silico screening cascade (Fig. 5.3). A 
pharmacophore query using the 2.7 million commercially available screening compounds 
and the eight features pharmacophore model were used as input. Seven out of eight 
pharmacophore features had to be addressed by a molecule in order to be selected as a 
hit. Pharmacophore features F2, F4, F6 and F8 were marked essential. The first 
conformation of a compound that obeyed all criteria of the pharmacophore model was 
selected as a hit and the screening automatically continued with the next compound in the 
database. After clustering and removal of structural analogs, this screen yielded a total of 




Next in the in silico screening cascade was an energy minimization step. The 
pharmacophore hit conformation of a compound was energy minimized inside the apo-
EphA4 binding site. During this experiment, the protein was kept completely rigid, with 
the exception of the gatekeeper threonine hydroxyl group. The behavior of each 
compound was carefully monitored during this energy minimization step. Compounds 
that retained hydrogen bond interactions with the protein hinge and gatekeeper residue 
were selected for further investigation. However compounds that lost these key 
interactions, or were even expelled from the protein binding site, were discarded.  
 
Figure 5.3: In silico screening cascade. The numbers of compounds processed in each 
step are indicated. 
 
The application of the energy minimization step yielded a set of 195 molecules that 
conformed to the criteria above. The molecules were subjected to a docking experiment 
using GOLD. The apo-EphA4 crystal structure, in which we introduced one mutation, 
was used for these docking studies. The sidechain of Lys653 was mutated into a 
methionine sidechain in order to overcome unwanted bias towards ionic interactions with 
the protonated nitrogen atom of the lysine. Ten poses for each compound were generated. 
Scoring and ranking of poses in the docking of fragments and drug-like molecules is still 
very challenging197 and therefore the poses were visually inspected. Here, the placements 
of the docked compounds were compared with the energy minimized poses of the same 
compounds generated in step 3 of the screening cascade. 
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Compounds that maintained key interactions (i.e., hydrogen-bonding) with the site 
were selected for further investigation. However, compounds that were docked with 
binding modes which deviated from the energy minimized poses, but were involved in 
hydrogen bonding with the hinge and gatekeeper residues, were also selected. This 
resulted in the identification of 80 compounds which were selected for purchase. Based 
on the availability, pricing and delivery times of these scaffolds, 27 compounds 
(including close structural analogs of in silico hits that were unavailable) were purchased 
at different vendors. The inhibitory properties of these compounds on the EphA4 kinase 
activity were tested in a phosphorylation inhibition assay. This assay resulted in the 
identification of 6,7,8,9-tetrahydro-3H-pyrazolo[3,4-c]isoquinolin-1-amine (24, Fig.5.4), 
a direct analog of in silico hit 25 which was unavailable for purchase. Compound 24 




Results from the pharmacophore screen and docking experiments were used to 
optimize the affinity for EphA4. The putative binding mode of 24 was derived from the 
in silico results of the structural analog 25 (Fig 5.4A). The proposed binding mode of 1, 
after pharmacophore placement, is shown in Figure 5.4B. The 5,6,7,8-
tetrahydroisoquinoline aromatic center matches the aromatic feature F4, while the 
nitrogen atom matches the H-bond acceptor feature F3. The vector projecting from this 
nitrogen atom intersects feature F2 that was marked essential. Pharmacophore feature F5 




donor extends towards the essential feature F6. The other pyrazolo nitrogen atom 
matches the acceptor/donor feature F7 and projects its hydrogen atom towards the 
essential feature F8. Upon docking of 25 using GOLD, however, a different binding 
mode for this scaffold was observed (Fig. 5.4C). In this pose, the scaffold is both rotated 
and flipped compared to the pharmacophore placement. Thus, the 5,6,7,8-
tetrahydroisoquinoline nitrogen atom is involved in hydrogen bonding with the threonine 
hydroxyl group of the gatekeeper. The pyrazolo NH group forms a hydrogen bond with 
the carbonyl oxygen atom of Glu700, while the other pyrazolo nitrogen atom is engaged in 
hydrogen bonding with the Met702 backbone NH group. The NH2 group of 4 forms a 
fourth hydrogen bond with the backbone carbonyl oxygen atom of Met702. Superimposing 
this binding mode with the pharmacophore model reveals that seven out of eight 
pharmacophore features are hit, including the marked essential features F2, F6 and F8. 
 
Figure 5.4. Comparison of alternative binding poses of in silico hit 25 during 
pharmacophore placement and after docking. Projecting vectors of hydrogen bond donors 
(purple), hydrogen bond acceptors (magenta) and aromatic centers (orange) are shown. 
A, structures of 24 and in silico hit 25. B, placement of 25 in the pharmacophore 
screening model. The EphA4 hinge and gatekeeper residues are shown for illustration. C, 
placement of 25 in EphA4 after GOLD docking. Dashed lines indicate hydrogen bonds. 
The pharmacophore model is added as illustration. 
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Inspection of Figure 5.4C reveals that the essential aromatic feature F4 is not 
contacted by 25 in the GOLD docking pose, as such, the scaffold would have been 
discarded during a pharmacophore screen which required that all eight pharmacophore 
features had to be addressed. However, a pose similar to the pharmacophore placement of 
25 was not observed during the GOLD docking experiment. The putative GOLD-derived 
binding mode indicates that the methyl group of 25 is pointing towards the hydrophobic 
back-pocket of EphA4 (Fig. 5.5A). In the Abl1 kinase complex II, this hydrophobic back 
pocket is occupied by the 2-chloro-6-methylphenyl moiety of dasatinib (Fig. 5.5B).  
 
 
Figure 5.5: A, GOLD-derived putative binding mode of 25 in EphA4 (PDB ID: 2HEL). 
B, binding mode of dasatinib in Abl1 (complex II, PDB ID: 2GQG). 
 
Upon superimposition of both complexes (image not shown), the methyl group of 
25 is located near carbon atom 1 of the 2-chloro-6-methylphenyl moiety of dasatinib. 
Thus, if the proposed binding mode of 25 is correct, growing into this hydrophobic back-
pocket on the methyl side of the fragment should be allowed and result in increased 
affinity for EphA4. To confirm this hypothesis, hit exploration experiments were 




compound concentration for inhibition of EphA4 kinase activity. The inhibition data 
indicated that introducing a phenyl substituent at position 5 of the 6,7,8,9-tetrahydro-3H-
pyrazolo[3,4-c]isoquinolin-1-amine scaffold  improved affinity (compound 26, Fig. 5.6). 
Therefore, synthesis of a series of 5-substituted analogues was performed. Among the 
compounds tested, a set of three compounds completely inhibited EphA4 activity 
exhibiting IC50 values between 2 and 8 µM. Therefore these compounds were submitted 
to structure determination via X-ray crystallography. Soaking experiments with 
compound 27 (IC50 4.5 + 0.5µM) yielded a 2.11 Å X-ray complex structure which is 
described below.  
 
Figure 5.6: Dose dependent inhibition of recombinant EphA4 kinase activity. The 
structures of compounds 24-27 are presented on the left. On the right, the enzyme 
inhibition curve of compounds 24, 26, 27 and dasatinib are shown. The curves represent 
the mean ± Standard Error of Mean (S.E.M) of the experiment performed in triplicate. 
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Crystal structure of the kinase domain of EphA4 in complex with compound 27 
 
To confirm the predicted binding mode of these scaffolds, efforts to soak compound 
27 into the available crystal of the EphA4 kinase domain were undertaken. Crystals of 
apo EphA4 (kinase domain aa 606-846) were grown and the structure was elucidated at 
1.7 Å (c.f. Chapter 4). Crystals of the apo protein were soaked in 30 mM 27 to obtain the 
complex, flash frozen and used to collect diffraction data to a resolution of 2.12 Å. The 
structure of the complex was solved using molecular replacement with the apo protein 
serving as the search model. The refined structure has been deposited at the protein data 
bank under the access code: 2XYU.  
Alignment of the structures of the apo kinase domain and the complex with 27 
indicates that the structure of the kinase is unchanged (r.m.s deviation of 0.179Å over 
228 Cα atoms). As predicted, compound 27 makes 4 hydrogen bond contacts within the 
hinge region of the kinase domain, between the tetrahydroisoquinoline core and Met702N, 
Met702O, Glu700O and Thr699OG1 (Fig. 5.7). The 5-fluoro-2-methyl-phenyl substituent makes 
extensive van der Waals interactions with Lys653, Glu670, Met674, Ile683 and Ile697. The αC 
helix is in the ATP proximal position allowing the formation of the conserved Lys653-
Glu670 salt bridge while the activation loop is in the “DFG-in” conformation, both of 






Figure 5.7: Structure of the complex of EphA4 with 27. The protein backbone is shown 
as a ribbon diagram. The compound and key residues of the protein with which it 
interacts are shown in a bond representation. The simulated annealing omit-map Fo-Fc 
electron density map contoured at 2.0 σ of 27 is also presented in mesh format. The 






Compound 27 was screened against a panel of 124 protein kinases at 10 µM compound 
concentration. It fully inhibits the all Eph kinases that were assayed, including EphA4 
(Fig. 5.8). However, there is only significant inhibitionof a few other protein kinases 
(including BTK, Lck, and YES1).199 Therefore, 27 seems to be a reasonably selective Eph 
kinase inhibitor, supporting the use of this scaffold in targeted EphA4 inhibition. 






















In this work we describe the fragment-based discovery of a novel EphA4 hinge 
binding compound. Using the structural information derived from crystal structures of 
two ligands bound to related kinases, a mixed pharmacophore model for the binding site 
of EphA4 was constructed. In silico screening efforts, using a virtual library containing 
commercially available compounds, led to the identification of a 6,7,8,9-tetrahydro-3H-
pyrazolo[3,4-c]isoquinolin-1-amine fragment i.e. compound 24. Subsequent optimization 
of this scaffold, by growing into the kinase hydrophobic back-pocket, resulted in the 
identification of an EphA4 inhibitor with 4.5 µM (IC50) activity. The binding  mode of 27 
was elucidated via X-ray crystallography and confirmed the predicted binding mode of 
this scaffold (PBD ID: 2XYU). Selectivity profiling against 124 protein kinases199 
revealed that this compound seems to be a moderately selective kinase inhibitor.  
The potential applicability of this scaffold was recently confirmed with the 
disclosure of a patent and publication by the Merck group.200, 201 The patent describes the 
[3,4-]isoquinolin-l-amine scaffold as an inhibitor of EphA4 (Fig. 5.9) for the treatment of 
diseases regulated by the EphA4 RTK signaling, such as neurological and 
neurodegenerative disorders and cancer. Meanwhile, the publication presents an 
extensive study, both in vitro and in vivo, of several compounds including 2 closely 
related to compound 27 (Fig. 5.9). The reported IC50 values of compounds 28 and 29 
were respectively of 1.5 and 2.1 μM which are consistent with the data presented in this 
work. Altogether, this data underscores the potential of our scaffold as a possible new 
drug for the treatment of cancer and neuronal injuries by inhibition of the EphA4 receptor 
tyrosine kinase.  




Figure 5.9:  Structures of compound 27, the scaffold and compounds 28 and 29 from the 



















Chapter 6   
 
Biophysical characterization of 







Major drug discovery efforts for novel targeted therapies of various human 
malignancies focus on the human kinome. Indeed, modulation of phosphorylation 
signaling pathways by small molecules has demonstrated considerable clinical efficacy in 
the treatment of devastating disorders such as cancer. Here we present the biophysical 
characterization of fragments interacting with the EphA4 receptor. Fragments discovered 
previously with the Target Immobilized NMR Screening approach, were characterized 
using Surface Plasmon Resonance (SPR) and [15N,1H]-HSQC experiments. We 
successfully developed a functional SPR assay for EphA4, binding affinities could be 
determined for several fragments and competition experiments with ATP were 
undertaken. Our results establish the utility of biophysical methods in the characterization 







From the approval of the first kinase inhibitor, imatinib45, for the treatment of 
chronic myelogenous leukemia (CML) in 2001 to the approval of vandetanib46 in early 
2011, protein kinases have developed into one of the most important target classes in 
oncology drug discovery. However, studies revealed that most approved kinase inhibitors 
have limited selectivity and target multiple kinases.47 EphA4, a receptor tyrosine kinase 
normally only expressed in the developing brain, was recently found to be highly 
overexpressed in tumor cells of cutaneous T-cell lymphomas (CTCL),180 prostate cancer 
and pancreatic cancer 58, 181, 182 suggesting that it might be a promising target for 
pharmacologic intervention. Furthermore, it has been suggested that EphA4 inhibition 
might be beneficial for the treatment of spinal cord injuries.60, 202  
Over the last decade, fragment based drug Discovery (FBDD) has been recognized as a 
powerful strategy to develop novel, small molecule drugs.105, 203 FBDD screens small 
libraries (1,000 - 20,000 compounds) of so-called drug “fragments” that are typically 
described by a “rule of threes”28 (Ro3, Mr < 300 Da, cLogP <3, H-bond donors < 3, H-
bond acceptors < 3, number of rotatable bonds < 3 and TPSA (total polar surface area) < 
60 Å2) for binding to the target. The crucial step in this drug discovery process is the 
reliable identification of the initial fragments that typically interact only weakly with the 
receptor due to their small size. Several biophysical methods such as NMR,126,27 protein 
crystallography204 and surface plasmon resonance (SPR)205 have been employed to 
identify such weak protein ligand interaction.  
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We have developed an NMR ligand screening approach, called Target Immobilized 
NMR screening (TINS) and have used the method to screen a fragment library for 
binding to the kinase domain of the EphA4 receptor (Chapter 3). We wished to compare 
the results of TINS and biochemical methods to those from alternative biophysical 
techniques such as Surface Plasmon Resonance (SPR) and [15N,1H]-HSQC 
(Heteronuclear Single Quantum Correlation) experiments. Thus the binding of all 
fragments discovered in Chapter 3 was studied by SPR. In addition, protein observed 
NMR was used to study the binding of fragments to the EphA4 KD under conditions 





Materials and method 
 
 
Protein purification for Surface Plasmon Resonance studies 
 
The enzymatically biotinylated AVI-KD of EphA4 was purified as described in 
Chapter 3, while the 6His fusion KD of EphA4 was purified as described in Chapter 4. 
 
Immobilization for Surface Plasmon Resonance studies 
 
All SPR studies have been performed using a Biacore T-200 instrument (GE 
Healthcare). Sensor Chip CM5 and NTA and the amine coupling kit were purchased from 
GE healthcare. All buffers were freshly prepared and filtered through 22 µm membranes. 
 
 
Immobilization of the 6His-Kinase Domain of EphA4: 
Capture was performed at 15 °C by injecting the His kinase fusion protein over a 
Ni-NTA chip previously charged with 0.5 mM NiCl2 at 10 µl/min for 5 min. The chip 
was regenerated with 1 M imidazole, followed by 350 mM EDTA and 2 M NaCl at 20 
µl/min. Injections were repeated until saturation or until the desired level was reached. 
The running buffer used in all subsequent binding and inhibition experiments was 
composed of 20 mM Tris Buffer, 200 mM NaCl, 1mM MgCl2, 0.05% Tween 20, pH 7.5 
with 5% of DMSO. On average, 3000 response units (RUs) of 6His-EphA4 were 
immobilized. 




Immobilization of the biotinylated Kinase Domain of EphA4: 
Coupling of NeutrAvidin (PierceNet Thermo Scientific) to the CM5 surface was 
performed using the amine coupling kit from GE healthcare according to the instructions 
of the manufacturer. In brief, NeutrAvidin was first dissolved (10 mM HEPES pH 7.5, 50 
mM NaCl and 0.01% Tween 20) at a concentration of 50 µM and then diluted to 5 µM in 
10 mM Na-acetate buffer at pH 4.8. The functional groups of the CM5 chip surface were 
first activated by injecting a mixture of carbodiimide (0.5 M) and N-hydroxysuccinimide 
(0.5 M), immediately followed by injecting the NeutrAvidin at a flow rate of 5 µl/min. 
The remaining activated carboxyl groups on the surface were blocked with 50 µM 
sodium hydroxide. Approximately 7500 response units (RUs) of NeutrAvidin were 
immobilized. The running buffer used in all subsequent binding and inhibition 
experiments was composed of 20 mM Tris Buffer, 150 mM NaCl, 2 mM MgCl2, 0.05% 
Tween 20, pH 7.5 with 5% of DMSO. The biotinylated protein was immobilized at a 
concentration of 5 µM for 5 min at 10 µl/min resulting in approximately 13000 RU of 
protein immobilized. As a reference, biotin was immobilized in the same conditions, 
reaching an immobilization level of approximately 80 RU. 
 
Analysis of fragment-EphA4 KD interactions by SPR biosensor 
 
Equilibrium binding experiments: 
A 100 mM stock solution of each compound in 100% DMSO was diluted into the 




containing 5% DMSO. For compound 27 from chapter 5, the stock solution of 500 µM in 
100% DMSO was diluted to 25 µM. For titration experiments, samples were injected in a 
series of 6 concentrations with a maximum of 750 µM or 1500 µM with the exception of 
compound 27 for which titrations were run with a maximum of 50 µM. These solutions 
were injected over the protein sensor surface for 25s at a flow rate of 30 µl/min and after 
every 25 injections the reference compound 27 was injected as a control at a single 
concentration of 25 µM. In addition, titrations of compound 27 were performed at the 
beginning and at the end of each plate, in order to assess the stability of the surface. 
These control measurements were performed to check both the stability and ligand-
binding activity of the immobilized proteins during a screen. SPR experiments using the 
6His fusion KD were performed at 15°C and those using the biotinylated KD were 
performed at 20 °C.  For the 6His fusion KD screen, regeneration of the surface between 
subsequent binding experiments was achieved by washing the surface extensively (30 s) 
with the running buffer plus 10% DMSO. Sensor responses were taken during each 
injection after a contact interval of 30 s. Report points at 5 seconds before the end of the 
injection were used for analysis. 
 
Data analysis: 
All sensorgrams were processed using a double-referencing method.206 First, the 
binding response from the reference surface was subtracted from the binding response 
from the surface containing EphA4 to correct for bulk refractive index changes. Second, 
the response from an average of the blank injections was subtracted to remove any 
systematic artifacts observed between the reaction and reference flow cells.  
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Assuming linearity between molecular weight and refractive index, the percentage 
of active protein immobilized could be estimated from the saturation response of the 






R ×=max                                           (1) 
Rmax is the saturation signal determined for the reference, Rprot is the signal measured 
for the amount of immobilized protein [RU], and MWcomp  and MWprot  are the respective 
molecular weights of reference compound and protein. 
 
Data was fitted using GraphPad Prism version 5.00 for Windows, GraphPad 
Software, La Jolla California USA. The KD value could be estimated using equation (2) 





= max                                              (2) 
Rmax, R, and C correspond to the normalized saturation response of the reference 
compound, the normalized response of the test compound, and the concentration of the 
test solution, respectively.   
 
Competition experiments: 
The competition experiments were performed by sequentially injecting the 
solution of the test compound (fragment), the reference compound at saturation 
concentration i.e. ATP (500 µM), and a mixture of fragment and reference compound 




(750 µM). A qualitative comparison of the signals observed for test compound, reference 
compound and mixture was then performed. For competition, experiments the running 
buffer was 20 mM Tris Buffer, 150 mM NaCl, 10 mM MgCl2, 0.05% Tween 20, pH 7.5 
with 5% of DMSO. In addition, a titration of ATP was performed. Samples were injected 
in a series of concentrations with a maximum of 1000 µM.  
The evaluation of competitiveness in this experiment required specific data 
analysis. Fragments displaying high affinity relative to the competitor and binding to the 
same binding pocket as ATP, showed a signal for the mixture (ATP + fragment) that was 
identical to the signal observed for the fragment alone. In the case of low affinity 
fragments, where saturation was difficult to reach, the response that would be observed if 
the compound is competitive with ATP for binding to EphA4 (i.e. binds to the ATP 
binding pocket) is given by the sum of the fractional occupancies (FO) of ATP and the 
fragment. The fractional occupancies of the mixture of the 2 compounds can be 











































            (4)  
 KD(A) and KD(B) are the equilibrium dissociation constants of the competing 
compounds, and CA and CB are the respective concentrations. In the case of competition 
between compounds of similar affinity and equal concentration, the occupancy of the 
binding sites by one of the components is heavily influenced by the presence of the other. 
From the estimation of the occupancies, the expected signals of the 2 compounds could 
be estimated using equation 5.  
)()()()( maxmax BRBFOARAFORobserved ×+×=                        (5) 
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in which Rmax(A) and Rmax(B) are the saturation responses of the 2 compounds and FO(A) 
and FO(B) are the respective fractional occupancies.  
  
 
Protein production for NMR studies 
 
The plasmid pET28b containing the kinase domain of EphA4 (amino acids 606-
846) was transformed in E. coli BL21 RP competent cells. The cells were incubated 
overnight at 37ºC on a LB/Kan/Cam (0.05 g/l Kanamycin, 0.034 g/l Chloramphenicol) 
plate. A single colony was inoculated in 50 ml M9 minimal medium  supplemented with 
0.3 g/l 15NH4Cl and 0.05 g/l Kanamycin, 0.034 g/l Chloramphenicol in a 250 ml flask. 
Five mL of the pre-culture was inoculated in 0.5 L M9 minimal medium (0.3 g/l, 
15NH4Cl, 0.05 g/l Kanamycin, 0.034 g/l Chloramphenicol). The cultures were grown at 
37ºC, shaking at 250 rpm to an OD600 of 0.6 before induction with 0.1 mM IPTG. At the 
same time the temperature was lowered to 18ºC and growth was continued overnight 
before harvesting. A cell pellet corresponding to 1 liter of culture was resuspended in 30 
ml of lysis buffer (50 mM Sodium phosphate pH 8.0, 300 mM NaCl, 20 mM imidazole, 
0.05% Tween 20, 10% glycerol and 0.01% beta-mercapto-ethanol) supplemented with a 
protease inhibitor cocktail (complete EDTA-free) from Roche, lysed using a French press 
and centrifuged at 37,000 х g for 45 min at 4°C. The supernatant was applied to a 5 ml 
HisTrap HP column (GE Healthcare) with a peristaltic pump at 4°C for 1 hour (Binding 
buffer: 20 mM Tris-HCl pH 7.6, 500 mM NaCl and 5 mM imidazole). After extensive 




The 6His fusion EphA4 was incubated with 20 mM ATP and 20 mM MgCl2 in order to 
fully activate it.  After an hour at 4°C, the protein was diluted 10 fold in 10 mM HEPES 
pH 7.5, 10 mM NaCl and applied to a 1 ml HiTrap Q column (GE healthcare) that had 
been pre-equilibrated with the same buffer. The fractions containing the EphA4 kinase 
domain, which did not bind to the column, were then concentrated to 5 ml and applied to 
a Sephacryl S-200 HR column (HiPrep 16/60; GE Healthcare) equilibrated in 10 mM 
HEPES, 500 mM KCl and 1 mM DTT.  
 
NMR sample preparation 
 
The 6-His fusion KD was concentrated using a Centricon-10 (Amicon). All protein 
samples contained identical buffer condition 20 mM HEPES, 150 mM NaCl, 2 mM DTT, 
pH 7.2, in 3% D2O. The sample for recording the apo protein spectra contained 80 μM 
15N-6His-KD. The sample for pH titration contained 100 μM of protein and the pH, 
ranging from 5.8 to 6.2, was adjusted with 0.1 M HCl or 0.5M NaOH. The samples for 
compound titration contained 100 μM of protein in buffer and 100 mM stock solutions of 




All NMR spectra were recorded at 298 K on a Brucker DMX600 spectrometer. 
[15N,1H]-HSQC were obtained with spectral widths of 28 ppm (15N) and 16.0 ppm (1H). 
Data was processed with Topspin 2.1 and analyzed with Sparky.208  





Development of SPR biosensor assay for EphA4 
  
Initially, the same immobilization strategy as the one used for TINS studies (c.f. 
Chapter 3), i.e. immobilization via the SNAP affinity tag was used for SPR biosensors 
studies. As a reference, the SNAP protein was immobilized in a separate channel. To 
establish the validity of the SPR assay, a well-characterized ligand was first titrated. As 
compound 27 was biochemically validated and the 3D structure was available (c.f. 
Chapter 5), this compound was chosen as a reference However, the titration of compound 
27 did not exhibit a concentration dependent response (Data not shown) suggesting that 
the SNAP mediated immobilization strategy was not suitable for SPR studies. 
As an alternative,, we attempted to immobilize the KD of EphA4 via the oligo 
histidine tag on an Ni-NTA sensor chip. Purified 6His fusion KD was captured on the 
sensor chip and a titration of compound 27 was performed (Fig. 6.1). As seen in Fig. 
6.1A, binding of 27 to the metal affinity immobilized KD was dose responsive and 
saturated at an appropriate level. The binding affinity of compound 27 was determined 
using equation (2) derived from the Langmuir adsorption isotherm (Fig. 6.1A).  Analysis 
of the titration data indicates that compound 27 binds with an affinity of 1 µM which is 
comparable with the affinity measured by biochemical assay (IC50= 4.5 µM, c.f. Chapter 
5). The IC50 of compound 27 is slightly higher than the KD, this was expected given that 




The kinetic association (ka) and dissociation (kd) constants for binding of 27 to 
immobilized EphA4 could be determined  by fitting the data to a 1:1 binding model. The 
fitting yielding values of ka =2 х 105 M-1s-1 and kd=0.5 s-1  (Fig. 6.1B). The resulting 
kinetically determined dissociation constant KD, of 2 μM matches the equilibrium affinity 
determined from the Langmuir isotherm.  
The binding curve in Figure 6.1 indicates that the saturation response for compound 27 is 
approximately 18 RU. Using the molecular weight of the immobilized protein and 
reference compound 27 (37,282 Da and 296 Da respectively) and the amount of 
immobilized protein (Rprot), the theoretical saturation response for 100% active protein is 
estimated to be 29 RU according to equation (1). Comparing the theoretical and 
experimental saturation responses, the percentage of immobilized protein that was active 
for ligand binding was estimated to be about 63%. Other known ligands such as ATP and 
ADP were assayed, but no binding was observed and therefore compound 27 was used as 
a reference for monitoring the stability of EphA4 during the SPR assay. 




Figure 6.1: SPR characterization of compound 27 binding to EphA4 6His-KD.  A) 
Representative saturation curve of compound 27 binding. The response signal is plotted 
against the concentration of compound 27. B) Sensorgrams measured at the following 
concentrations: 1.56, 3.125, 6.25, 12.5, 25 and 50 µM. The sensorgrams were processed 
using the double referencing method. The red lines overlaid on the experimental black 
curves result from the fit of the experimental data with the Biacore T200 evaluation 






Biophysical characterization by SPR of hits from SNAP fusion KD TINS screen 
 
Initially, compounds from the TINS screen of the SNAP fusion KD were selected 
and biochemically characterized (c.f. Chapter 3). We wished to compare the biochemical 
results to the SPR results. The SPR experiment was carried out on the 6His KD of EphA4 
immobilized on an NTA chip and 134 compounds were assayed at a single concentration 
of 750 μM. In order to compare the results from the SPR assay to the biochemical assay 
and the ligand screening results from TINS, compounds were categorized in groups for 
more clarity (Table 6.1). Compounds considered as hits in the TINS screen (for more 
details refer to Chapter 3) and demonstrating biological activity were classified in group 
I. Group II contained hits from the TINS experiment but that did not show biological 
activity. Fragments that exhibited inhibition in the enzymatic assay but were not 
considered as hits in TINS screen belonged to group III. Finally, negative controls i.e. 
compounds that did not show either binding in TINS experiment nor biological activity, 
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Table 6.1: Comparison of hits from TINS, biochemical assay and SPR. In the TINS 
screen of SNAP KD fusion, compounds were selected as binders when the T/R was lower 
than 0.4 (Chapter 3, fig. 3.5).For the enzyme inhibition assay, compounds were 
considered as inhibitors when the PIN was above 10 % (Chapter 3, table 3.1). Regarding 
the SPR experiments, fragments were identified as hits when the signal exceeded 3 times 
the SD and lower than the maximal theoretical response (see below). 
 Group I Group II Group III Group IV 








SPR positives 6  63  1  3  
SPR negative 6  48  1  6  
Total of 
compounds 
12 111 2 9 
E.I.: Enzyme inhibition assay 
 
Fragments were identified as hits in the SPR assay when the signal exceeded 3 
times the noise and the response was lower than the maximum theoretical response at 
saturation (i.e. binding was 1:1). Ill-behaved compounds were eliminated if they showed 
evidence of super stoichiometric binding, precipitation and/or  a sensorgram that 
indicates non-equilibrium behavior.209 Using these criteria, 73 out 134 compounds were 
considered as hits in this SPR assay. 
Half of the compounds from group I and a majority of compounds from group II 
were categorized as binders in the SPR assay suggesting a correlation between the SPR 
experiment and the TINS assay. As the detection window was quite small (11 RU in the 




to insufficient sensitivity. Moreover, the extremely high sensitivity of TINS (up to ~20 
mM KD)149 allows identification of many compounds that may not be detected in the SPR 
assay which has an upper limit of 2-5 mM under ideal conditions.210 
Of the compounds from group II that were hits in TINS and biochemically negative, 
63 were confirmed as hits in the SPR experiment suggesting that either these compounds 
bind too weakly to inhibit or that they bind at a non-biologically productive site. Out of 
the two compounds from group III, one fragment that was negative in TINS but positive 
in the bioassay was detected as positive in the SPR experiment. This compound was 
deemed to be a false negative for TINS. Interestingly, the other compound which was 
negative in both TINS and SPR, showed activity in the biochemical assay, possibly 
suggesting that the compound was a false positive in the biochemical assay. The 3 
compounds in group IV categorized as positive in the SPR experiments are probably false 
positives. 
In order to gather more biophysical information, the 73 well behaved compounds 
from the single concentration SPR assay were subsequently titrated. Compounds 
exhibiting low response at 750 μM (i.e. less than 0.5 x the Rmax observed for compound 
27) were titrated using a concentration range from 46 μM to 1500 μM. Meanwhile, 
compounds exhibiting a higher response in the single concentration assay were titrated 
using a concentration range from 23 to 750 μM.  Out of these 73 compounds, 12 
presented a clear concentration-dependent response. The binding affinity of these 
fragments was estimated by SPR to range from 0.75 to 3 mM (Appendix C). Out of these 
12 fragments, 3 were from group I and 9 from group II. Compounds from group III and 
IV were titrated but did not show any concentration dependent response.  
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For compounds 2, 3 and 8 from group I i.e. positive in the TINS screen and 
biochemical assay, the binding affinities were estimated to be 800±400, 900±400, 
1100±700 µM (Fig. 6.2). The measured responses were analyzed using a non-linear 
method derived from the Langmuir model  and points where the binding was less than 
5% of the maximum response are considered to be highly inaccurate and were ignored.211 
The large uncertainty derives from the fact that binding could not be saturated. 
It is known that the NTA surface has the inherent problem of leaching of the 
immobilized protein which leads to a “drooping” baseline.212 Consequently, it was 
difficult to determine with precision the binding affinities for many of the compounds 
analyzed. Despite a highly variable level of immobilization (between 1500 and 3000 RU, 
also frequently encountered with this immobilization strategy) and the leaching off the 
surface, useful data was still achieved and a rough estimate of the binding affinity could 
be determined for a few compounds. Nonetheless, a more stable system with a larger 
response window would clearly be advantageous.  
 
Figure 6.2: SPR analysis of fragment binding to EphA4 KD immobilized via the 6His 
tag. Representative saturation curves of compounds 2, 3 and 8 from Group I compounds. 




Biophysical characterization by SPR of hits from the Biotinylated KD TINS screen 
 
To further characterize the hits selected during the TINS ligand screen of the 
biotinylated KD, binding to EphA4 was characterized by SPR using the same 
immobilization approach as used in TINS. The kinase domain of EphA4 was 
enzymatically biotinylated at the AVI tag and captured on a biosensor chip via 
immobilized NeutrAvidin. To validate the assay, the binding of compound 27 was 
monitored and results were compared to those from the immobilization using the 6His tag 
(Data not shown). The KD of 27 for biotin immobilized EphA4 KD was estimated to be ~ 
1.9 μM and the percentage of active protein was approximately 95%. This binding 
affinity for compound 27 is similar to the one obtained with the 6His KD immobilization 
on the NTA chip (1.9 μM for the present immobilization compared to 1-2 μM for the 
immobilization on NTA chip) while the percentage of active protein is significantly 
higher. Further comparison of the two immobilization methods is presented below.  
A total of 62 compounds was selected as hits in the TINS experiment using 
biotinylated EphA4 (c.f. Chapter 3) and assayed for binding at a concentration of 750 μM 
via SPR technology. Of these 62 compounds, 51 were positive for binding in the SPR 
experiment, while 11 did not show binding, giving an 82% validation of the selected 
TINS hits. The well-behaved compounds (as previously defined) amongst the 51 binders 
were further analyzed to determine their equilibrium binding affinity by titration 
experiments. Reproducible, concentration dependent curves were obtained for 8 
compounds. Examples of the experimental binding curves are shown in Figure 6.4 for 
compounds 7 and 44 and in Appendix D for the remaining compounds.  Binding 
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affinities of these 8 fragments were estimated to range from 0.4 to 2.6 mM. The binding 




Figure 6.3 SPR analysis of fragments binding to EphA4 KD immobilized via 
NeutrAvidin. Saturation binding curves of compounds 7 and 44. The response signal is 
plotted against the concentration of each compound. Compounds 7 and 44 are 
represented in black and red respectively.  
 
 
Comparison of the two SPR immobilization approaches  
 
We wished to compare the relevance of the two SPR approaches: immobilization of 
6His fusion KD on the NTA chip and ligand capture of biotinylated EphA4. A total of 13 
compounds were tested in both SPR assays, 8 were positive in both assays and 3 were 
negative in both assays. Meanwhile 2 compounds were detected as binding in the SPR 
assay on the biotinylated KD but not in the 6His SPR assay. One possible explanation 




chip, the level of immobilization was significantly lower than the one in the ligand 
capture of biotinylated KD (3,000 RU vs. 13,000 RU). This resulted in a smaller window 
for ligand detection: ~11 RU for 6His KD immobilization vs. ~100 RU for biotinylated 
KD immobilization. It is likely that the SPR signal for these 2 compounds was close to 
the noise in the 6His KD immobilization, thus they appeared as false negatives. In 
addition, compound 32 was titrated using the 2 different immobilization procedures and 
the binding affinities obtained were very similar. (KD ~900±400 μM in the SPR screen of 




Competition binding experiments allow one to differentiate artifactual ligand 
binding from real binding and can provide insight into the binding site on the target. 
Given the inability to obtain crystal structures of screening hits bound to EphA4, the 
information from competition binding experiments could be used to enhance the 
reliability of computational docking experiments.  
Among the compounds titrated using SPR technology, compounds 7 and 44 
presented the highest affinity relative to the other fragments. Therefore, these two 
compounds were assayed for competitive binding with the natural ligand ATP using SPR. 
Since immobilization via enzymatic biotinylation proved superior, this approach was 
used to conduct the competition experiments. It was necessary to first demonstrate well-
behaved binding of ATP to the immobilized KD. Since kinases typically bind ATP as a 
complex with Mg2+, MgCl2 was included in the running buffer and binding of ATP was 
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now clearly observed. This result suggests that the reason for the lack of ATP binding to 
the SNAP-KD may have been the absence of Mg2+. ATP was subsequently titrated in 
order to determine the binding affinity (Fig. 6.4).  Binding of ATP to immobilized EphA4 
KD was characterized by kon and koff rates that were faster than the maximal detectable 
rates of the Biacore instrument, as has been previously observed for other kinases213 (Fig. 
6.5A). Hence, the KD value was calculated from the equilibrium response of the ATP 
injections at various concentrations. The fit of the Langmuir isotherm for ATP (Fig. 
6.4B) gave a KD value of 270 ±15 μM.  
 
Figure 6.4: A) Sensorgram of ATP binding to immobilized EphA4 KD measured at the 
following concentrations: 35.25, 62.5, 125, 250, 500 and 1000 µM.  B) Representative 




Two compounds that simultaneously bind to the KD would be expected to 
generate an additive binding response in SPR.214 In contrast, a compound that binds to the 
ATP binding pocket would compete with ATP and therefore give a non-additive response 
in SPR. Based on the crystal structure of compound 27 in complex with EphA4, which 
showed the compound bound in the ATP binding pocket, this particular compound was 
chosen to validate the SPR competition binding assay (Fig. 6.5). Compound 27 was 
tested in the presence and absence of ATP at a saturating concentration.  The SPR 
response observed in the presence and absence of ATP is the same for 27.  This result is 
what is expected when a 10 fold more potent ligand competes with a weaker ligand, i.e. 
complete displacement of the weaker ligand.   
Figure 6.5 summarizes the results of the competition experiments that were 
performed with fragments 7 and 44 versus ATP. In these cases, we observe that the signal 
of the mixture (black bars) is different from the individual signals of compounds 7 and 44 
(white bars) or ATP (dark gray bars). It has been shown that in the case of competition 
between compounds of similar affinity, the occupancy of the binding site lies between the 
individual occupancies and the sum of the 2 individual occupancies.207 The expected 
signal of the two compounds could be estimated using equations 4 and 5 in the material 
and method section.  
The response for the mixture (ATP + fragment) was calculated in the case of 
fragment competing with ATP for the same binding site (Rcalc competition, light gray 
bars). To be consistent, the response in case of noncompetition (i.e., in the case of 
independent binding sites for each of the compounds) was also calculated (Rcalc 
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noncompetitive, striped bars). When there is no competition, the expected signal is the 
sum of the two individual responses observed for the fragments.  
For compounds 7 and 44, the experimental responses for the mixtures ATP + 
fragment are closer to Rcalc competition than to Rcalc non competition (Fig. 6.5) Since the 
experimental binding response is closer to the expected result for competitive binding 
within experimental error, the data is strongly in favor of competition and suggest that the 
binding site of compounds 7 and 44 overlaps with ATP. These results imply that 
compounds 7 and 44 both bind at the ATP binding site. 
 
 
Figure 6.5: SPR analysis of competition binding experiments. The measured response 
for each compound is indicated by the white bars: compound 27 (2 µM) compounds 7 
and 44 (750 µM), the response for ATP (500 µM) by dark gray bars and the response for 
the mixture (ATP (500 µM) + compound (2 µM for compound 27 or 750 µM for 
compounds 7 and 44) is shown by black bars. The calculated signal for the mixture 
(ATP+7, ATP+44) expected for fractional occupancy of the same binding pocket using 
the measured affinities and known concentrations, is shown by the striped bars. The 
calculated signal for the mixture (ATP+7, ATP+44) expected for different binding 
pockets (i.e. non-competitive binding) is shown in light gray bars. The mean value is 




NMR characterization of apo-EphA4  
 
Specific binding of a small molecule to a protein will result in concentration 
dependent, observable changes of the NMR resonances of the protein.27 The most 
convenient manner to observe these spectral changes is to monitor the amide chemical 
shifts of a 15N labeled protein. Chemical shifts of both 1H and 15N amide atoms are 
recorded in the [15N,1H]-HSQC (Heteronuclear Single Quantum Correlation) spectrum. In 
addition, when the sequential assignment of a protein is available, analysis of chemical 
shifts perturbation data affords rapid access to low resolution structural data to 
characterize the ligand binding site.27, 215 [15N,1H]-HSQC NMR titration experiments were 
used to characterize binding of fragments to EphA4 at a pH equivalent to the one in 
crystallographic soaking experiments. While the resonance assignment of the kinase 
domain of EphA4 is not available, spectra of the kinase domain of EphB2 are of high 
quality, resulting in a complete backbone resonance assignment for this protein.133 The 
[15N,1H]-HSQC spectrum of uniformly 15N labeled EphA4 protein in the apo-form  is 
presented in Fig. 6.7. The spectrum displayed good resonance dispersion, however the 
spectrum was sufficiently different from that of EphB2 that the assignments could not be 
readily transferred. Even in the absence of assignments, chemical shift perturbation 
studies can be used to characterize binding of a fragment to a protein.  
 




Figure 6.7: [15N,1H]-HSQC spectrum of 80 μM 15N EphA4-KD. The resonance 
frequencies  of the [15N,1H]-HSQC spectrum of EphB2-KD are represented by blue 



















pH titration of 15N EphA4 KD  
 
Since it is well known that even small changes in pH can cause changes in the 
[15N,1H]-HSQC spectrum, it was important to first assess the sensitivity of EphA4 to pH. 
To do so the pH was titrated in small increments while monitoring the protein by 
[15N,1H]-HSQC NMR. Spectra were acquired at pH 5.8, 6.0, and 6.2 in order to 
investigate the possible effect of small changes to the pH used for crystal soaking (pH 6) 
potentially caused by titration of ligands to high concentration. The superimposition of 
the [15N,1H]-HSQC spectra at various pH values is presented in Appendix E, while the 
region showing peaks used for analysis of ligand binding is presented in Figure 6.8. 
There were no significant chemical shift differences observed in this pH range.   
 
 
Figure 6.8: pH titration of 15N EphA4 KD. A region of the overlaid [15N,1H]-HSQC 
spectra of 100 μM EphA4 KD is recorded at pH 5.8, 6.0 and 6.2. This region shows 
peaks used for analysis of ligand binding.  
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Titration of compound 27  
 
Initially the well characterized ligand 27 was used to assess the effect of compound 
binding on the [15N,1H]-HSQC spectrum of EphA4. Addition of compound 27 to 15N 
EphA4 KD resulted in significant changes in the [15N,1H]-HSQC spectrum. The 
resonances exhibiting the largest changes upon compound 27 binding are shown in 
Figure 6.9 while the full spectra are presented in Appendix F.  We observe that upon 
addition of compound 27, peaks 1-3 exhibit significant changes in resonance position that 
are primarily indicative of slow exchange (that is koff <<Δ(δbound-δfree)).  On the other 
hand, peak 4 showed both a gradual decrease in peak intensity and concentration 
dependent chemical shift change, suggesting intermediate exchange (that is koff ≈ 
Δ (δbound-δfree)).  As the resonance assignment of EphA4 is not available, these 4 
peaks, which report on ligands binding at the ATP site, are simply referred to by number. 
Since the binding of 27 to EphA4 could readily be detected, it was deemed worthwhile to 





Figure 6.9: NMR analysis of compound 27 binding to 15N EphA4 KD. A region of the 
overlaid [15N,1H]-HSQC spectra of 100 μM of 15N EphA4-KD with increasing 
concentration of compound 27 is shown. Peaks whose resonance position changes with 
increasing concentration of compound 27 are indicated with arrowheads and numbers. 
 
Fragment binding to 15N EphA4 KD 
   
Perturbations in the spectrum of EphA4 KD were monitored upon addition of 
different fragments. For clarity, we focused on a small region of the spectrum containing 
peaks reporting on binding to the ATP pocket as determined from the titration of 27 (Fig. 
6.10). We selected compounds 3 and 5 from the TINS screen of the SNAP fusion KD 
since they were also active in the enzyme inhibition assay yet negative for 
crystallography. Figure 6.11, shows that upon addition of compound 3, peaks 2 and 3 are 
shifted, meanwhile in presence of compound 5 peaks 1 and 3 are shifted. The same peaks 
are shifted in the presence of compound 27 (Fig 6.11B) and these peaks are not related to 
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a change in pH (Fig. 6.11C). It is likely that compounds 3 and 5 bind in a similar site as 
27 i.e. in the ATP binding site.  
 
 
Figure 6.10:  NMR analysis of ligand binding to EphA4-KD. A region of the overlaid  
[15N,1H]-HSQC spectra of 100 μM apo 15N EphA4-KD and in the presence of the 
indicated compounds is presented. Compound 3 (blue)and compound 5 (green) were 
added to 2 mM and compound 27 (yellow) was added to 100 μM. Peaks whose resonance 




















The initial plan of this collaborative research project was to develop potent, specific 
inhibitors of EphA4 kinase activity using both computational and experimental 
approaches. As we have seen, the computational approach has led to a reasonably potent 
and specific compound (27) for which a crystal structure has been elucidated bound to 
EphA4. Surprisingly, the experimental approach of using a biophysical assay for ligand 
screening and confirming with a biochemical assay has failed to yield a single compound 
for which a crystal structure could be determined. Moreover, several fragment screening 
hits were selected for elaboration studies but these did not lead to compounds with 
similar potency as 27. There are a number of possible explanations for these 
observations. One is that the form of the protein that was screened using TINS was not 
biologically relevant. A second is that the biochemical assay was not functioning as a 
proper filter to differentiate real from artifactual binding. The experiments described in 
this chapter aimed to determine whether either of these explanations were correct.  
Surface Plasmon Resonance (SPR) was employed to provide orthogonal 
biophysical characterization of the compounds binding to EphA4. To obtain high quality 
SPR data, the target protein has to be immobilized in a way that maintains its activity. 
The SPR characterization was conducted with 2 different recombinant proteins (6His 
fusion KD and biotinylated AVI fusion KD) using 2 different mechanisms of protein 
immobilization (via Ni-NTA surface and NeutrAvidin immobilized on CM5 surface). As 
compound 27 was biochemically validated and the binding mode was confirmed by 
crystallography (c.f. Chapter 5), this fragment was chosen as a reference compound for 
Biophysical characterization of fragments discovered with TINS 
 
 163 
all SPR studies. The kinetics for compound 27 binding to EphA4-KD immobilized via 
both methods were fit to a 1:1 binding model yielding kinetic constants ka =2 х 105 M-1s-1 
and kd=0.5 s-1, and a KD ~ 1.5 ±0.5 μM. This binding affinity is comparable with the 
affinity measured by biochemical assay (IC50= 4.5 µM, c.f. Chapter 5). The data 
suggested that both immobilization protocols resulted in an SPR assay capable of 
characterizing small molecules binding to immobilized EphA4 KD. However, 
immobilization of biotinylated KD presented several advantages when compared to 
immobilization of the 6His fusion EphA4 KD: (i) the level of immobilization is 
significantly higher yielding a greater window to study compound binding, (ii) 95% of 
the calculated binding capacity is retained and (iii) immobilization via the biotin 
NeutrAvidin interaction is more stable.  
Compounds selected as hits from the TINS screen were characterized by SPR using 
both Ni-NTA and biotinylated KD mediated immobilization. Overall, there was a good 
correlation between the results from TINS screen and the SPR characterization. 
Approximately 55% of the hits from the TINS screen on the SNAP-KD protein were 
determined as binders in the SPR assay, while 82% of TINS hit from the screen of the 
biotinylated KD were validated. Several compounds that were positive for binding in 
TINS may have been negative in SPR experiments due to the limited sensitivity of the 
method. It has been shown that dynamic range limitations of SPR can lead to false 
negatives.100 In SPR experiments, the observed response is directly proportional to the 
ratio [L]/KD. The lower limit of  [L]/KD leading to a detectable response in is in the order 
of 0.2.216 Since concentrations higher then 0.75-1 mM of ligand tend to lead to poor 




Compounds with weaker affinity than this will appear as false negatives in the SPR 
experiment. 
Subsequently well behaved fragment with reproducible curves that showed clear 
dose–response and the same qualitative sensorgram shape for each concentration were 
selected for titration. The binding affinities of several fragments could be estimated and 
ranged from 0.4 to 3 mM, approximately. However, the binding affinity could not be 
obtained for a majority of the compounds. There are several possible explanations for this 
observation. One is that the fragments were too weak and thus saturation could not be 
reached. In some case compounds may have exhibited promiscuous binding via a 
concentration-dependent aggregation mechanism.209 In addition, it may also have been 
possible that the stringent curation of the dose–response curves may have resulted in 
some false negatives.210   
The fragments with highest affinity and best SPR behavior were assessed for 
competition binding using ATP. The two compounds, 7 and 44, were originally selected 
from the two different TINS screen of EphA4 KD. Compounds 7 and 44 had reasonable 
ligand efficiencies of 0.3 and 0.25 (ΔG/# of heavy atoms) respectively and were likely to 
bind in the ATP binding site. In principle these compounds could form starting points for 
hit to lead studies to generate novel EphA4 inhibitors. Interestingly, compound 7 has a 
very similar structure to compound 27 (Figure 6.11) and the affinity is similar to 
precursors of 27 that lack the attached derivatized benzene ring. The X-ray 
crystallographic structure of 27 showed that it binds the hinge region of the ATP binding 
site. Based on the similarity to compound 27, it seems likely that compound 7 exhibits a 
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closely related binding mode to EphA4 KD, that is, it forms hydrogen bonds to the 
backbone atoms of the hinge residues. 
 
 
Figure 6.11: Structures of compound 7 (left) and compounds 27 (right). 
 
In order to investigate whether the low yield of fragment structures obtained with 
X-ray crystallography was related to the difference in pH between screening and 
biochemical characterization on the one hand and crystallography on the other, protein 
observed NMR was employed. [15N,1H]-HSQC spectra of EphA4-KD were acquired in 
the presence of different fragments at the same pH as for crystallography i.e pH~6.0. The 
experiments conducted on fragments 3 and 5, indicate that the change in pH does not 
preclude compound binding for these 2 fragments. These compounds were submitted to 
X-ray crystallography but exhibited weak diffraction i.e. higher than 7 Å.  
The lack of crystal structures of compounds from the TINS screen, in addition to 
the odd behavior of the compounds in the biochemical assay, lead us to question the 
relevance of the TINS screen. In this chapter, SPR and [15N,1H]-HSQC NMR were used 




44, each originating from a different TINS screen, were shown to bind to the ATP 
binding site. The similarity of the structure of compound 7 and 27 suggests that the same 
compounds found computationally have also been found experimentally, a reassuring and 






















Chapter 7   
 
 

















Due to their involvement in a large number of pathologies, protein kinases present 
an important pharmacological interest. Among this family, EphA4 has been recognized to 
be differentially expressed in various human tumors.  The aim of the research project that 
forms the subject this thesis was to develop potent, specific inhibitors of EphA4 kinase 
activity using both computational and experimental approaches. 
 
Target Immobilized NMR screen applied to the EphA4 kinase domain 
 
As described in Chapter 2, nuclear magnetic resonance spectroscopy (NMR) is a 
powerful tool that can provide important information at each and every step of drug 
development. From ligand screening to hit validation, NMR is commonly used for 
characterizing the structure and molecular dynamics of target or ligand molecules. During 
structure-based lead optimization, NMR gives insight into the structural and dynamic 
properties of the target-ligand complex. NMR screening methods range from the 
detection of signal from protein observed to ligand-observed methods. Recently, we 
developed a screening method called target immobilized NMR screening (TINS), in 
which a target and a reference protein are immobilized on solid media and binding of 
fragments to the immobilized proteins is monitored by NMR. Among the advantages of 
this method is the small amount of protein required as TINS uses a single sample of the 
target to screen an entire fragment library. 
In Chapter 3, a fragment library was initially screened against the Kinase Domain 
(KD) of EphA4 using the TINS technology. In order to insure the physiological relevance 
of ligands discovered using TINS, it was important to retain full enzymatic activity of 
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EphA4 upon immobilization. Therefore a number of immobilizations chemistries were 
investigated and we determined that oriented immobilization mediated by an affinity tag 
was required in order to obtain a functional immobilization of EphA4 KD. Subsequently, 
TINS was applied to the SNAP fusion KD of EphA4 using two different T2 relaxation 
periods of 80 ms and 2 ms. These screens resulted in a 6.8% and 3.9 % hit rate 
respectively, with a final set of 180 fragments which were selected for further 
characterization using a kinase inhibition assay. 
Subsequent SPR studies described in Chapter 6 yielded an alternative means of 
immobilization via interaction between enzymatically biotinylatedEphA4 and 
streptavidin covalently bound to a bead. Since the biotin mediated immobilization yielded 
more biochemically active enzyme, the same technique was employed to perform an 
additional TINS screen. The results from this second screen were compared to those from 
the SNAP-KD screen. Despite the fact that TINS screens typically exhibit good 
reproducibility, little correlation was observed between the two screens and the TINS 
profiles were different. At this point it was not clear where the variability came from. 
Moreover, the protein was successfully crystallized using different protein batches and 
yielded several structures as described in Chapters 4 and 5 and below. Thus variation in 
the quality of the protein preparation was not a likely source of the unexpected results. As 
a functional SPR assay was developed, the technique was employed to investigate the 
source of this variability. 
In Chapter 6, two compounds (compounds 7 and 44), each originating from a 
different TINS screen, were characterized with SPR and shown to bind to the ATP 




which the crystal structure was determined bound to EphA4 KD (Chapter 5). Based on 
the structural similarity of compounds 7 and 27, it seems that the same chemical scaffold 
has been found both computationally and experimentally, suggesting that both 




Many strategies are available for obtaining crystals of protein-ligand complexes. 
The most resource-effective method of obtaining the structure of a protein–ligand 
complex is by soaking the ligand of interest into apo protein crystals. Therefore, the first 
step was to obtain diffracting crystals of apo-EphA4. (Chapter 4) Crystallographic 
experiments were undertaken with the support of the Nederlands Kanker Instituut (NKI-
AVL) in Amsterdam and the structure of the native EphA4 kinase domain was elucidated 
(PDB ID: 2Y6M). In addition, the crystal structure of EphA4 in complex with dasatinib 
was solved (PDB ID: 2Y6O) and revealed a binding mode closely related to the one 
exhibited by Src family members, c-Src and Lyn. Analysis of the two structures revealed 
a hydrophobic back-pocket in the ATP-binding site of EphA4 which was unknown 
before. The access to this hydrophobic pocket is governed by the gatekeeper residue.172 It 
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Discovery of a series of potent and specific inhibitor 
 
In parallel, a computational approach toward EphA4 was performed by the Ph.D. 
candidate Oscar van Linden in the group of Dr. de Esch in Amsterdam (Chapter 5). 
Using the structural information derived from crystal structures of two ligands bound to 
related kinases, a mixed pharmacophore model for the binding site of EphA4 was 
constructed. An in silico screening procedure led to the identification of a 6,7,8,9-
tetrahydro-3H-pyrazolo[3,4-c]isoquinolin-1-amine fragment. Optimization of this 
scaffold by growing into the kinase hydrophobic back-pocket discovered in the apo 
structure of EphA4, resulted in the identification of compound 27. Soaking experiments 
were undertaken to obtain structural information and yielded a 2.11Å X-ray structure of 
the EphA4 – inhibitor complex. The binding mode observed in the crystal structure was 
in concordance with the binding mode of the scaffold as proposed by the initial in silico 
work (PBD ID: 2XYU). This compound was further biophysically characterized using 
Surface Plasmon Resonance (SPR) technology in Chapter 6 and the binding affinity was 
estimated to be 2 μM. The kinetics for compound 27 binding to immobilized EphA4-KD 
were fitted to a 1:1 binding model yielding kinetic constants ka =2.155 х 105 M-1s-1 and 
kd=0.497 s-1, and a KD ~ 1-2 μM. This binding affinity is comparable with the affinity 







Development of a functional SPR assay for characterization of small molecules 
binding to EphA4 KD 
 
SPR was employed to provide biophysical characterization of the compounds 
binding to EphA4. The SPR characterization was conducted with 2 different recombinant 
proteins (6His fusion KD and biotinylated KD) using 2 different mechanisms of protein 
immobilization (via Ni-NTA surface and NeutrAvidin immobilized on a CM5 surface). 
Binding of compound 27 was characterized by SPR using the two different 
immobilization procedures and was found to be optimal with the biotinylated protein. 
Immobilization of biotinylated KD had several advantages when compared to 
immobilization of the 6His fusion EphA4 KD: (i) the level of immobilization is 
significantly higher yielding a greater window to study compound binding, (ii) 95% of 
the calculated binding capacity is retained and (iii) immobilization via the biotin 
NeutrAvidin interaction is more stable. 
 
Biochemical and biophysical characterization of the TINS fragments hits 
 
The hits obtained with TINS were biochemically characterized using an enzyme 
inhibition assay. Surprisingly, most of the compounds did not exhibit any inhibition of 
EphA4 activity while only 15% of the fragments exhibited biological activity. Among the 
fragments that were characterized as inhibitory, most presented peculiar dose response 
curves with a steep Hill slope and the curves appeared to level at less than 100% 
inhibition. One possible explanation for the biochemical data was either aggregation or 
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precipitation of the compounds. However, these explanations were deemed unlikely as 
the library used for the screen was carefully designed and tested for solubility. However, 
a moderate number of compounds were found that exhibited some inhibition and 
presented an interesting chemical scaffold were therefore selected for crystallographic 
structure determination. 
As the soaking experiments successfully yielded a structure of compound 27 in 
complex with EphA4, compounds originating from TINS were submitted to the same 
procedure. However, none of the fragments yielded a structure. Most of the crystals that 
had been soaked with a fragment did not diffract to high resolution and when they did, 
the experimental electron density map that could be obtained revealed no density for the 
ligand. As there is a pH difference between the crystallographic conditions and the 
biochemical assay, this could negatively influence binding of the fragments. Thus protein 
observed NMR was employed in Chapter 6 to investigate whether the pH difference 
could be the cause for the lack of crystal structures. [15N,1H]-HSQC experiments on 
EphA4-KD were conducted and indicated that the change in pH does not preclude 
compound binding for the 2 fragments assessed. To gain further insight into the possible 
sources of the difficulties to obtain protein-ligand structures, SPR characterization of the 
fragments was performed. 
Compounds selected as hits from the TINS screen were characterized by SPR using 
both Ni-NTA and biotinylated KD mediated immobilization. For simply detecting 
binding, a good correlation was observed between the results from the TINS screen and 
the SPR analysis: 55% of the hits from the TINS screen of the SNAP-KD protein and 




compounds with weaker affinity than 4 mM could have been characterized as false 
negatives in SPR due the dynamic range limitations of SPR (Chapter 6). The binding 
affinities of several fragments could be estimated and ranged from 0.4 to 3 mM. 
However, for a majority of the compounds the binding affinity could not be obtained. 
Many factors likely contributed to the inability to determine the affinity including: the 
fragments may bind too weakly and thus saturation could not be reached, compounds 
may have exhibited promiscuous binding via a concentration-dependent aggregation 
mechanism and it may also have been possible that the stringent curation of the dose–
response curves may have resulted in some false negatives. 
SPR competition experiments using ATP were performed on two compounds 
presenting the highest affinity. The two compounds, 7 and 44, were originally selected 
from the two different TINS screen of EphA4 KD and were shown to bind to the ATP 
binding site. Compounds 7 and 44 had reasonable ligand efficiencies of 0.3 and 0.25 
(ΔG/# of heavy atoms) respectively. These compounds constitute starting points for the 














Generally, fragments are identified using a biophysical screening method, 
supported by a biochemical assay to validate their biological relevance. Using only 
affinity to guide drug discovery has been successful in numerous HTS campaigns in 
which potent hits are uncovered.17 However, in our case, most of the fragments did not 
display biological activity in the biochemical assay even if their binding was 
demonstrated with both TINS and SPR approaches. It is likely that the biochemical assay 
used in this project was not sensitive enough for weak inhibitors. As a biological assay is 
am important tool in a drug discovery project, it is important to carefully develop and 
select a relevant methodology. 
Once hits are identified, their binding needs to be confirmed and the three 
dimensional structure of the protein-fragment complex should be determined, ideally by 
X-ray crystallography. Among the approaches available to obtain protein-ligand 
structures, soaking fragments into existing crystals was chosen in this study. The soaking 
approach yielded a protein ligand structure for compound 27 but was unsuccessful with 
the compounds originating from the TINS screen. It is possible that the protein 
conformation was not optimal for ligand binding of some ligands, or the fragments were 
not sufficiently ordered to yield observable electron density. As most of the crystals did 
not diffract to high resolution, it would be interesting to investigate post-crystallization 
treatments for improving diffraction quality of protein crystals.217 Furthermore, another 
approach for obtaining structures of ligand-target complexes, cocrystallization, has been 




resource intensive and therefore not realistic for the large numbers of fragments assayed 
in this project. However, in the few cases where the diffraction quality of the fragment 
soaked crystals was low, it would be interesting to perform co-crystallizations 
experiments on EphA4 KD with confirmed hits from TINS. 
In this study, the in silico approach led to the identification of compound 27, a 
6,7,8,9-tetrahydro-3H-pyrazolo[3,4-c]isoquinolin-1-amine fragment. This compound was 
demonstrated to be reasonably potent and the binding mode was elucidated via 
crystallography. Selectivity profiling against 124 protein kinases199 revealed that this 
compound appeared to be a reasonably selective kinase inhibitor. Moreover, this scaffold 
was recently disclosed in a patent and publication by the pharmaceutical company Merck 
200, 201 thus confirming the potential of this scaffold for generating EphA4 inhibitors. It is 
interesting to note that a small academic collaboration discovered the same chemical 
scaffold as a large pharmaceutical company with, one assumes, considerably less 
resources. Considering the selectivity of this compound, even though moderate, and the 
ligand efficiency of 0.35, it represents an interesting starting point to design specific 
inhibitors. Further improvements of this scaffold could lead to a new drug for the 









Appendix A: Summary of the compounds studied in this thesis 
The compounds studied in this thesis are all presented in the table below with the 
corresponding structure, molecular weight, origin, and when available biochemical data 














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































a Origin of the compound: fragments from the TINS screen made on the SNAP fusion 
KD at either 80 ms or 2 ms (Binder SNAP 80 ms or 2ms), Non binders from the same 
screen (Non binder SNAP 80 ms), compounds selected or optimized during the in silico 
screen (In silico), hits selected from the TINS screen made on the biotinylated KD 
(Binder Biot 2 ms) 
b Percentage of inhibition (P.I.N) of the compound at a concentration of 500 µM in the 
biochemical assay. Above 6% of inhibition, compounds are considered as inhibitory. 





Appendix B. Enzyme Inhibition Data for Selected TINS screening hits. 
 
Enzyme inhibition curves for selected hits from the TINS screen. All data was 
generated by Wim Zoutman in the laboratory of Cornelis Tensen at the LUMC.  As a 
reference, the dasatinib dose-response curve is shown in black. Each curve represents the 
mean ± S.E.M of experiments performed in triplicate. Curve fitting was performed using 
GraphPad Prism version 5.0 using a sigmoidal dose response curve model with variable 
slope. Inhibitory constants, upper and lower asymptote values and Hill coefficients for 
each fragment are provided in the table.  
In the program Prism, the curves are fitted to the equation: 
y = bottom + [(top-bottom) / (1+10(Log IC50–x) – Hill slope)] 
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Appendix C:  SPR analysis of fragment binding to EphA4 KD immobilized via the 
6His tag.  
In Chapter 6, SPR experiments were conducted on the 6His EphA4-KD. After 
elimination of ill-behaved compounds, 73 out of 134 compounds were considered as hits 
in this SPR assay. Twelve of them presented a clear concentration dependent response 
curve. The representative saturation curve of each compound and an estimation of the 
equilibrium dissociation constant are summarized in the table below. The response signal 




































































































Appendix D: SPR analysis of fragment binding to EphA4 KD immobilized via 
NeutrAvidin.  
In Chapter 6, SPR experiments were conducted on EphA4 KD immobilized via 
NeutrAvidin. A total of 62 compounds were selected as hits in the TINS experiment on 
the biotinylated EphA4 (Chapter 3) and assayed for binding by SPR. Out of these 62 
compounds, 51 were positive for binding and reproducible concentration dependent curve 
could be obtained for 8 of them. A representative saturation curve of each compound and 
an estimation of the equilibrium dissociation constant are summarized in the table below. 




































































Appendix E:  pH titration of 15N EphA4 KD.  



































Appendix F:  NMR analysis of compound 27 binding to 15N EphA4 KD.  
Overlay of [15N,1H]-HSQC spectra of 100 µM of 15N EphA4-KD with increasing 






Appendix G:  NMR analysis of ligand binding to KD EphA4  
A region of the overlaid [15N,1H]-HSQC spectra of 100 μM 15N-KD is presented. Overlay 
of the spectra of: apo –protein (red), EphA4 KD upon titration of 2 mM compound 3 
(blue), EphA4 KD upon titration of 2 mM of compound 5 (green) and EphA4 KD upon 
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In multicellular organisms, communication between individual cells is essential 
for the regulation and coordination of complex cellular processes such as gene 
expression, metabolic pathways, cell growth and differentiation. Receptors tyrosine 
kinases or RTKs are cell surface receptors that regulate such cellular processes, but also 
have a critical role in the development and progression of many types of cancer. The 
overexpression of EphA4, a member of the RTK family, has been observed in a variety 
of malignant carcinomas including gastric cancer and cutaneous lymphomas among 
others. Therefore, the aim of the research project that is associated with this thesis was to 
develop high affinity inhibitors of the tyrosine kinase EphA4.  
Fragment-based drug discovery (FBDD) has been particularly successful in 
developing kinase inhibitors. Chapter 1 presents the drug discovery process and 
introduces the notion of FBDD. Historically, most pharmaceutical companies have used 
combinatorial chemistry and high throughput screening (HTS) to identify active 
molecules. In the past decades, FBDD has emerged as an alternative method used for 
finding lead compounds. This approach is based on identifying small molecules, or 
fragments (< 300 Da), which may bind only weakly to the biological target, and then 
growing them or combining them to produce a lead with a higher affinity. To detect weak 
binding of fragments to a protein, biophysical methods such as Nuclear Magnetic 
Resonance (NMR) are required.  Chapter 2 presents an overview of biomolecular NMR 
in drug discovery. From ligand discovery to in cell applications, NMR is used at each 
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stage of the drug discovery process. Due to the sensitivity of the technique, NMR is the 
most frequently used method of fragment screening.  
In this project, ligand discovery was based on two complementary approaches, a 
computational screen and an NMR based screen using Target Immobilized NMR 
Screening (TINS). The TINS technology involves immobilization on resin of a target 
protein and a reference protein with minimal small molecule binding properties.  
Identification of fragments which bind specifically to the target can be done by simple 
comparison of the 1D 1H signal intensities of the fragments in the presence of the 
reference or target.   In Chapter 3, the TINS approach was applied to EphA4. A portion of 
the receptor, the kinase domain which contains the catalytic function, was chosen as the 
target protein. Several immobilization strategies were investigated in order to yield a 
functional protein on resin and the target was subsequently screened. The hits obtained 
were biochemically characterized and selected compounds were submitted to 
crystallographic structure determination. The biochemical data yielded a surprisingly low 
validation rate of the compounds, and crystallography failed to give structures of 
fragments in complex with EphA4. Thus an alternative immobilization was investigated 
and an additional TINS screen was performed. Furthermore, analysis of putative 
fragment binding using orthogonal biophysical methods including Surface Plasmon 
Resonance (SPR) and protein observed NMR was employed as described in Chapter 6. 
The crystal structure of the EphA4 kinase domain was solved in Chapter 4. In 
addition, the structure of the kinase domain in complex with dasatinib, a well-known 
kinase inhibitor, was also elucidated. The two structures were examined and compared 




hydrophobic back pocket in the ATP binding site of EphA4 kinase domain which was 
unknown before. This newly discovered pocket, when followed up, could lead to 
inhibitor specificity during drug design.   
In parallel to the NMR based screen, a computational approach towards EphA4 
was performed by the Ph.D. candidate Oscar van Linden in the group of Dr. de Esch in 
Amsterdam (Chapter 5). This in silico approach yielded an interesting and potent 
inhibitor of the kinase domain. This compound was biophysically characterized using 
SPR in Chapter 6. Furthermore, soaking experiments into crystals of the native EphA4 
were undertaken and the binding mode was elucidated (Chapter 5). 
The same soaking procedure was employed with the compounds originating from 
the TINS screen, however none of the fragments yielded a structure (Chapter 3). As the 
crystallographic conditions are far from physiological pH, [15N,1H]-HSQC NMR 
experiments were conducted to test ligand binding at the pH used for crystallography in 
order to investigate whether this difference could be the cause for the lack of crystal 
structures (Chapter 6). Results show that, for the compounds assessed, the change in pH 
does not preclude compound binding.   
Biophysical characterization of the compounds previously identified in Chapter 3 
was conducted using SPR technology (Chapter 6). Several immobilization strategies were 
investigated and a good correlation was observed between the results from the TINS 
screen and the SPR analysis. In addition, two fragments were assessed for competition 
binding using ATP, and were shown to bind in the ATP binding site. Although the 
binding mode could not be determined via X- ray crystallography, the similarity of 
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structures between one of these fragment and the potent inhibitor discovered via in silico 
suggested a similar binding mode.  
Finally, Chapter 7 describes the conclusions and perspectives of this thesis. This 
research project led to the identification of several compounds that were biochemically 
and biophysically characterized. The in silico approach discovered a potent inhibitor of 
EphA4 for which the binding mode was elucidated via X-ray crystallography. Moreover, 
the TINS approach identified two compounds that may constitute starting points for the 
generation of more potent EphA4 inhibitors. Further improvement of these compounds 
could lead to the development of a new drug for the treatment of cancer and neuronal 



















Communicatie tussen individuele cellen in meercellige organismen is essentieel 
voor de regulatie en coördinatie van complexe cellulaire processen zoals gen expressie, 
metabolisme, cel groei en differentiatie. Receptor Tyrosine Kinases of RTK’s zijn 
receptoren die aan de cel oppervlakte dit soort cel processen reguleren, maar ze spelen 
ook een kritieke rol in de ontwikkeling en vooruitgang van diverse soorten kanker. De 
over-expressie van EphA4, lid van de RTK familie, is waargenomen in diverse 
kwaadaardige carcinomen zoals onder andere darmkanker en huidlymfomen. Daarom is 
het doel van het onderzoek gerelateerd aan dit proefschrift het ontwikkelen van hoge 
affiniteit remmers voor tyrosine kinase EphA4. 
Fragment –based drug discovery (FBDD) is een succesvolle techniek gebleken 
voor de ontwikkeling van kinase remmers. Hoofdstuk 1 beschrijft het proces van 
medicijn ontwikkeling en introduceert het begrip FBDD. In het verleden hebben de 
meeste farmaceutische bedrijven gebruik gemaakt van combinatorische chemie en 
experimenten met een hoge doorvoer oftewel high throughput screening (HTS) om 
actieve moleculen te identificeren. De laatste jaren is FBDD naar voren gekomen als 
alternatieve methode om interessante moleculen te vinden. Deze methode is gebaseerd op 
de identificatie van kleine moleculen of fragmenten (<300 Da), die misschien maar zwak 
aan het biologische doelwit binden, om ze vervolgens uit te breiden of the combineren tot 
een molecuul met een hogere affiniteit. Om de zwakke binding van fragmenten aan een 
eiwit te detecteren zijn biofysische methoden zoals kernspinresonantie (Nuclear 
Magnetic Resonance, NMR) noodzakelijk. Hoofdstuk 2 geeft een overzicht van 
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biomoleculaire NMR in geneesmiddelenontwikkeling. Van de ontdekking van liganden 
tot “in cel” applicaties, NMR wordt gebruikt binnen elke fase van het proces van 
geneesmiddelenontwikkeling. Vanwege de gevoeligheid van de techniek, is NMR de 
meest gebruikte methode voor het screenen van fragmenten. 
In dit project zijn twee complementaire methodes gebruikt voor het vinden van 
liganden: een computersimulatie en een NMR gebaseerde methode, Target Immobilized 
NMR screening (TINS). Bij TINS technologie worden het eiwit van interesse en een 
controle eiwit, met de eigenschap minimale binding van kleine moleculen te vertonen, 
geïmmobiliseerd op sepharose bolletjes. Identificatie van fragmenten die specifiek aan 
het eiwit van interesse binden vindt plaats door simpele vergelijking van de 1D 1H 
signaal intensiteiten van de fragmenten in aanwezigheid van eiwit van interesse of 
controle eiwit. In hoofdstuk 3 wordt beschreven hoe de TINS technologie toegepast 
wordt op EphA4. Een deel van de receptor, het kinase domein met katalytische functie, is 
gekozen als eiwit van interesse. Verschillende immobilisatie technieken zijn onderzocht 
teneinde functioneel eiwit aan sepharose bolletjes te verkrijgen. De verkregen treffers zijn 
biochemisch gekarakteriseerde en geselecteerde organische verbindingen, die zijn 
gebruikt voor structuur bepalingen middels kristallografie. De biochemische 
karakterisatie leverde een verrassend lage validatie ratio op van deze organische 
verbindingen en kristallisatie heeft niet geleidt tot een structuur van fragmenten in 
complex met EphA4. Om deze reden is een alternatieve wijze van immobilisatie 
onderzocht en een tweede TINS experiment uitgevoerd. Daarnaast is vermeende 




methoden zoals Surface Plasmon Resonance (SPR) en eiwit observatie in NMR zoals 
beschreven in hoofdstuk 6. 
Het oplossen van kristalstructuur van het EphA4 kinase domein is beschreven in 
hoofdstuk 4. Daarnaast is de structuur opgehelderd van het kinase domein in complex 
met dasatinib, een bekende kinase-remmer. De twee structuren zijn onderzocht en 
vergeleken met de kristalstructuren van andere Eph kinase domeinen. Deze analyse 
onthulde een hydrofobe holte in de ATP bindingsplaats van het EphA4 kinase domein die 
nog niet eerder bekend was. Deze nieuw ontdekte holte zou bij nader onderzoek kunnen 
leiden tot specificiteit van een remmer tijdens het proces van 
geneesmiddelenontwikkeling. 
Naast het NMR onderzoek, is er ook een gecomputeriseerde aanpak gebruikt 
richting EphA4 door promovendus Oscar van Linden uit de groep van Dr. de Esch in 
Amsterdam (hoofdstuk 5). Deze in silico aanpak leverde een interessante en potentiële 
remmer op van het kinase domein. Deze organische verbinding is biofysisch 
gekarakteriseerd door middel van SPR zoals vermeld in hoofdstuk 6. Daarnaast zijn 
experimenten uitgevoerd waarbij de kristallen van het natieve EphA4 werden 
geïncubeerd met de organische verbindingen en is de bindingswijze verhelderd. 
Dezelfde methode van incubatie is gebruikt met de organische verbindingen die 
naar voren kwamen tijdens het TINS experiment; helaas leverde geen van deze 
fragmenten een bruikbare structuur (hoofdstuk 3). De omstandigheden tijdens 
kristallografie verschillen zeer van de fysiologische pH. Hierom zijn [15N,1H]-HSQC 
NMR experimenten uitgevoerd om te onderzoeken of dit verschil de oorzaak kan zijn 
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voor het gebrek aan kristalstructuren (hoofdstuk 6). Resultaten van de beoordeelde 
organische verbindingen laten zien dat een verandering in pH binding niet uit sluit. 
Biofysische karakterisatie van de verbindingen die eerder werden geïdentificeerd 
zoals beschreven in hoofdstuk 3 is uitgevoerd door gebruik te maken van SPR 
technologie (hoofdstuk 6). Meerdere strategieën voor immobillisatie zijn onderzocht en 
er werd een goede correlatie gevonden tussen de resultaten uit het TINS experiment en de 
SPR analyse. Daarnaast zijn twee organische verbindingen beoordeeld op concurrerende 
binding waarbij gebruik werd gemaakt van ATP en waarvan is aangetoond dat deze de 
ATP bindingsplek binden. Hoewel de wijze van binding niet kon worden bepaald via 
kristallografie, doet de overeenkomst in structuur tussen één van deze organische 
verbindingen en de potentiële remmer eenzelfde wijze van binding vermoeden. 
Ten slotte beschrijft hoofdstuk 7 de conclusies en vooruitzichten van dit 
proefschrift. Dit onderzoeksproject heeft geleidt tot de identificatie van meerdere 
organische verbindingen die biochemisch en biofysisch zijn gekarakteriseerd. De in silico 
aanpak leverde een redelijk potentiële remmer van EphA4 op waarvan de bindingswijze 
via kristallografie is verhelderd. Bovendien heeft de TINS aanpak twee organische 
verbindingen geïdentificeerd die een startpunt kunnen vormen voor ontwikkeling van een 
meer potente remmer van EphA4. Verdere verbetering van deze organische verbindingen 
kan leiden tot de ontwikkeling van een nieuw geneesmiddel voor de behandeling van 









Au sein des organismes multicellulaires, la communication intercellulaire s’avère 
essentielle pour la régulation et la coordination de processus cellulaires complexes, tels que 
l’expression des gènes, la voie métabolique, ou encore la croissance et la différenciation des 
cellules.  Les récepteurs à activité tyrosine kinase ou «RTK» sont des récepteurs situés à la 
surface des cellules, qui non seulement régulent de tels processus mais jouent également un rôle 
fondamental dans le développement et la progression de nombreux types de cancer ; on a ainsi 
observé une surexpression du récepteur EphA4 ⎯ de la famille des RTK ⎯ dans différents 
carcinomes malins dont, entre autres, des cancers gastriques et des lymphomes cutanés.  
L’objectif du projet de recherche associé à cette thèse était donc de développer des inhibiteurs 
haute affinité du récepteur à activité tyrosine kinase EphA4. 
La conception de médicament basé sur des fragments de molécules ou «FBBD» 
(fragment-based drug discovery) s’est révélée particulièrement fructueuse en ce qui concerne le 
développement d’inhibiteurs de kinase.  Le chapitre 1 présente le processus de conception de 
médicament et introduit la notion de FBBD.  De tous temps, la plupart des entreprises 
pharmaceutiques ont eu recours à la chimie combinatoire et au criblage à haut débit (HTS : High 
Throughput Screening) pour identifier des molécules actives.  Au cours des dernières décennies, 
la FBBD s’est révélé être une méthode alternative pour la recherche de composés phares pouvant 
être a l’origine de médicaments.  Cette approche s’appuie sur l’identification de petites 
molécules, ou fragments (<300 Da), qui se lient faiblement à la cible biologique, pour ensuite les 
faire croître ou les combiner pour produire une molécule ayant une affinité plus élevée.  Des 
méthodes biophysiques, telles que la résonance magnétique nucléaire (RMN), sont nécessaires 
pour détecter de faibles affinités de liaison. Le chapitre 2 traite des tenants et aboutissants de la 
 
 220 
RMN biomoléculaire dans le domaine de la conception de médicament.  De la découverte de 
ligand aux applications intracellulaires, la RMN intervient à chaque étape du processus de 
conception de médicament et, en raison de sa sensibilité, est la méthode la plus usitée pour le 
criblage de fragment.   
Dans ce projet, deux méthodes complémentaires de modélisation ont sous-tendu la 
découverte de ligand : une première assistée par ordinateur et une seconde basée sur la RMN au 
moyen d’un criblage RMN sur une protéine cible immobilisée ou «TINS» (Target Immobilized 
NMR Screening).  La technologie TINS implique l’immobilisation sur résine de la protéine cible 
et d’une protéine témoin ayant des propriétés de liaison intermoléculaire minimales.  
L’identification de fragments se fixant spécifiquement à la cible se fait ainsi par la simple 
comparaison des intensités du signal 1D 1H des fragments en présence de la protéine témoin, puis 
de la protéine cible.  Le chapitre 3 est consacré à l’application de la méthode TINS au récepteur 
EphA4.  Une partie de celui-ci, à savoir le domaine kinase responsable de la fonction catalytique, 
se vit conférer le rôle de protéine cible.  Plusieurs stratégies d’immobilisation ont été tentées afin 
d’obtenir un échantillon de protéine sur résine utilisable, la cible étant par la suite modélisée.  Les 
résultats obtenus ont été biochimiquement caractérisés, et la structure cristallographique des 
composés obtenus déterminée.  Les données biochimiques ont livré un taux de validation 
étonnamment faible, et la cristallographie n’a pas permis de déterminer des structures de 
fragments susceptibles de former un complexe avec le récepteur EphA4.  Une méthode 
d’immobilisation alternative a alors été recherchée, et une modélisation TINS supplémentaire 
réalisée.  Il a été en outre mené une analyse des liaisons des fragments putatifs, décrite au 
chapitre 6, au moyen de méthodes biophysiques orthogonales, dont la résonance plasmon de 
surface (SPR) et la RMN aux fins d’observation de protéine. 
La structure cristalline du domaine kinase du récepteur EphA4 a été déterminée au 




dasatinib, qui est un inhibiteur de kinase bien connu.  Les deux structures ont fait l’objet d’un 
examen approfondi et d’une comparaison avec les structures cristallines des domaines kinases 
d’autres récepteurs Eph.  Cette étude a révélé une partie hydrophobe ⎯ inconnue jusqu’alors ⎯ 
dans le site de liaison ATP du domaine kinase.  L’étude de cette face nouvellement découverte a 
montré qu’il pourrait ouvrir la voie à une spécificité inhibitrice au cours de la conception de 
médicament.   
En parallèle de la modélisation basée sur la RMN, Oscar van Linden, doctorant faisant 
partie de l’équipe du Dr. de Esch à Amsterdam, a réalisé une modélisation informatique du 
récepteur EphA4 (chapitre 5).  Cette méthode in silico a produit un puissant et intéressant 
inhibiteur du domaine kinase.  Le chapitre 6 explique comment les caractéristiques biophysiques 
de ce composé ont été déterminées au moyen de la résonance plasmon de surface (SPR).  De plus, 
des expériences de trempage de cristaux natifs dans une solution contenant cet inhibiteur ont 
permis de résoudre le mode de liaison de l’inhibiteur à la protéine. (chapitre 5).  
La même procédure a été utilisée sur les composés issus du criblage TINS, mais sans qu’aucun 
des fragments ne livre de structure (chapitre 3).  Les conditions cristallographiques étant 
éloignées du pH physiologique, des expériences s’appuyant sur la RMN [15N,1H]-HSQC ont été 
menées afin de déterminer si cette différence pouvait être la cause de l’absence de structures 
cristallines (chapitre 6).  Les résultats montrent que, pour ce qui est des composés examinés, la 
différence de pH n’empêche pas la liaison. 
Les caractéristiques biophysiques des composés précédemment identifiés au chapitre 3 
ont été définis en ayant recours à la technologie RPS (chapitre 6).  Plusieurs stratégies 
d’immobilisation ont été tentées, et une bonne corrélation a pu être observée entre les résultats 
fournis, d’une part, par la modélisation TINS et, d’autre part, par l’analyse RPS.  En outre, deux 
fragments ont été soumis à un test de liaison en utilisant de l’ATP et se sont effectivement 
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attachés sur le site de liaison ATP.  Bien que le mode de liaison n’eût pu être déterminée par une 
cristallographie aux rayons X, la similarité des structures entre un de ces fragments et le puissant 
inhibiteur découvert in silico semblait indiquer un mode de liaison analogue.   
Enfin, le chapitre 7 présente les conclusions et perspectives de cette thèse.  Ce projet de 
recherche a abouti à l’identification de plusieurs composés dont les caractéristiques biochimiques 
et biophysiques ont été déterminées.  La méthode in silico a permis la découverte d’un inhibiteur 
de l’EphA4 relativement puissant dont le mode de liaison a été décrypté en utilisant la 
cristallographie aux rayons X.  De plus, la méthode TINS a permis d’identifier deux composés 
qui peuvent être considérés comme les prémices d’une génération d’inhibiteurs EPhA4 plus 
puissants.  Une version plus aboutie de ces composés pourrait mener au développement d’un 
nouveau médicament pour le traitement du cancer et des dommages neurologiques par inhibition 
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